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Abstract 
Dysfunction of the central 5-HT system has been implicated in affective disorders such 
as anxiety and depression.  However, one factor which has restricted the progress of 
investigations into possible changes in brain levels of 5-HT in affective disorders is the 
limited tools available to estimate in vivo 5-HT levels in the human brain.  The in vivo 
imaging technique Positron Emission Tomography (PET) could address this issue. 
This thesis describes the chemical synthesis and biological characterisation of the 5-
HT1A receptor PET ligand 4-(2’-methoxy-)phenyl-1-[2’-(N-2”-pyridinyl-)4-
[18F]fluorobenzamido-]ethyl piperazine (4-[18F]MPPF), with the aim of determining 
whether this might be a suitable ligand to estimate in vivo 5-HT levels in the brain.  
Development of a routine radiosynthesis starting with low activity was performed.  
Successful 4-[18F]MPPF production was achieved using a combination of the Eckert 
and Zielgler ModularLab and a microwave reactor via a fluorodenitration reaction of 4-
(2’-methoxy-)phenyl-1-[2’-(N-2”-pyridinyl-)4-nitrobenzamido-]ethyl piperazine (4-
MPPNO2) with fluorine-18.  A radiochemical yield of 33.5% was achieved with a total 
synthesis time of 60 minutes. 
PET and autoradiography studies in rats revealed 4-[18F]MPPF specifically bound in 
areas rich in 5-HT 1A receptors and binding could be blocked by pre-treatment with cold 
4-MPPF. 
The ability of the 5-HT releasing agent fenfluramine to increase the concentration of 
endogenous 5-HT in the brain and displace radioligands from the 5-HT 1A receptor was 
examined in parallel with PET, in vitro and ex vivo autoradiography, and microdialysis 
studies.  The microdialysis studies revealed that fenfluramine (3 mg/kg) increased 5-HT 
levels to approximately 400% of basal levels, reaching a maximum concentration of 1 x 
10-8 M 5-HT (in hippocampus).  PET and autoradiography studies indicated that 4-
[18F]MPPF was not displaced using this dose of fenfluramine. 
These studies demonstrate that the Eckert and Zielgler ModularLab is an effective 
radiosynthesis platform for the synthesis of 4-[18F]MPPF for use in PET and 4-
[18F]MPPF is a suitable PET ligand for the examination of the distribution of 5-HT 1A 
receptors in the rat brain.  However, this study suggests that 4-[18F]MPPF may not be 
suitable for use in examining possible changes in 5-HT in the brain in affective 
disorders.
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Chapter 1.  Introduction 
The development of non invasive in vivo 3-D imaging techniques such as PET 
(positron emission tomography) and MRI (magnetic resonance imaging) has 
provided the ability to examine the biological basis for many diseases including 
diseases of the central nervous system (CNS).  Such imaging techniques are 
used to diagnose and study the progression of disease in addition to quantifying 
the efficacy of pharmacological treatments.  Such techniques are used in both 
pre-clinical animal research as well as clinically in human studies and 
diagnostics (Garcia-Alloza and Bacskai, 2004). 
In vivo brain imaging techniques should ideally have high temporal and spatial 
resolution (Garcia-Alloza and Bacskai, 2004).  These criteria are especially 
important when applied to small animal research, as the smaller brain size 
makes examining sub cellular structures and mechanisms a greater challenge.  
MRI has both high spatial and temporal resolution.  However, although PET has 
lower spatial and temporal resolution compared to MRI, it has the ability to 
provide quantitative metabolic data such as the kinetics of neurotransmission 
and specific receptor densities, both of which can be altered in CNS diseases.  
In addition, the high sensitivity of PET means it can detect low concentrations 
relevant for many molecules studied in neuropsychiatric disorders, in the range 
of 10-9 to 10-12 M (Fumita and Innis, 2002, Levin and Zaidi, 2007).  Small animal 
models of disease therefore commonly employ PET to study the pathology of 
CNS diseases as well as pharmacological treatments of these diseases 
(Garcia-Alloza and Bacskai, 2004).
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1.1 The 5-HT system  
It has been known since 1868 that blood contained a vasoconstrictive 
substance, and in 1937 Vittorio Erspamer isolated 5-HT in the gut, naming it 
enteramine (Erspamer, 1986).  However, it was the work of Irvine Page, Arda 
Green and the post-doctoral student Maurice Rapport, between 1946 and 1949, 
which finally isolated the substance and named it serotonin (Green, 2006).  
Serotonin was further identified as 5-hydroxytryptamine (5-HT ) by Maurice 
Rapport in 1949 (Rapport, 1949).  Since then over 90,000 papers have been 
published on the subject of 5-HT (Green, 2006). 
5-HT is a neurotransmitter and neuromodulator of the central nervous system.  
Initially it contributes to the neurodevelopmental process and in the adult 
regulates a wide variety of functions and behaviours, including emotion and 
cognition (Aznavour and Zimmer, 2007, Whitaker-Azmitia et al., 1996). 
5-HT neurones originate in the dorsal and median raphe nucleus (DRN and 
MRN).  Approximately a third of the neurones in the DRN, a number of around 
11,000, are 5-HT . However, few axon terminals are found here and most of the 
5-HT release in the DRN is pre-synaptic (somatodendritic) in origin (Aznavour 
and Zimmer, 2007). 
A wide distribution of brain areas receive input from the raphe nuclei, such as 
the hippocampus, frontal cortex, septum, amygdala and hypothalamus and 
these areas are rich in post synaptic 5-HT receptors (Sharp et al., 2007, Lesch 
and Gutknecht, 2004).  
Fourteen different subtypes of 5-HT receptors have been identified, all (except 
the 5-HT 3 family) belonging to the G-protein-coupled receptor family.  They are 
divided into seven families, with subtypes within each family denoted by a letter 
(Savitz et al., 2009). The 5-HT 1A receptors are the best characterised of all the 
5-HT receptor subtypes in terms of distribution, structure and 
electrophysiological properties.   
The 5-HT 1A receptors found on the soma-dendrites of 5-HT neurones in the 
raphe nucleus act as autoreceptors, controlling the firing rate of 5-HT neurones, 
quantity of 5-HT released in an action potential and the synthesis of 5-HT .  
Therefore it can be inferred that these autoreceptors have a powerful control of   
5-HT transmission in the projection areas (Savitz et al., 2009).   
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5-HT 1A receptors have been implicated in a variety of processes including 
regulation of body temperature, sleep and mood states, and neurogenesis 
(Aznavour and Zimmer, 2007) making them an important biological target in 
both the research and treatment of CNS disease. 
 
1.1.1 5-HT 1A receptors in disease  
Dysfunction of the 5-HT 1A receptor has been implicated in affective disorders 
such as anxiety and depression.  Studies have examined 5-HT 1A knockout 
mice or transgenic mice over expressing 5-HT 1A receptors.  Such animals 
displayed anxiety like behaviours supporting the role of 5-HT 1A receptors in 
mood disorders (Heisler et al., 1998, Kusserow et al., 2004, Parks et al., 1998, 
Ramboz et al., 1998).   
The evidence that 5-HT 1A receptor dysfunction plays a role in depression 
comes from four sources; Firstly, pharmacological challenges, where increased 
extracellular 5-HT and post synaptic 5-HT 1A receptor function/transmission is 
altered, gives rise to an antidepressant effect (Detke et al., 1995, Haddjeri et al., 
1998, Savitz et al., 2009).  Secondly, post mortem studies have revealed 
changes in 5-HT 1A ligand binding in the brains of patients with depression vs. 
healthy controls (Arango et al., 1995, Boldrini et al., 2008, Matsubara et al., 
1991, Stockmeier et al., 1998, Savitz et al., 2009).  Thirdly, neuroreceptor 
imaging, such as PET, has reported reduced 5-HT 1A ligand binding in 5-HT 1A 
receptor rich areas, such as the hippocampus and raphe nucleus, in patients 
with depression (Didelot et al., 2008, Drevets et al., 2000, Hirvonen et al., 2008, 
Sargent et al., 2000, Shively et al., 2006, Savitz et al., 2009).  Lastly, genetic 
analysis has revealed characteristic and abnormal allele phenotypes for the 5-
HT 1A receptor gene in depressed patients vs. healthy controls (Savitz et al., 
2009, Neff et al., 2009, Szewczyk et al., 2009, Zhang et al., 2009). 
5-HT 1A dysfunction is also implicated in disorders such as schizophrenia, where 
5-HT 1A receptor density has been found to be high in the frontal cortices of 
patients, as well as panic disorders, where antidepressant drugs that alter 5-HT 
1A receptor function alleviate symptoms.  In addition, 5-HT 1A receptor 
modulation, using agonists such as (±)-8-OH-DPAT, has been shown to have a 
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therapeutic role in Parkinson’s disease by improving symptoms caused by 
degeneration of dopamine neurones (Jones and Blackburn, 2002, Ohno, 2011). 
1.1.2 Altered 5-HT levels in disease 
Whilst it has long been proposed that affective disorders are associated with 
decreased 5-HT levels in the brain, direct evidence for this is limited.  There are 
some reports of a decrease in the CSF levels of the 5-HT metabolite, 5-
hydroxyindolacetic acid (5-HIAA) in depressed patients (Asberg et al., 1976, 
Traskman-Bendz et al., 1984).  However, not all studies have reported similar 
results.  Furthermore, it is debatable whether 5-HIAA levels are a good indicator 
of the levels of 5-HT itself.  In the main, the evidence for altered 5-HT levels 
contributing toward the neuropathology of affective disorders is indirect and 
comes from studies where manipulations of brain 5-HT levels have been shown 
to have effects on mood.  Thus, the classic tryptophan depletion challenge 
(described below), which causes an acute decrease in brain 5-HT levels, results 
in lowering of mood in euthymic depressed patient and individuals at risk of 
depression (Ruhé et al., 2007).  One factor which has restricted the progress of 
research into possible changes in brain levels of 5-HT in affective disorders is 
the limited tools available to estimate 5-HT levels in the human brain in vivo.   
 
1.1.3 Pharmacological interventions to alter 5-HT levels in the brain 
Endogenous 5-HT can be manipulated by pharmacological intervention.  A 
number of drugs can either increase or reduce the amount of extracellular 5-HT 
, giving a route to characterise radioligands in the presence of changing levels 
of endogenous 5-HT .  Drugs such as fenfluramine, a 5-HT releasing agent, 
fluoxetine and citalopram, which are selective serotonin reuptake inhibitors 
(SSRI) can increase the amount of extracellular 5-HT . In addition, loading with 
5-HT precursors tryptophan or 5-hydroxytryptophan can increase 5-HT 
synthesis and release.  
It is also possible to reduce 5-HT synthesis and 5-HT release by using p-
ethynylphenylalanine or p-chlorophenylalanine, inhibitors of tryptophan 
hydroxylase (Stokes et al., 2000, Gál et al., 1970) or by introducing a low 
tryptophan diet for 24 hours, followed by a tryptophan free amino acid drink 
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prior to the start of an experiment (tryptophan depletion challenge) (Udo De 
Haes et al., 2002a).  
 
1.1.4 The opportunity for investigating the 5-HT system using PET 
imaging  
Investigation of neurochemical changes involving the 5-HT system provides a 
vital opportunity to characterise the pathology of the diseases discussed above, 
as well as developing and assessing the efficacy of novel therapies.  PET 
imaging provides the functionality and sensitivity to study such neurochemical 
systems and is a proven tool in the research of neurotransmitter changes, both 
clinically and pre-clinically. 
It has previously been demonstrated that some radioligands are sensitive to 
changes in levels of extracellular neurotransmitter, whereas others are not 
(Laruelle, 2000).  Where a radioligand is sensitive to changes in extracellular 
neurotransmitter levels, the radioligand could be used to examine any possible 
changes in extracellular neurotransmitter levels.  Thus, the extent of binding of 
the ‘displaceable’ radioligand would depend on the existing concentration of the 
extracellular neurotransmitter and would therefore be an indicator of 
endogenous neurotransmitter levels.  However, where a radioligand is not 
sensitive to changes in levels of extracellular neurotransmitter, the radioligand 
may only be used to examine receptor number and distribution (Udo De Haes et 
al., 2002a). 
A number of displaceable radioligands are already available for clinical PET 
imaging studies examining dopaminergic function, such as the D2 receptor 
ligand [11C]raclopride, the D2/D3 receptor ligand [18F]fallypride and the 
dopamine antagonist [123I]iodobenzamide (Slifstein et al., 2010, Breier et al., 
1997, Laruelle et al., 1999).  In one study in healthy patients, an amphetamine 
induced release of dopamine resulted in reduced binding of  [18F]fallypride, 
suggesting the radioligand is sensitive to changes in endogenous dopamine 
release (Slifstein et al., 2010).  In another study investigating the reduction in 
binding of [11C]raclopride after an amphetamine induced release of dopamine, 
patients with schizophrenia had significantly greater reductions in ligand binding 
vs. healthy controls.  From this it was inferred that the schizophrenic patients 
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had enhanced pre-synaptic dopamine function (Breier et al., 1997).  This and 
other imaging studies have concluded that the dopamine dysfunction 
characteristic in schizophrenia, is possibly due to a dysregulation of the pre-
synaptic neurone, rather than changes in post synaptic receptor sensitivity 
(Laruelle et al., 1999). 
Currently the 5-HT 1A antagonist [carbonyl-
11C]WAY100635 is a suitable PET 
ligand for the quantification and brain distribution of 5-HT 1A receptors.  
However, this ligand is not displaceable by endogenous 5-HT , so there is a 
need to develop displaceable 5-HT 1A PET ligands to examine pre-synaptic 5-
HT function (Zimmer and Le Bars, 2013).   
The 5-HT 1A antagonist PET ligand 4-[
18F]MPPF (4-(2’-methoxy-)phenyl-1-[2’-
(N-2”-pyridinyl-)4-[18F]fluorobenzamido-]ethyl piperazine) has been studied and 
shows promise as a suitable PET ligand to study pre-synaptic 5-HT function, as 
a number of studies report this ligand is displaced by endogenous 5-HT, 
(Zimmer et al., 2002b, Zimmer et al., 2002a, Zimmer et al., 2003, Aznavour et 
al., 2006, Rbah et al., 2003, Riad et al., 2004, Udo de Haes, 2005).  However, 
others report 4-[18F]MPPF binding is not affected by changes in endogenous 5-
HT , or that it is only detectable in certain 5-HT 1A receptor rich areas but not 
others (Aznavour et al., 2006, Ginovart et al., 2000, Moulin-Sallanon et al., 
2009, Riad et al., 2004, Riad, 2008, Udo De Haes et al., 2006).  
 
1.2 Positron emission tomogrophy 
PET is a non invasive in vivo imaging technique which detects molecules 
labelled with a positron emitting radioisotope to give metabolic information 
about the biological structure of interest.  Some positron emitting radionuclides  
such as 11C, 13N and 15O (Table 1) are isotopes of elements found naturally in 
bio-molecules and it is therefore possible to label such molecules without 
altering their biological activity (Miller et al., 2008).  In addition to those shown in 
Table 1 gallium-68 (half-life 68 min, 68Ge : 68Ga by β+ decay) is another well 
known radionuclide. 
Positron emission is a type of beta radioactive decay, indicated by the symbol 
β+.  A proton rich and therefore unstable nucleus converts a proton to a neutron 
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by emission of a positron (the antimatter equivalent of an electron) and a 
neutrino. 
Once a molecule of biological interest is identified it can be labelled with a 
positron emitter and administered to the test subject.  The PET radionuclide 
decays by positron (β+) emission in the body which travels a short distance (0.5-
2.0 cm depending on the kinetics of the particular isotope) before colliding with 
an electron within the nearby tissue.  The collision of matter with antimatter 
causes mutual annihilation producing two gamma (γ) ray photons of 511 keV, 
that travel 180° from each other. The PET scanner, which consists of a series of 
detectors in a ring around the test subject, detects the pair of γ rays which 
allows the approximate determination of the location of the radiolabelled 
molecule (Figure 1).  Used in combination with an anatomical imaging method 
such as X-ray computed tomography (CT), where the PET image is overlaid on 
the CT image,  the anatomical location of the radiolabelled molecule can be 
determined (Miller et al., 2008). 
PET is a quantitative imaging method which can monitor the distribution and 
concentration of radiolabelled molecules over time,  giving invaluable evidence 
of physiological and pathological events (Miller et al., 2008). 
 
 
Table 1: The most commonly used short-lived radionuclides in PET, their half-lives, method 
of production, target products, and decay products (Miller et al., 2008). 
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Figure 1: Positron decay and an example of a PET image in the human brain (Cai et al., 
2008) 
 
1.2.1 Small animal PET scanners   
In biomedical research the use of animal models to study disease is of great 
importance, not only for examining the pathology of disease, but also for 
assessing the efficacy and safety of new treatments.  In the last two decades 
the availability of small animal PET, among other imaging techniques, has 
contributed to our ability to study these animal models in vivo (Yao et al., 2012).   
However, there are a number of factors unique to small animal PET that need to 
be addressed. Firstly, there is a need for a dedicated small animal PET 
scanner, rather than using scanners designed for human use in preclinical 
studies.  The spatial resolution, defined as the minimum distance between two 
points in an image that a scanner can differentiate (Saha, 2010), must be 
optimised in these machines to accommodate the smaller size of research 
animals. To obtain the same structural detail as a human PET scanner, the 
spatial resolution of a small animal PET scanner needs to be around 1 mm for 
the rat and 0.4 mm for the mouse (Yao et al., 2012).  Indeed, the system 
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sensitivity, defined as the number of counts per unit time detected for each unit 
of activity present (Saha, 2010), is approximately three times greater in small 
animal PET scanners compared to human PET scanners.  There is also the 
need for dedicated small animal scanners that can be located separately from 
human scanners, which may be necessary for regulatory purposes as well as 
being more conveniently placed near animal housing and laboratories (Myers 
and Hume, 2002). 
Small animal PET also suffers from a number of practical problems.  Firstly 
there is the need to anaesthetize the animal, not only to prevent movement 
which would spoil images, but also to reduce stress on the animal.  A 
consideration of the pharmacological effects of the anaesthetic must therefore 
be taken into consideration when investigating neurotransmitter systems (Myers 
and Hume, 2002, Yao et al., 2012, Alstrup and Smith, 2013, McCardle and 
Gartside, 2012).  Secondly, there is a need for a stereotaxic frame to firmLy fix 
the animal in the correct orientation and prevent movement which may arise 
from breathing and other movements under anaesthesia (Myers and Hume, 
2002).  Thirdly, rodents are susceptible to heat loss during scanning and 
therefore a heating source must be used to maintain body temperature (Yao et 
al., 2012).  This is important not only to ensure the animal is kept in peak 
physical state and able to recover, but also to provide reproducible and reliable 
results when physiological parameters, such as blood flow, affect outcome 
measurements.  Lastly, there are limits to the mass and volume of ligand that 
can be injected into an animal. Therefore ligand radioactivity and specific 
activity must be sufficient to allow detection at small doses (Yao et al., 2012). 
Small animal PET must be used in conjunction with an anatomical imaging 
modality such as X-ray CT or MRI.  As PET imaging is primarily functional, the 
image quality is often too poor to identify the region of interest which can be 
overcome when used in combination with an anatomical imager (Myers and 
Hume, 2002, Ritman, 2002, Yao et al., 2012).  There are a number of 
multimodality scanners that can perform PET and CT or MRI in tandem.  
However, it is also possible to perform these imaging techniques separately and 
co-register the images at a later stage. 
A number of small animal PET scanners are now commercially available 
including the Mediso NanoScan PET/CT which has a very high spatial 
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resolution of 0.7 mm (Mediso) and the SofieBiosciences G4 PET/X-ray which 
has a spatial resolution of 1.4 mm but boasts a sensitivity of 14%, 2 – 4 times 
that of competitors (SofieBiosciences).  A number of commercially available 
small animal PET scanners are compared in Table 2.  In this thesis the Phillips 
Mosaic HP small animal PET scanner is used, with a spatial resolution of 1.9 – 
2.7 mm and a sensitivity of 1.1 - 3.6% (Surti et al., 2005, Yao et al., 2012, 
Huisman et al., 2007). 
 
 
Table 2: Comparison of the specifications of commercially available small animal PET 
scanners (Yao et al., 2012). 
 
1.2.2 Radioligands 
A radioligand is composed of two elements; the molecular compound, which in 
the case of imaging neuroreceptors is a specific receptor ligand, and the 
positron emitting radionuclide.  The ligand is responsible for the biological 
characteristics and defines how the molecule will interact both chemically and 
biologically in vivo.  The radionuclide provides a signal which is detectable by 
the PET scanner (Wadsak and Mitterhauser, 2010).  Addition of a radionuclide 
onto a ligand, rather than exchange of an existing atom with its radioactive 
isotope, can both positively and negatively affect the bio-characteristics of the 
molecule as a whole.  This must be assessed during development to ensure the 
new characteristics still provide the necessary requirements for a radioligand, 
as detailed below. 
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1.2.3 Requirements for a radioligand for brain imaging 
i. High selectivity and affinity for the receptor 
ii. None, or relatively small amounts of, metabolites 
iii. Relatively slow clearance matched with the half-life of the radionuclide 
iv. Moderate lipophilicity for brain imaging agents 
v. Low molecular weight for brain imaging agents 
A molecular mass of around 400-600 daltons and high lipophilicity are required 
for a molecule to pass the lipid bilayer of the blood-brain-barrier.  However, 
once within the brain, low lipophilicity and high affinity and selectivity for the 
target receptor is required to ensure high specific binding.   High lipophilicity can 
increase binding to plasma proteins increasing non-specific binding resulting in 
poor differentiation between the target receptor and the surrounding tissue, 
known as the signal to noise ratio.  It can be seen therefore that the lipophilicity 
must be balanced to accommodate these two opposing needs (Fumita and 
Innis, 2002).  
The data from the PET scan is used to produce a ligand time-activity curve in 
the volume of interest, which characterizes the uptake and washout periods.  
The lipophilicity and affinity of the radioligand must be balanced so that uptake 
and washout in the brain is in a time scale suitable for measurements to be 
taken.  In addition, washout must be aligned to the half-life of the radionuclide.  
It must not be so slow that washout phase measurements cannot be made 
before the specific radioactivity of the radioligand is too low for detection 
(Fumita and Innis, 2002). 
Lastly, it is necessary to ensure radioligands do not produce unwanted 
metabolites which can interfere with measurements.  Even if not biologically 
active, those that can pass through the blood-brain-barrier can still interfere with 
measurements by increasing non-specific binding (Fumita and Innis, 2002). 
It can be seen therefore that, with such specific requirements, the development 
of suitable radioligands is the major bottleneck to the progression of PET 
imaging. 
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1.3 Synthesis of Radioligands 
 
1.3.1 Radiosynthesis of radioligands 
Development of rapid synthetic methods for labelling ligands with radioisotopes 
continues to be a challenge in radiochemistry.  Due to the short half-lives of the 
radioisotopes (Table 1) radioligands must be synthesised, purified and analysed 
within an extremely short time frame to ensure there is enough radio-emitting 
nuclide to be detectable during PET imaging (Miller et al., 2008).  As a 
guideline, synthesis should take no more than approximately three isotope half-
lives (Miller et al., 2008).  Therefore, it is advantageous to have a cyclotron or 
generator for the production of radioisotopes and radiosynthesis and PET 
facilities in immediate vicinity to each other to facilitate speedy production and 
imaging of PET ligands (Miller et al., 2008). 
Two important factors that must be taken into consideration when radiolabelling 
a ligand are the radiochemical yield (RCY) and the specific activity (SA) of the 
final radiolabelled compound. The RCY is dependent on the chemical yield and 
the half-life of the radioisotope used in labelling and is expressed as a 
percentage of the radioactivity originally present (Miller et al., 2008).  This value 
can be calculated as either decay or non-decay corrected, where decay 
corrected takes into account the time elapsed producing the radiolabelled 
ligand.  The SA gives the amount of radioactivity per unit mass of radiolabelled 
ligand with typical activities for PET ligands in the range of 50-500 GBq µmol-1 
(Miller et al., 2008).  Low specific activity can occur due to dilution with the 
stable isotope of the element. 
 
1.3.2 Fluorine-18 in PET imaging 
Fluorine-18 is the most widely used radionuclide in PET imaging (Miller et al., 
2008).  Its benefits over other radionuclides are summarised below: 
 Due to the production method it is obtained as “no carrier added”; a high 
ratio of [18F]fluoride ion radioactivity vs. the total mass of carrier or 
fluoride ion leads to a high specific activity.  High specific activity allows 
for the administration of low volumes of radiolabelled ligands. This is 
 13 
 
essential for small animal imaging where body size restricts the volume 
of PET ligand which can be administered.  It is also an advantage in 
human patients where low volume injections ensures low toxicity (Cai et 
al., 2008). 
 Fluorine-18 has a half-life of 109.7 min which allows sufficient time for 
transportation of the isotope to the radiochemist, a multistep synthesis of 
the radiolabelled ligand and subsequent transportation to the PET 
facilities for administration and imaging of the subject (Cai et al., 2008, 
Miller et al., 2008). 
 Fluorine-18 emits a low energy positron (max 0.635 MeV) which travels 
only a short distance in vivo before annihilation with an electron.  The 
distance the positron travels is related to the spatial resolution of the 
PET image. The short path taken by positrons emitted from fluorine-18 
gives the best quality PET images compared to other radioisotopes (Cai 
et al., 2008, Miller et al., 2008, Rowland et al., 2002). 
 Fluorine-18 decays to give the harmLess 18O decay product (Cai et al., 
2008). 
 
1.3.3  Fluorine-18 production and preparation  
The most common method of production of fluorine-18 is the proton irradiation 
of 18O-enriched water.  This nuclear reaction 18O(p,n)18F is performed in a 
cyclotron (Cai et al., 2008).  This produces [18F]fluoride ions in [18O]water which 
reduces its reactivity due to its high strength and degree of hydration.  To 
achieve the necessary nucleophilicity required for most reactions, the majority 
of the water must be removed and the subsequent [18F]fluoride ion must be 
dissolved in an organic solvent to perform chemical reactions (Cai et al., 2008).   
The most common method for preparing the [18F]fluoride ion is detailed below 
(Figure 2) though variations on this procedure can be made, such as alternative 
base (hydrogen carbonate, oxalate), kryptand and counterion (Rb+, Cs+).  
Firstly, to recover the 18O water, the [18F]fluoride ion is absorbed onto ion 
exchange resin and then eluted using a weak aqueous base such as potassium 
carbonate (K2CO3).  This is followed by several cycles of azeotropic evaporation 
with acetonitrile which removes the water from the solution.  Use of a kryptand 
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in this step, such as aminopolyether (K222), allows the counter ion to coordinate 
with [18F]fluoride ion.  At this stage the cation is physically separated from the 
[18F]fluoride anion making the anion more available for further reaction.  Finally 
the product is dried under nitrogen in a small vessel.  As the [18F]fluoride ion 
can absorb onto the vessel wall during drying, only certain materials can be 
used which reduce the possibility of absorption. Of these, platinum is the best 
vessel material.  Truly dry [18F]fluoride ions are never obtained as each water 
molecule of hydration becomes successively more difficult to remove, therefore 
some will remain hydrated by trace amounts of residual water.  As the 
nucleophilicity increases with each reduction in hydration a well dried product is 
needed for more difficult reactions such as aromatic nucleophilic substitution 
(Cai et al., 2008).   
 
 
Figure 2: [
18
F]fluoride ion preparation flow chart showing [
18
F]fluoride ion-K222-K
+ 
complex 
(Cai et al., 2008) 
 
1.3.4 Labelling with fluorine-18 
There are a large variety of methods to radiolabel bio-molecules of interest for 
PET imaging.  However, this review will concentrate on two methods that are 
within the scope of this project.  
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Aromatic nucleophilic substitution 
Direct aromatic nucleophilic substitution is the most successful method to 
introduce fluorine-18 onto aryl carbons.  The reaction requires a good leaving 
group on the aryl ring in addition to an electron withdrawing group in the 2- or 4- 
position.  Usual leaving groups in order of increasing reactivity are I < Br < Cl < 
F < NO2 ≤ N
+Me3 and usual electron-withdrawing groups in order of increasing 
withdrawing properties are 3-NO2 < 4-Ac < 4-CHO < 4-CN ≤ 4-CF < 4-NO2.  
Harsh reaction conditions are required, such as 120-180°C in DMSO in the 
presence of a kryptand and a base, such as K2CO3 (Cai et al., 2008). 
This reaction was employed by Bars et al. to synthesise 4-[18F]MPPF.  
Substitution of the nitro leaving group in the precursor MPPNO2 (4-(2’-methoxy-
)phenyl-1-[2’-(N-2”-pyridinyl-)4-nitrobenzamido-]ethyl piperazine) with 
[18F]fluoride ion (Scheme 1) gave a radiochemical yield (RCY) of 25% (Bars et 
al., 1998). 
 
 
 
  A        B 
 
Scheme 1: Radiosynthesis of 4-[
18
F]MPPF (B) by aromatic nucleophilic substitution of 4-
MPPNO2 (A) 
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19F/[18F] isotopic exchange 
 
Table 3: Van der Waals radii, electronegativity and bond lengths to carbon of various atoms 
(Cai et al., 2008) 
 
A fluorine atom may substitute for a hydrogen atom resulting in similar biological 
activity.  However a fluorine atom is more sterically similar to oxygen and has a 
comparable bond length to carbon, so may also substitute for a hydroxyl group  
(Table 3) (Cai et al., 2008). The replacement of a hydrogen or hydroxyl group 
with a fluorine atom affects pharmacokinetics and pharmacodynamics and is 
therefore often used in drug development (Blom et al., 2009).  For this reason it 
is common to have fluorinated drug molecules, including 4-MPPF, that contain 
one or more fluorine-19 (Scheme 2).  However isotope exchange is prone to 
producing low specific activity (SA) due to an equilibrium being formed between 
the [18F] and 19F fluorinated materials. 
Blom et al. report heating 4-MPPF (17.5 mM) with no carrier added fluorine-18 
(approx. 0.5 GBq) in DMF (200 µL) at 150 °C for 15 minutes.  This resulted in a 
radiochemical yield of 8 ± 1% and specific activity of 0.01 GBq/µmol (Blom et 
al., 2009). 
 
 
 
  A        B 
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Scheme 2: Isotopic exchange of 4-[
19
F]MPPF (A) to 4-[
18
F]MPPF (B) 
1.3.5 Microwave and microfluidic techniques 
Microwave reactors 
In comparison to traditional thermal heating the use of microwave reactors 
(Figure 3) in radiosynthesis can decrease reaction time, thereby increasing 
RCY and also decreasing the quantity of precursor required to perform the 
reaction, all of which have popularised the use of this technique.  In addition, 
certain reactions which are difficult to achieve under normal thermal conditions  
can be achieved using a microwave reactor as well as producing cleaner 
reaction mixtures through decreased sample decomposition (Cai et al., 2008, 
Stone-Elander and Elander, 2002).  
 
Figure 3: Typical laboratory microwave reaction cavity and infrared thermometer containing 
a 5 mL reaction vial (Resonance Instruments Inc., 2011) 
 
Microfluidic reactors 
Microfluidic reactors, such as the commercially available Advion Nanotek 
(Figure 4) allow reactions to take place on a miniaturised scale and can provide 
a high degree of reproducibility.  In addition they can be controlled remotely 
from behind shielding, which is an especially important safety consideration 
when dealing with radioisotopes.  They consist of micron-sized channels (in the 
range of 100-300 µm), filters, separation columns and reaction loops.  The 
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internal volume of the reaction loops is in the range of 30 µL for a 4 m length 
with a diameter of 100 µm.  Reaction mixtures that enter the reaction loops mix 
under laminar flow and equilibrate to the reactor set temperature.  The reaction 
time is set by the flow rate and is essentially the residence time within the 
reactor.  Microfluidic system reactions can be performed rapidly under precisely 
controlled conditions of time, temperature and reaction stoichiometry.  In 
addition the temperature can be set above the boiling point of most organic 
solvents due to containment of the increased pressure in the system.  Another 
valuable feature of this technique is that only milligram quantities of precursors  
are required which is especially important when using expensive or difficult to 
obtain compounds (Chun et al., 2010, Cai et al., 2008). 
 
 
 
 
Figure 4: Schematic diagram showing a possible set up for the Advion Nanotek microfluidic 
system. The [
18
F]fluoride
 
ion 
 
is separated from H2
18
O by absorption onto an ion exchange 
resin (I.E.R), eluted into the vessel below using K2CO3/K222, then azeotropically dried using 
acetonitrile followed by further drying under N2 and heat. The kryptand coordinated 
[
18
F]fluoride ion 
 
is then dissolved in a polar aprotic solvent, such as dimethylformamide and 
is sent to the reactor in tandem with the precursor for the reaction to take place. Original 
image created by C. Reed. 
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1.4 Development of 5-HT 1A ligands for PET 
1.4.1 5-HT PET ligands  
There is still a great need to develop new PET ligands to examine the 5-HT 
system as, to date, only five 5-HT receptors and the serotonin transporter have 
PET ligands available to examine their function.  These include 5-HT1A, 5-HT1B, 
5-HT2A, 5-HT4 and 5-HT6, as well as the serotonin transporter (SERT) (Zimmer 
and Le Bars, 2013, Paterson et al., 2013).  Out of those available, table 4 
summarises the 5-HT PET ligands currently of most interest. 
 
Target Radioligand Pre-clinical studies 
5-HT1A [
11C]WAY-100635 10 
 
[18F]MPPF 27 
 
[18F]FCWAY 7 
5-HT2A [
18F]setoperone 3 
 
[18F]altanserin 6 
 
[11C]MDL100907 5 
SERT [11C]DASB 17 
  [11C]MADAM 1 
 
Table 4; Summary of the current leading 5-HT PET ligands (Paterson et al., 2013) 
 
Table 5 summarises the 5-HT1A ligands that have been studied for PET and 
SPECT.  As can be seen, some of these ligands have already failed to meet the 
requirements for a PET or SPECT ligand, and most have known problems.  
This highlights the ongoing need for the development of new 5-HT1A PET 
ligands with superior characteristics. 
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Table 5: PET and SPECT radioligands studied for the 5-HT1A receptor; showing both failed 
ligands and those with ongoing studies (Paterson et al., 2013). 
 
Although the need to find displaceable 5-HT ligands is of great interest, not all 
studies are set up to examine this characteristic and instead focus on other 
factors such as biodistribution, specificity for receptor type and metabolite 
studies.  For instance, 4[18F]MPPF has been examined in twenty-seven pre-
clinical studies, but only twelve of these attempted to establish whether it is 
displaceable by endogenous 5-HT (Aznavour et al., 2006, Ginovart et al., 2000, 
Millet et al., 2008, Moulin-Sallanon et al., 2009, Rbah et al., 2003, Riad, 2008, 
Riad et al., 2004, Udo de Haes, 2005, Udo De Haes et al., 2006, Zimmer et al., 
2002a, Zimmer et al., 2002b, Zimmer et al., 2003).  This trend continues for 
other 5-HT ligands.  For example the 5-HT2A PET ligand [
18F]altanserin has 
been examined in six pre-clinical studies, but only one examines whether it is 
displaceable by endogenous 5-HT (Staley et al., 2001). 
This paucity of studies examining the displacable nature of 5-HT PET ligands 
highlights the need for further studies focused on displacability by endogenous 
5-HT starting at the pre-clinical level. 
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1.4.2 5-HT 1A PET ligands  
5-HT 1A receptor PET ligands generally fall into one of two classes; (i) those 
which are structurally similar to the 5-HT 1A antagonist WAY-100635 or (ii) 
derivatives of the 5-HT 1A agonist (±)-8-OH-DPAT (Scheme 3) 
 
       A    B 
Scheme 3: WAY100635 (A) and (±)-8-OH-DPAT (B) 
 
To date all PET radioligands used in clinical studies are antagonists, although 
efforts continue in the development of 5-HT1A agonist ligands (Kumar and 
Mann, 2007, Lemoine et al., 2010, Zimmer and Le Bars, 2013). 
 
WAY100635 is a potent 5-HT 1A receptor antagonist and was the first fully 
selective 5-HT 1A antagonist to be discovered.  The first radiolabelled version 
[O-methyl-11C]WAY100635 was found to have a radiolabelled metabolite with 
the ability to pass through the blood-brain-barrier, which interfered with PET 
measurements by increasing non-specific binding.  This was overcome by 
incorporating the radiolabel at the amide carbonyl position, resulting in 
[carbonyl-11C]WAY-100635 (Scheme 4).  This analogue maintained a high 
affinity for 5-HT 1A receptors (KD = 0.2 nM) in addition to having no interfering 
metabolites.  These features now make [carbonyl-11C]WAY-100635 a 
commonly used 5-HT 1A PET radioligand (Kumar and Mann, 2007, Cliffe, 2000, 
Lang et al., 1999).   
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  A      B 
Scheme 4: [O-methyl-
11
C]WAY-100635 (A) and  [carbonyl-
11
C]WAY-100635 (B) 
 
However, [carbonyl-11C]WAY100635 has a fast metabolism and is rapidly 
cleared from the brain.  In addition, the short half-life of carbon-11 results in low 
radioactivity in plasma samples making it unsuitable for kinetic quantification of 
the radioligand in the brain (McCarron et al., 2004).  Therefore compounds 
labelled with the isotope fluorine-18 are more desirable as its longer half-life (t1/2 
= 109.7 min vs. 20.3 min for 11C, Table 1) allows for both longer radiosynthetic 
methods and increased PET imaging time. 
One analogue of WAY100635, FCWAY (Scheme 5), was developed and 
successfully radiolabelled with fluorine-18.  [18F]FCWAY showed some 
pharmacokinetic improvements over [carbonyl-11C]WAY100635 but has the 
major disadvantage of fluorine-18 defluorination in vivo (Cliffe, 2000, Kumar and 
Mann, 2007).  In addition one study suggests it is not sensitive to changes in 
endogenous 5-HT (Jagoda et al., 2006). 
 
 
 
Scheme 5: FCWAY (A) and [
18
F]FCWAY (B) 
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The aromatic version of FCWAY is 4-MPPF, which has also been successfully 
labelled with fluorine-18 and shows many promising attributes needed for a 5-
HT 1A antagonist radioligand.  One feature is its lower affinity towards 5-HT 1A 
receptors compared to WAY100635.  4-MPPF binding to 5-HT 1A receptors has 
been shown to be reversible and could therefore potentially be displaced by 
endogenous 5-HT (Kumar and Mann, 2007).  This feature is of particular 
interest in the scope of this project as displacement by endogenous 5-HT could 
reveal possible changes in neurotransmitter levels associated with affective 
disorders. 
 
1.4.3 Towards MPPF as a 5-HT PET ligand 
A series of 4-(2’-methoxyphenyl)-1-[2’(N-2”-pyridinyl)halobenzamido] 
ethyl]piperazines were prepared by Zhuang et al. to develop new radiolabelled 
antagonists of the 5-HT 1A receptor.  Among these was a fluorinated version, 
with the fluorine in the 4- position, 4-MPPF and three iodinated versions, 2-, 3- 
and 4-MPPI (Figure 5) (Zhuang et al., 1994).  
 
 
Figure 5: 2-MPPI (A), 3-MPPI (B) and 4-MPPI (C) 
 
The brain distribution of 4-MPPI radiolabelled with iodine-123 or iodine-125 was 
examined in the rat brain.  4-MPPI displayed good initial uptake in the brain 
(1.22% dose/organ 2 minutes after i.v injection) and demonstrated high 
selectivity for the 5-HT 1A receptor.  This was shown by the high uptake in the 
hippocampus, where 5-HT 1A  receptor density is high, and low uptake in the 
cerebellum, which is almost devoid of 5-HT 1A receptors (Pazos et al., 1987).   
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The selectivity was further demonstrated with blocking studies which pre-treated 
with the selective 5-HT 1A antagonist WAY100635 or the 5-HT 1A agonist (±)-8-
OH-DPAT.  This had the effect of a dramatic reduction of hippocampal uptake, 
with the hippocampus : cerebellum uptake ratio reducing from 3.69 to 1.21 for 
(±)-8-OH-DPAT and 1.07 for WAY100635.  This reduction is explained by 
binding competition at the receptor with the agonist or antagonist therefore 
suggesting 4-MPPI is selective for the 5-HT 1A receptor (Kung et al., 1996a, 
Zhuang et al., 1994). 
However an in vivo study in non-human primates revealed 4-MPPI produces 
iodinated metabolites which dramatically reduced the binding to 5-HT 1A 
receptors (Kung et al., 1996a, Aznavour and Zimmer, 2007). 
Therefore, other studies were focusing on 4-MPPF as a possible new 5-HT 1A 
antagonist.  The distribution of 4-[18F]MPPF binding in the rat brain was 
confirmed to match that of 5-HT 1A  receptors by autoradiography, which was in 
line with immunocytochemistry using specific antibodies against 5-HT 1A  
(Aznavour and Zimmer, 2007).  4-MPPF has been shown to be a selective 
antagonist of the 5-HT 1A pre-synaptic autoreceptors and postsynaptic 
heteroreceptors (Thielen and Frazer, 1995, Thielen, 1996, Zhuang et al., 1994).  
The brain uptake is low (0.055% whole brain, 0.066% DRN, 0.018% cerebellum 
injected dose/g after 30 min in rats) (Plenevaux et al., 2000, Zimmer et al., 
2002b).  However, this uptake has been shown in subsequent studies to be 
sufficient for PET detection.  4-MPPF demonstrated high selectivity for the 5-HT 
1A receptor (Kung et al., 1996c) and has a comparable affinity (Inhibition 
constant Ki=3.3nM ± 0.8) (Zhuang et al., 1994), compared to the endogenous 
neurotransmitter 5-HT (Ki=4.17nM) (Van Wijngaarden et al., 1990), where Ki is 
the inhibition constant of compounds on the binding of (±)-8-OH-DPAT).  
Therefore it can be inferred that endogenous 5-HT could displace 4-MPPF from 
the 5-HT 1A receptor, giving a measure of changes in the endogenous 5-HT 
levels.  In addition 4-[18F]MPPF has been found  to have no unwanted 
radioactive metabolites (Plenevaux et al., 2000).   
In summary, 4-[18F]MPPF has been shown to fit many of the criteria for a good 
PET tracer.  It has the ability to cross the blood-brain-barrier followed by 
washout indicating adequate lipophilicity, has high selectivity and affinity for the 
5-HT 1A receptor, binds reversibly to the 5-HT 1A receptor and has a washout 
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time in the scale suitable for PET imaging, in addition to producing no unwanted 
metabolites. 
 
1.4.4 Synthesis and purification of 4-[18F]MPPF  
Initially 4-MPPF was radiolabelled with iodine-123 or iodine-125 (Zhuang et al., 
1994) and tritium (Kung et al., 1996b) but later was successfully radiolabelled 
with fluorine-18 by Shiue et al. (Shiue et al., 1997).  An optimised synthesis of 
the regio-isomers of both MPPF and MPPNO2 to produce cold standards 
(Scheme 6) and a general procedure for [18F]fluorination via a nucleophilic 
substitution of the nitro precursor, MPPNO2, (Scheme 1) was published by Bars 
et al.  (Bars et al., 1998).  The radiosynthesis, performed on a Liege robotic 
system, gave methods for both standard (150 ºC, 20 min, aluminium block) and 
microwave heating (3 min, 500 W), resulting in a 25% radiochemical yield, 37 – 
185 GBq/µmol specific activity in 70 min and was the general protocol followed 
by subsequent papers.  It has since been shown that radiosynthesis of 4-
[18F]MPPF via a fluorodenitration reaction can be fully automated on a Tracer 
Lab FXFN (Shao et al., 2011) and a NIRS synthesis module (Hayashi et al., 
2012). 
Chromatographic and spectrographic techniques were assessed by Koivula et 
al. in relation to the notoriously difficult to separate 4-[18F]MPPF from the 
precursor MPPNO2. (Koivula et al., 2010).  Optimised separation methods using 
HPLC (C18 semi preparative column, THF/MeOH : 0.05 M NaOAc (18:27:55 v/v) 
pH 5, 2 mL/min. Retention times; 4-[18F]MPPF 15 min, MPPNO2 22 min) and 
TLC (60 F254 silica gel plates, CH3CN : H2O 90:10% mobile phase) were 
described. 
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Scheme 6: General synthesis of 2-, 3- and 4- regioisomers of MPPF and MPPNO2 as 
performed by Bars et al. (Bars et al., 1998) 
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1.5 Aims of thesis 
The aims of this thesis are to: 
 Optimise the synthesise the 4-[18F]MPPF precursors, 4-MPPF and 4-
MPPNO2, for analytical method & reaction development. 
 Develop a routine radiosynthetic method for the production of 4-
[18F]MPPF suitable for low radioisotope activity. 
 Use parallel standardised protocols in in vivo microdialysis, 
autoradiography and PET imaging to characterise the binding distribution 
and displacability of 4-[18F]MPPF in the rat brain.  
 
The thesis is organised into two main research areas.  Chapters 2 and 3 
describe the development of the chemistry and radiochemistry for the synthesis 
of 4-[18F]MPPF and its precursors.  Chapters 4 and 5 describe the 
characterisation of the 4-[18F]MPPF in the rat brain.  
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Chapter 2. Synthesis of 4-MPPF and 4-MPPNO2 
 
2.1 Introduction 
It is the aim of this thesis to characterise the PET ligand 4-[18F]MPPF using PET 
imaging and autoradiography.  As the radioisotope fluoride-18 has a short half-life, 
the radioligand must be produced on the day of use.  Therefore precursors to 4-
[18F]MPPF must first be obtained.  This study requires relatively large quantities of 
precursors to complete extensive analytical and radiosynthesis development and in 
vivo studies.  Therefore it was necessary to synthesise the precursors as part of the 
present study in order to obtain sufficient quantities for the project.  These precursors 
are used in Chapter 3 to radiosynthesise 4-[18F]MPPF. 
As discussed in the Chapter 1 (Section 1.3.4), two possible radiosynthesis reaction 
routes are being considered in this study; 19F/[18F] isotopic exchange and aromatic 
nucleophilic substitution, in the form of a fluorodenitration reaction.  Each reaction 
route requires a precursor; 4-MPPF and 4-MPPNO2 respectively and therefore the 
synthesis of these materials will be described in this chapter. 
Therefore, the aims of this chapter are to; 
 Synthesise the 19F standard, 4-MPPF 
 Synthesise the nitro precursor, 4-MPPNO2. 
 To evaluate alternative synthesis routes. 
.
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2.2 Results and Discussion 
It was an aim of this project to synthesise 4-MPPF and 4-MPPNO2 for use in 
later studies.  The 2-, 3- and 4- regioisomers of MPPF and MPPNO2 have 
previously been synthesised by Bars et al. (Bars et al., 1998) (Scheme 6) using 
a four step synthesis.  Therefore synthesis was undertaken following the 
general procedure as reported by Bars et al. (Bars et al., 1998).  A small scale 
synthesis was first undertaken to ensure the published procedure could be 
replicated, with some work up procedures modified as required.  Of the small 
scale crude products, 4-MPPF was purified and characterised by 1H, 13C and 
19F NMR.  The successful small scale synthesis was followed by large scale 
synthesis of both 4-MPPF and 4-MPPNO2.  4-MPPF was obtained in a yield of 
61% (2.85 g) and the structure was confirmed using 1H, 13C, 19F NMR and 
elemental analysis.  Crystals suitable for x-ray crystallography analysis were 
grown from dissolving 4-MPPF in ethyl acetate (60 ⁰C to RT), followed by 
addition of petrol. (Figure 6, Appendix A).  4-MPPNO2  gave a yield of 40% 
(0.83 g) and the structure was confirmed using 1H,13C NMR and elemental 
analysis. 
 
 
Figure 6:  Solid state structure of 4-MPPF, as determined by x-ray crystallography. Atomic 
key: black: carbon, red: oxygen, blue: nitrogen, green: fluorine. 
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In addition, alternative synthesis routes were evaluated with the aim of 
removing a step from the published synthesis and therefore reducing synthesis 
time.  The third step of the synthesis is a reduction step, which could be avoided 
if an alkyl group was introduced directly rather than via the intermediate acetyl 
group.  Therefore, four alternative syntheses were attempted (Scheme 7) with 
the proposed full synthesis shown in Scheme 8 and 9.  In each case TLC and 
1H NMR revealed only starting materials at the end of the reaction, confirming 
no reaction took place. 
 
A. 
 
 
B. 
 
 
C. 
 
 
D. 
 
 
Scheme 7: Four alternative first step reactions attempted for the synthesis of MPPF.  
Reaction conditions; A1. Tetrahydrofuran (THF), NaH, RT, 12 hr. A2. THF, NaH, reflux, 12 
hr.  B1. THF, NaH, reflux, 12 hr.  B2. 1, 2-dichloroethane, NaH, relux,12 hr.  B3. THF, NaH, 
reflux, 72 hr. C. THF, NaH, reflux, 12 hr. D. CH3CN, K2CO3, reflux, 4 hr. 
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Scheme 8: Proposed synthesis scheme using alternative reaction steps A, B or C (Scheme 
7) 
 
 
 
 
Scheme 9: Proposed synthesis scheme using alternative reaction step D starting with a 
model compound (Scheme 7). 
 
 32 
 
2.3 Summary 
In this chapter 4-MPPF and 4-MPPNO2 were synthesised with suitable purity 
and in sufficient volume to be used in Chapter 3 as the 4-[18F]MPPF precursors 
to develop a radiosynthesis method and then routinely radiosynthesise 4-
[18F]MPPF for PET and autoradiography experiments. 
It was also shown a number of alternative synthesis routes did not produce 
product at the given conditions.  It should also be noted that although a reaction 
step was removed in the alternative synthesis routes, the new proposed 
reaction step is likely to react more slowly than in the reaction step in the 
original synthesis, therefore may not have an overall benefit. 
 
2.4 Experimental 
Reactions requiring anhydrous conditions were performed with glassware dried 
with heat under vacuum and reactions conducted under a positive pressure of 
nitrogen.  Anhydrous solvents were prepared using standard protocols or by 
storage over molecular sieves (4Å).  Flash chromatography was performed on a 
Varian 971-FP Flash purification system. Thin layer chromatography was 
performed using Kieselgel 60F254, 0.2 mm silica gel plates with aluminium 
backing and visualised using short (254µm) and long (356µm) UV light and 
KMnO4 solution.  
1H and 13C NMR spectra were carried out on a JeolECS 400 
MHz spectrometer with residual protic solvent as the reference.  19F NMR 
spectra were recorded on a Jeol ECS 400MHz spectrometer using CFCl3 as an 
external reference. Melting points were determined using a Gallenkamp MF-370 
melting point apparatus and are uncorrected.  Elemental analysis were 
performed by London Metropolitan University Elemental Analysis Service and 
are reported as the average of two runs.  X-ray crystal structures was 
performed by the Newcastle University X-ray crystallography department..  
Analytical HPLC was performed on the Agilent Technologies 1200 series with a 
Phenomenex polystyrene divinylbenzene, 50 x 4 mm, 5 micron column.  
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2.4.1 Synthesis of 2-, 3- and 4-MPPF, 3- and 4-MPPNO2 
 
2-chloro-N-2-pyridinyl acetamide, 1 (Bars et al., 1998) 
 
 
2-Aminopyridine (0.95 g, 10 mmol) was added to CH2Cl2 (20 mL) and Et3N 
(1.68 mL, 0.012 mol) and stirred in an ice bath.  Chloroacetyl chloride (0.97 mL, 
12 mmol) was then added and allowed to stir in an ice bath for 85 min.  After 
confirmation by TLC that the 2-aminopyridine had been consumed, water (10 
mL) was added.  The organic layer was separated and the aqueous layer was 
extracted with CH2Cl2 (x3).  The combined organic layers were dried (MgSO4), 
filtered and concentrated in vacuo to give the crude product as grey-brown 
solid. The product was used in the next step without further purification. 
 
Small scale  
Grey-brown solid (1.59 g, 9.32 mmol). (Rf = 0.65 (1:3 petrol : ethyl acetate, 2 
developments); 1H NMR(CDCl3, 400 MHz): signals selected from crude; δ 
(ppm) 8.84 (br, 1H), 8.31 (m, 1H), 8.18 (d, J=8.4 Hz, 1H), 7.72 (ddd, J=8.4, 7.5, 
1.9 Hz, 1H), 7.09 (ddd, J=7.4, 4.9, 1.0 Hz, 1H), 4.18 (s, 2H); 13C NMR(CDCl3, 
101 MHz): δ (ppm) 164.5, 150.4, 148.2 and 148.1, 138.7 and 138.5, 120.9 and 
120.6, 114.1 and 113.9, 42.9. 
 
Large Scale 
With 2-aminopyridine (50 g, 530 mmol).  Grey-brown solid (94.46 g, 550 mmol, 
104%). Rf = 0.56 (1:1 petrol : ethyl acetate).  NMR data matches above. 
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4-(2’-Methoxy-)phenyl-1-(2’-pyridinylaminocarbonyl-)methyl piperazine, 2 
(Bars et al., 1998) 
 
 
The crude 2-chloro-N-2-pyridinyl acetamide (1) (1.32 g, 7.76 mmol) was added 
to DMF (12 mL) followed by K2CO3 (3.25 g, 23.3 mmol) and stirred vigorously 
for 5 min.  1-(2’-methoxyphenyl)piperazine (2.01 g, 8.54 mmol) was added to 
the mixture and stirred vigorously at room temperature for 18 h.  After 
confirmation by TLC that 1-(2”-Methoxyphenly) piperazine had been consumed, 
water (20 mL) was added.  The mixture was extracted with CH2Cl2 and the 
organic layer was dried (MgSO4), filtered and concentrated in vacuo.  
Purification using column chromatography (SiO2, ethyl acetate : petrol 40-60, 30 
: 70) gave the product as a pale yellow solid. 
 
Small scale 
Pale yellow solid (1.47 g, 4.52 mmol, 58%).  Mp 84 -85 °C (lit.(Park et al., 2005) 
84 ⁰C) from acetone, Rf = 0.68 (1:4 petrol : ethyl acetate, 2 developments); 
1H 
NMR(CDCl3, 400 MHz): δ (ppm) 9.66 (s, 1H), 8.32 – 8.27 (m, 1H), 8.24 (d, 
J=8.3 Hz, 1H), 7.69 (t, J=7.9 Hz, 1H), 7.05 – 6.89 (m, 4H), 6.85 (d, J=8.0 Hz, 
1H), 3.85 (s, 3H), 3.25 (s, 2H), 3.18 (br, 4H), 2.84 (t, 4H); 13C NMR(CDCl3, 101 
MHz): δ (ppm) 152.3, 151.1, 148.1, 140.9, 138.4, 123.4, 121.1, 120.0, 118.5, 
114.0, 111.3, 62.3, 55.5, 53.9, 50.6. 
 
Large scale 
With 2-chloro-N-2-pyridinyl acetamide(1) (58 g, 340 mmol).  Final purification 
was performed by recrystallisation (x2) with acetone and petrol 40-60 to give a 
pale yellow solid. 
Formatted: Font: Not Bold
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Pale yellow solid (37.17 g, 111 mmol, 34%).Mp 85 - 86°C (lit.(Park et al., 2005) 
84 ⁰C) from acetone; Rf = 0.47 (1 : 1 petrol : ethyl acetate); NMR data matches 
above. 
 
4-(2’-Methoxyphenyl)-1-[2’-(2”-pyridinyl-)amino]ethyl piperazine, 3 (Bars et 
al., 1998) 
 
 
4-(2’-methoxy-)phenyl-1-(2’-pyridinylaminocarbonyl-)methyl piperazine (2) (510 
mg, 1.56 mmol) in THF (10 mL) was added dropwise at room temperature to a 
slurry of LiAlH4 (190 mg, 5.01 mmol) also in THF (10 mL).  The mixture was 
heated at reflux (75 °C for1 hr) then cooled to room temperature.  After 
confirmation by TLC that (2) had been consumed, the mixture was diluted with 
diethyl ether (20 mL) then cooled to 0 °C in an ice bath.  Water (0.2 mL), NaOH 
(15% aqueous solution, 0.2 mL) and water (0.6 mL) were added successively 
dropwise and the mixture was allowed to warm to room temperature.  MgSO4 
(~1 g) was added and the solution allowed to stir for 15 min.  The solution was 
vacuum filtered and concentrated in vacuo to give the crude product as an 
orange oil.  The product was used in the next step without further purification. 
 
Small scale 
Orange oil (0.33 g, 0.99 mmol, 64%). Rf = 0.22 (1:4 petrol : ethyl acetate, 2 
developments); 1H NMR(CDCl3, 400 MHz): δ (ppm) 8.07 (dd, J=5.0, 1.4 Hz, 
1H), 7.43 – 7.36 (m, 1H), 7.02 – 6.81 (m, 4H), 6.55 (ddd, J=7.2, 5.1, 0.7 Hz, 
1H), 6.42 (d, J=8.3 Hz, 1H), 5.25 (s, 1H), 3.84 (s, 3H), 3.41 (dd, J=11.2, 5.4 Hz, 
2H), 3.11 (s, 4H), 2.79 – 2.67 (m, 6H); 13C NMR(CDCl3, 101 MHz): δ (ppm) 
158.8, 152.3, 148.1, 141.2, 137.4, 123.1, 121.1, 118.3, 112.8, 111.2, 107.4, 
56.9, 55.4, 53.2, 50.5, 38.4. 
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Large scale 
With 4-(2’-methoxy-)phenyl-1-(2’-pyridinylaminocarbonyl-)methyl piperazine (2) 
(14.88 g, 46 mmol).  The product was purified by recrystallisation (ethyl acetate 
and petrol) to give a white crystalline solid. 
White crystalline solid (4.93 g, 0.016 mol, 34%). Mp 96 - 97 °C (lit.(Park et al., 
2005) 63- 64 ⁰C)from ethyl acetate; Rf= 0.24 (1:4 petrol : ethyl acetate); NMR 
data matches above. 
 
4-(2’-Methoxy-)phenyl-1-[2’-(N-2”-pyridinyl-)4-fluorobenzamido-]ethyl 
piperazine (4-MPPF), 4 (Bars et al., 1998) 
 
 
 
4-(2’-,methoxy-)phenyl-1-[2’-(2”-pyridinyl-)amino]ethyl piperazine (3) (0.21 g, 
0.71 mmol) and Et3N (0.24 mL, 0.17 mol) were added to CH2Cl2 (5 mL) and the 
solution allowed to cool to 0 °C in an ice bath.  4-Fluorobenzoyl chloride (0.1 
mL, 0.85 mol) in CH2Cl2 (5 mL) was added dropwise at 0 °C and the mixture 
allowed to stir for a further hour at room temperature.  After confirmation by TLC 
that (3) had been consumed, water (2 mL) was added and the mixture extracted 
with CH2Cl2 (x3).  The combined organic layers were dried (MgSO4), filtered 
and concentrated in vacuo.  Purification using column chromatography (SiO2, 
ethyl acetate : petroleum  ether 40-60 °C % 50 : 50) gave a white solid. 
 
Small scale 
White solid (0.07 g, 0.17 mmol, 24%).Rf= 0.37 (1:4 petrol : ethyl acetate, 2 
developments); 1H NMR(CDCl3, 400 MHz): δ (ppm) 8.41 – 8.39 (m, 1H), 7.42 – 
7.37 (m, 1H), 7.34 – 7.28 (m, 2H), 7.01 (ddd, J=7.3, 4.9, 0.8 Hz, 1H), 6.98 – 
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6.80 (m, 6H), 6.74 (d, J=8.1 Hz, 1H), 4.28 (t, J=6.7 Hz, 2H), 3.81 (s, 3H), 2.93 
(s, 4H), 2.76 (t, J=6.5 Hz, 2H), 2.66 (s, 4H); 13C NMR(CDCl3, 101 MHz): δ (ppm) 
169.7, 164.9, 162.4, 156.5, 152.3, 148.8, 141.3, 137.3, 132.3, 131.2 and 131.1, 
122.9, 121.1 and 121.0, 118.2, 115.3and 115.1, 111.2, 56.4, 55.4, 53.4, 50.5, 
45.5.; 19F NMR(CDCl3, 376 MHz): δ (ppm) -109.2. 
 
Large scale 
With 4-(2’-methoxy-)phenyl-1-[2’-(2”-pyridinyl-)amino]ethyl piperazine (3) (3.2 g, 
10.8 mmol). Purified by column chromatography (SiO2,ethyl acetate 100%) and 
recrystallisation (diethyl ether and petrol) to give a white crystalline solid. 
White crystalline solid (2.85 g, 6.56 mmol, 61%).Mp 82 – 83 ⁰C (lit. (Bars et al., 
1998) 81.8 ⁰C); Rf = 0.59 (1:4 petrol : ethyl acetate); NMR data matches above. 
 
4-(2’-Methoxy-)phenyl-1-[2’-(N-2”-pyridinyl-)4-nitrobenzamido-]ethyl 
piperazine (4-MPPNO2), 5, (Bars et al., 1998) 
 
 
 
4-(2’-methoxy-)phenyl-1-[2’-(2”-pyridinyl-)amino]ethyl piperazine (3) (1.56 g, 5 
mmol) and Et3N (0.17 mL, 6 mmol) were added to CH2Cl2 (20 mL) and the 
solution allowed to cool to 0 °C in an ice bath.  4-Nitrobenzoyl chloride (0.93 g, 
5 mmol) in CH2Cl2 (20 mL) was added dropwise at 0 °C and the mixture allowed 
to stir for a further hour at room temperature.  After confirmation by TLC that (3) 
had been consumed, water was added (10 mL) and the mixture extracted with 
CH2Cl2 (x3).  The combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo.  Purification using column chromatography (SiO2.100% 
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ethyl acetate) and recrystallisation (ethyl acetate and petrol) gave a yellow 
crystalline solid. 
 
Yellow crystalline solid (0.83 g, 2 mmol, 40%). Mp 153 - 156 °C (lit. (Bars et al., 
1998) 166 ⁰C); Rf = 0.28 (1:4 petrol : ethyl acetate); 
1H NMR(CDCl3, 400 MHz): 
δ (ppm) 8.40 – 8.34 (m, 1H), 8.06 – 7.99 (m, 2H), 7.49 – 7.40 (m, 3H), 7.08 – 
7.02 (m, 1H), 6.99 – 6.92 (m, 1H), 6.91 – 6.79 (m, 4H), 4.26 (t, J=6.6 Hz, 2H), 
3.81 (d, J=6.7 Hz, 3H), 2.91 (s, 4H), 2.73 (t, J=6.6 Hz, 2H), 2.62 (s, 4H); 13C 
NMR(CDCl3, 101 MHz): δ (ppm) 168.5, 155.7, 152.3, 149.1, 148.3, 142.5, 
141.3, 137.7, 129.6, 123.3, 122.9, 122.5, 121.7, 121.0, 118.1, 111.3, 56.3, 55.4, 
53.4, 50.7, 45.8. Anal. Calcd for C25H27N5O4: C, 65.06; H, 5.90; N, 15.17; 
Found: C, 64.89; H, 4.92; N, 15.33. m/z (ESI) 462 (M+H+, 100%), 163 (4). 
Found: M+ 462.2130. C25H28O4N5 requires 462.2136. 
 
4-(2’-Methoxy-)phenyl-1-[2’-(N-2”-pyridinyl-)2-fluorobenzamido-]ethyl 
piperazine (2-MPPF),6, (Bars et al., 1998) 
 
 
 
4-(2’-methoxy-)phenyl-1-[2’-(2”-pyridinyl-)amino]ethyl piperazine (3) (1.56 g, 5 
mmol) and Et3N (0.17 mL, 6 mmol) were added to CH2Cl2 (20 mL) and the 
solution allowed to cool to 0 °C in an ice bath.  2-Fluorobenzoyl chloride (0.59 g, 
5 mmol) in CH2Cl2 (20 mL) was added dropwise at 0 °C and the mixture allowed 
to stir for a further hour at room temperature.  After confirmation by TLC that (3) 
had been consumed, water was added (10 mL) and the mixture extracted with 
CH2Cl2 (x3).  The combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo to give an orange solid. 
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Orange solid (1.19 g, 2.7 mmol, 55%). Rf= 0.39 (1:4 petrol : ethyl acetate);
 1H 
NMR(CDCl3, 400 MHz): δ (ppm) 8.32 (m, 1H), 7.85 – 7.86 (m, 1H), 7.24 – 7.25 
(m, 1H), 6.94 – 6.98 (m, 1H), 6.84 – 6.89 (m, 8H), 4.39 (t, J=6.4 Hz, 2H), 3.82 
(s, 3H), 3.12 (br, 4H), 3.01 (t, J = 6.4 Hz, 2H), 2.97 (br,4H) 
 
4-(2’-Methoxy-)phenyl-1-[2’-(N-2”-pyridinyl-)3-fluorobenzamido-]ethyl 
piperazine (3-MPPF), 7 (Bars et al., 1998) 
 
 
 
4-(2’-methoxy-)phenyl-1-[2’-(2”-pyridinyl-)amino]ethyl piperazine (3) (1.56 g, 5 
mmol) and Et3N (0.17 mL, 6 mmol) were added to CH2Cl2 (20 mL) and the 
solution allowed to cool to 0 °C in an ice bath.  3-Fluorobenzoyl chloride (0.60 g, 
5 mmol) in CH2Cl2 (20 mL) was added dropwise at 0 °C and the mixture allowed 
to stir for a further hour at room temperature.  After confirmation by TLC that (3) 
had been consumed, water was added (10 mL) and the mixture extracted with 
CH2Cl2 (x3).  The combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo to give a brown oil. 
Brown oil (0.056 g, 0.12 mmol, 3%),  Rf= 0.38 (1:4 petrol : ethyl acetate); 
1H 
NMR(CDCl3, 400 MHz): δ (ppm) 8.34 – 8.35 (m, 1H), 7.77 – 7.79 (m, 1H), 6.86 
– 7.03 (m, 10H), 4.33 (t, J=6.6 Hz, 2H), 3.82 (s, 3H), 3.04 (br, 4H), 2.90 (t, J = 
6.6 Hz, 2H), 2.84 (br,4H) 
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4-(2’-Methoxy-)phenyl-1-[2’-(N-2”-pyridinyl-)3-nitrobenzamido-]ethyl 
piperazine (3-MPPNO2),8 (Bars et al., 1998) 
 
 
 
4-(2’-methoxy-)phenyl-1-[2’-(2”-pyridinyl-)amino]ethyl piperazine (3) (1.56 g, 5 
mmol) and Et3N (0.17 mL, 6 mmol) were added to CH2Cl2 (20 mL) and the 
solution allowed to cool to 0 °C in an ice bath.  3-Nitrobenzoyl chloride (0.93 g, 
5 mmol) in CH2Cl2 (20 mL) was added dropwise at 0 °C and the mixture allowed 
to stir for a further hour at room temperature.  After confirmation by TLC that (3) 
had been consumed, water was added (10 mL) and the mixture extracted with 
CH2Cl2 (x3).  The combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo to give a dark brown oil (0.80 g, 1.7 mmol, 35%). 
Dark brown oil (0.80 g, 1.7 mmol, 35%),  Rf= 0.54 (1:4 petrol : ethyl acetate); 
1H 
NMR(CDCl3, 400 MHz): δ (ppm) 8.37 (m, 1H), 8.14 – 8.15 (m, 2H), 7.63 – 7.64 
(m, 2H), 7.47-7.48 (m, 1H), 6.89 – 6.92 (m, 6H), 4.26 (t, J=6.6 Hz, 2H), 3.82 (s, 
3H), 2.75 (br, 4H), 2.73 (t, J = 6.6 Hz, 2H), 2.64 (br,4H) 
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Chapter 3. Radiochemistry 
3.1 Introduction 
As discussed in the main introduction fluorine-18 is the radioisotope of choice 
for producing a PET ligand.  However the short half-life means a rapid on-site 
synthesis of the PET ligand is required in order to perform subsequent PET and 
autoradiography studies (Reed et al., 2012, Pascalia et al., 2010).  In addition, a 
high level of automation is preferable to reduce exposer of the operator to 
radiation.   
Due to the limitations of fluoride delivery from external suppliers and the design 
of the in house ABT cyclotron, the [18F]fluoride available for this study had a 
relatively low activity (approx. 1 – 3 GBq).   
Therefore, the development of a fast and reliable radiosynthesis method, 
starting with low activity, to produce 4-[18F]MPPF was essential for this study. 
The aims of this chapter are; 
 To investigate two different production methods;  
o The Advion NanoTek, a microfluidic reactor capable of rapid and 
repeated synthesis. 
o The Eckert and Zielger ModularLab, a batch reaction platform. 
 
 To investigate two reaction routes to synthesise 4-[18F]MPPF;  
o 19F/[18F] isotopic exchange using the precursor 4-MPPF  
o Fluorodenitration reaction using the precursor 4-MPPNO2  
The purpose of the project was to produce 4-[18F]MPPF which was suitable for 
PET and ex vivo autoradiography experiments rather than to fully optimise the 
radiochemical reaction.  Therefore only preliminary optimisation was performed 
in order to assess feasibility of the synthesis route for PET ligand production. 
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3.2 Methods 
 
3.2.1 Materials and general methods 
All solvents were commercially available HPLC grade (Fisher Scientific, UK) 
and used without any further purification unless otherwise stated.  DMSO was 
passed through an Al2O3 SPE cartridge (Waters Sep-Pak Light Accell Plus, 
Waters, Ireland) dried on molecular sieves (24 h 4 Å molecular sieves, 24 h 3 Å 
molecular sieves) and kept under positive nitrogen flow.  Fluorine-18 in 
[18O]H2O was purchased from Erigal (Preston, UK), Petnet Solutions 
(Nottingham, UK) or produced on the in house ABT Cyclotron (18O(p,n)18F 
reaction, 7.5 MeV, 4 µV, 310 µL 18O-water, 30-60 min).  4-MPPF and 4-
MPPNO2, were passed through an Al2O3 SPE cartridge (Waters Sep-Pak Light 
Accell Plus, Waters, Ireland). Tetraethylammonium hydrogen carbonate 
((CH3CH2)4N.HCO3) and potassium carbonate (K2CO3) were purchased from 
Sigma Aldrich (UK).  QMA anion exchange resign cartridges were used to trap 
[18F]fluoride ions (QMA: Waters Sep-Pak Light Accell Plus, Waters, Ireland.) 
Pre-condition method A: 500 mM K2CO3 (10 mL) followed by H2O (20 mL) then 
air (20 mL)) then with 5 mL solution of (CH3CH2)4N.HCO3 ((CH3CH2)4N.HCO3 
(39.73 mM) in 4.5 mL CH3CN and 0.5 mL H2O.  Method B: 50 mM NaOH (5 mL) 
followed by H2O (10 mL) then air (2 x 20 mL)).  [
18F]fluoride ions were eluted 
with a solution of (CH3CH2)4N.HCO3 (131 mM in 0.8 mL CH3CN and 50 µL 
H2O)). Radioactivity was measured using a Capintec (CRC-25PET, Southern 
Scientific Ltd, England).  
The identity and radiochemical yield (RCY) of crude product was determined 
using radio/UV high performance liquid chromatography (HPLC).  This was 
performed using an Agilent 1200 (fitted with a vacuum degasser G1379B, 
binary pump G1312A, auto-sampler G1329A, column oven G1316A, variable 
wavelength detector (λmax 276 nm) G1314B in series with a radio-detector B-
FC-4100, LabLogic, Germany and a 500 µL injection loop) with Laura software 
(LabLogic v. 4.1.3.50).  A manual switch box allowed the exit bolus to be 
directed to waste or a collection vial.  All radioactivities are quoted as 
uncorrected values. 
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3.2.2 Initial HPLC Method 
Before radiosynthesis could commence, an HPLC method had to be developed.  
A solvent system suitable for in vivo injection was required, therefore aqueous 
ethanol was chosen.  4-MPPF and 4-MPPNO2 (2.3 mM in DMF) were injected 
(10 µL) on to the HPLC fitted with an analytical column (Phenomenex Polymer 
X (G013-4326-D0), Ace 5 C18 (ACE-121-1546) or an ACE 5 phenyl column 
(ACE-125-1546), 4.6 x 100 mm) at RT.  An isocratic or gradient elution was 
used with ethanol (20 – 80%) and water (0.1% formic acid, 20 – 80%) at a flow 
rate of 0.5 – 2.5 mL/min.  The optimal separation was found using an ACE 5 
phenyl column (4.6 x 100 mm, ACE, UK) at RT eluting with ethanol : water 
(0.1% formic acid) (30:70% isocratic) at 1 mL/min. The retention time for 4-
MPPF was 14 min and 17.5 min for 4-MPPNO2 .  
This method was used for radiosynthesis experiments performed on the Advion 
NanoTek.  However, changes were made for radiosynthesis performed on the 
Eckert and Ziegler ModularLab, as described later. 
 
3.2.3 Advion NanoTek methods 
Apparatus of the Advion NanoTek Microfluidic System  
Drying of [18F]fluoride and radiosynthesis was conducted on an Advion 
NanoTek Microfluidic system (Advion, USA), which consists of a concentrator 
module (CM), base module (BM) and a reactor module (RM) controlled by the 
Advion NanoTek 1.4 software.  The CM is comprised of a low pressure six-way 
valve, reagent cartridge and vessel chamber (5 mL vial).  This module is used 
to prepare dry [18F]fluoride via several azeotropic distillations with acetonitrile 
using a combination of reduced pressure and positive nitrogen gas flow.  The 
BM consists of two reagent cartridges (P1 and P2), which comprise a high-
pressure syringe pump connected to an eight way bridge valve with a looped-
reservoir from which measured quantities of reagents are dispensed to the 
microreactor.  The RM comprises the isotope reagent cartridge (P3) connected 
to an eight-way distribution valve (DV) and has slots for up to four microreactor 
cartridges.  P3 receives [18F]Et4NF from the concentrator module (CM) and the 
distribution valve (DV) is used to route the reaction bolus to the desired location 
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(Figure 7).  The electronic injection valve (Smartline Valve Drive, Knauer, 
Germany) injects the reaction mixture into the HPLC (Reed et al., 2012). 
 
 
 
 
Figure 7: Advion Nano Tek Microfluidic System set-up (Reed et al., 2012). 
 
Production of no-carrier added [18F]fluoride using the Advion NanoTek  
No carrier added [18F]fluoride in [18O]H2O (5 mL, 2.19 – 4.23 GBq) was 
absorbed on to a QMA cartridge (Pre-condition method A) into a V-Vial,( 2 mL, 
Wheaton)).  The solution was dried by two successive azeotropic evaporations 
with CH3CN (450 µL, 100⁰C) under a positive nitrogen flow.  The dry 
[18F](CH3CH2)4N.F was dissolved in DMSO (1 mL) and loaded on to the Advion 
NanoTek storage loop (P3) (Reed et al., 2012). 
 
Radiofluorination of 4-MPPF and 4-MPPNO2 using the Advion Nanotek 
Several reaction runs were performed to prime the system and check all 
equipment was functioning prior to performing experimental runs.  Dry 
[18F]Et4NF (2.19 – 4.23 GBq, 1 mL DMSO, from P3) and precursor solutions (4-
MPPF 22.56 – 58.04 mM in DMSO or 4-MPPNO2 ), 20.82 – 23.43 mM in 
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DMSO, from P1) were loaded on to storage loops 3 and 1 respectively and 
capillary lines, running from pumps 1 & 3 to the microreactor, were primed with 
reagent.  A range of volumes of dry [18F]fluoride (10 - 180 µL) and precursor (10 
– 180 µL) were simultaneously injected into the pre-heated microreactor (4 or 8 
m, 110 – 200 ⁰C) at a range of flow rates (5 – 50 µL/min).  After passage 
through the reactor the crude reaction mixture was swept into the electronic 
injection valve for injection onto a radio/UV HPLC (10 µL).  Identity of the 
product was confirmed by comparing the elution time of the UV HPLC peak to a 
known standard.  The RCY was calculated by integration of the product 
associated radio HPLC peak and taken as a percentage of the total integrated 
area under the radio-curve.  The base module (BM), reactor module (RM), 
microreactor and transfer lines were flushed with DMSO and the concentrator 
module (CM) with acetonitrile at the start and end of each experiment series. 
The Advion Nanotek has a maximum temperature setting of 200 ⁰C so all 
reactions were carried out at or below this temperature. 
 
3.2.4 Eckert and Ziegler ModularLab methods 
Apparatus of Eckert and Ziegler ModularLab and microwave reactor 
Drying of [18F]fluoride and radiosynthesis was conducted on an Eckert and 
Ziegler Modular Lab (Eurotope GmbH, Germany), which consists of four 
solenoid valve modules (SVM), a stopcock manifold module (SMM), activity 
detectors, a Peltier-reactor module (PRM, temperature range -40 ⁰C – 150 ⁰C)) 
with camera (Vrmagic USB camera development kit 3.9a msi) and pneumatic lift 
(0-58 mm), heat exchanger (HE-006, temperature range -10 ⁰C – 40 ⁰C) and 
electrical cabinet (EC-0084), controlled by the Modular-Lab4 software (Rev. 
04\02.2007, Eurotope GmbH).  The apparatus were connected for the 
production of no-carrier added [18F]Et4NF (Figure 9) with the dry [
18F]Et4NF in 
DMSO passing into a microwave reactor (Resonance Instruments Inc., USA, 
Model 521-I with IR thermometer, 39667-10, Cole Parmer.  The apparatus was 
also connected for C-18 Sep-Pak SPE cartridge formulation (Waters, Ireland, 
pre-conditioned with 10 mL water followed by 5 mL ethanol) (Figure 9)  
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Figure 8: Eckert and Ziegler Modular Lab set-up for [
18
F]fluoride drying and radiosynthesis. 
  
Figure 9: Eckert and Ziegler Modular Lab set-up for C-18 Sep-Pak SPE cartridge 
formulation  
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Production of no-carrier added [18F]fluoride using the Eckert and Ziegler 
Modular Lab 
No carrier added [18F]fluoride in [18O]H2O (0.3-5 mL, 1.48 – 5.61 MBq) was 
absorbed on to a QMA cartridge (precondition: method B) into a V-Vial (5 mL) in 
the RM.  The resulting solution of [18F](CH3CH2)4N.F was dried by azeotropic 
evaporations (110⁰C and 90⁰C) under reduced pressure and positive nitrogen 
gas flow. 
 
Radiofluorination of 4-[18F]MPPNO2 using the Eckert and Ziegler Modular 
Lab and microwave reactor 
To improve reaction yields, the following parameters were varied; reaction 
solvent (DMF and DMSO, 0.45 – 1.0 mL), microwave settings (time (100 – 200 
s), power (50 – 100 W), temperature (120 – 180 ⁰C)) and repeat microwave 
heating (2 – 6 repeats). In addition free fluoride ions were extracted from the 
precursor by passing through an Al2O3 SPE cartridge.  This resulted in the 
following method; DMSO (0.45 mL) was added to the dry [18F](CH3CH2)4N.F in 
the Peltier-reactor module, stirred, then transferred to a vented reaction vial (5 
mL, Wheaton) containing the precursor (4-MPPNO2, 4.5 - 7.2 mg) in the 
microwave reactor.  The solution was heated (2 x 100 s/100 W/ 175⁰C, 2 x 100 
s/70 W/ 175⁰C) under stirring, then manually injected onto the radio/UV HPLC. 
 
3.2.5 UV/radio-HPLC alternative method for scaled up reaction 
A change in the HPLC method was required for the production of 4-[18F]MPPF 
on the Eckert and Ziegler ModularLab as the experiment was scaled up in order 
to produce sufficient radioactivity for in vivo work.  A change in solvent system 
improved separation of the precursor from the product.  
UV/radio HPLC was used to separate the radiolabelled product from the crude 
reaction mixture and to measure RCY. The HPLC used an ACE 5 phenyl 
column (4.6 x 100 mm, ACE, UK) at RT and eluted with (THF/MeOH (40:60)) : 
0.05M NaOAC (aq.) 45:55) (Koivula et al., 2010), at 4 mL/min. The retention 
time for 4-[18F]MPPF was 11 min and 13.5 min for 4-MPPNO2. 
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3.2.6 C-18 Sep-Pak SPE cartridge formulation  
The Eckert and Ziegler ModularLab (Eurotope GmbH, Germany) was set-up for 
product formulation (Figure 9) and was controlled manually from the PC.  4-
[18F]MPPF collected from the HPLC in mobile phase was diluted 1:2 in water 
and loaded onto a C-18 Sep-Pak light cartridge (Vandecapelle et al., 2004). The 
cartridge was washed with water (10 mL) and the product eluted in ethanol (0.5 
mL). 
 
3.2.7 Radio-TLC  
The identity and radio-purity of formulated product was determined by radio thin 
layer chromatography (TLC). TLC was performed using silica gel plates with 
aluminium backing (Kieselgel 60F254 , 0.2 mm ) and CH3CN:H2O (90:10) mobile 
phase.  Radio-purity was determined using a LabLogic imaging scanner (AR-
2000 with Laura software version 4.0.1.5.0, LabLogic, UK) and the identity was 
confirmed by comparison of a standard Rf value for 4-MPPF.  
 
3.2.8 4-MPPF UV HPLC calibration curve  
To create a UV HPLC standard calibration graph for the UV absorption of 4-
MPPF, ten standard solutions of 4-MPPF in DMSO (0.24 - 480 nmol, Pipet-Lite 
XLS, Rainin Instrument, LLC, USA) were prepared by serial dilution, except for 
0.0092 µmol and 0.00483 µmol solutions of 4-MPPF which were prepared 
separately. The solutions were injected on to the HPLC (20 µL injection, Agilent 
1200 HPLC, ACE 5 phenyl column (ACE, UK, 150 x 10 mm), mobile phase: 
(THF:Methanol 40:60):0.05 M NaOAc (aq) (45:55 isocratic) eluting at 4 mL/min).  
Each solution was run through the HPLC three times.  The area under the UV 
peak (mAU) was measured and the mean was taken for each data point.  The 
UV absoption was plotted against the number of moles (µmol) and the intercept 
set to (0,0).  Linear regression resulted in the equation; Y = 133852x, R2 = 
0.9999.   
.   
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Figure 10: 4-MPPF calibration curve, with linear regression. Values are mean ±sem. 
 
4-MPPF 
conc. 
(µmol) 
HPLC UV 
absorption 
Sample 1 
(mAU) 
HPLC UV 
absorption 
Sample 2 
(mAU) 
HPLC UV 
absorption 
Sample 3 
(mAU) 
mean n Std Dev sem 
0.48 63452.5 64993.2 64014.8 64153.5 3 779.7 450.1 
0.23 31116.1 30986.1 30878.1 30993.4 3 119.2 68.8 
0.13 17413.5 17215.2 17211.1 17279.9 3 115.7 66.8 
0.0483 6664.7 6767.2 6747.6 6726.5 3 54.4 31.4 
0.0242 3323.2 3378.5 3364.6 3355.4 3 28.8 16.6 
0.0092 1294.6 932.9 919.3 1048.9 3 212.9 122.9 
0.0048
3 
256.9 687.1 684.3 542.8 3 247.6 142.9 
0.0024
2 
535.8 547.1 545.4 542.8 3 6.1 3.5 
0.0004
83 
69.3 70.2 66.5 68.7 3 1.9 1.1 
0.0002
42 
42.0 41.7 42.4 42.0 3 0.4 0.2 
 
Table 6: 4-MPPF UV HPLC calibration curve data 
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3.2.9 Measurement of specific activity of 4-[18F]MPPF 
The 4-MPPF calibration graph was used to convert the UV absorption (mAU), 
as measured from integrating the UV HPLC peak of the collected product, to 
µmoles of 4-[18F]MPPF.  The activity of the product was also taken at time of 
collection, so in combination with the number of moles, the specific activity 
(GBq/µmol) of the product was calculated. 
3.2.10 Data analysis 
Two tailed bivariate Pearson’s correlation analysis was performed to determine 
any relationship between the initial activity of the [18F]fluoride used in the 
radiosynthesis, on the final activity, RCY and specific activity of the 4-[18F]MPPF 
produced.   
 
3.3 Results 
3.3.1 Advion NanoTek radiosynthesis  
Reaction optimisation 
In total 120 radiofluoronation reactions were carried out on the Advion NanoTek 
microfluidic system, of which 94 were isotopic exchange reactions (Scheme 2) 
and 26 were fluorodenitration reactions (Scheme 1).  Factors varied during 
optimisation were; precursor concentration (mg/mL), reaction temperature (⁰C), 
reactor length (m), stoichiometry (precursor: radioisotope) and flow rate 
(µL/min). 
The RCY of 4-[18F]MPPF was calculated from the radio HPLC trace (Figure 11). 
Mean RCY were calculated only from reactions that produced radiolabelled 
product and excluded those which did not result in a measurable yield. 
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Figure 11: Example of radio (left) and UV (right) HPLC trace from Advion NanoTek 
radiosynthesis of 4-[
18
F]MPPF.  Separation of product and precursor can be seen on the UV 
trace.  EtOH: water (0.1 % formic acid) 30:70% solvent system with Ace-5 phenyl column 
(4.6 x 100 mm), RT. 
 
Isotopic exchange reactions: 
44 of 94 isotopic exchange reactions produced 4-[18F]MPPF, with a mean RCY 
of 10.4 ±1.1% (range; 2.1 - 36.8%) (Appendix B). 
 
Effect of precursor concentration 
For each reaction condition (Table 7, No. 1 – 4) it was found the precursor 
concentration had no direct effect on the RCY. 
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No. 
Precursor 
(mg) 
Mean 
RCY 
n sem 
Reactor 
Length 
(m) 
Flow 
rate 
(µL/min) 
Stoichiometry 
Reactor 
Temperature 
(⁰C) 
1 
18 0.0 6 0.0 4 5 1 190 
20 19.2 8 2.9 4 5 1 190 
21 2.5 2 0.4 4 5 1 190 
         
2 
18 14.9 5 1.4 8 5 1 190 
25 7.4 3 0.6 8 5 1 190 
         
3 
21 5.1 2 0.6 8 10 1 190 
23 4.6 3 0.5 8 10 1 190 
         
4 
10 0.0 3 0.0 8 30 1 190 
23 3.8 2 0.2 8 30 1 190 
25 11.3 2 0.9 8 30 1 190 
 
Table 7: Reaction conditions for isotopic exchange reactions in the Advion NenoTek 
  
 
Effect of reaction temperature 
For each reaction condition (Table 8, No. 1 – 2) it was found product was 
produced at 190 ⁰C but surprisingly not 200 ⁰C. 
No. 
Reactor 
Temperature 
(⁰C) 
Mean 
RCY 
n sem 
Precursor 
(mg) 
Reactor 
Length 
(m) 
Flow 
rate 
(µL/min) 
Stoich-
iometry 
1 
190 15.9 10 3.2 18-21 4 5 1 
200 0.0 3 0.0 18-21 4 5 1 
         
2 
190 12.1 8 1.6 18-21 8 5 1 
200 0.0 2 0.0 18-22 8 5 1 
Table 8: Reaction conditions for isotopic exchange reactions in the Advion NenoTek 
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Effect of reactor length 
At the reaction conditions shown in Table 9 it was found the reactor length had 
no directional effect on the RCY. 
No. 
Reactor 
Length 
(m) 
Mean 
RCY 
n sem 
Precursor 
(mg) 
Flow 
rate 
(µL/min) 
Stoich-
iometry 
Reactor 
Temperature 
(⁰C) 
1 
 
4 15.9 10 3.18 18-25 5 1 190 
8 12.1 8 1.63 18-25 5 1 190 
Table 9: Reaction conditions for isotopic exchange reactions in the Advion NenoTek 
 
 
Effect of stoichiometry 
At the reaction conditions shown in Table 10 it was found the stoichiometry 
had no directional effect on the RCY. 
No. Stoichiometry 
Mean 
RCY 
n sem 
Precursor 
(mg) 
Reactor 
Length 
(m) 
Flow 
rate 
(µL/min) 
Reactor 
Temperature 
(⁰C) 
1 
 
0.5 11.1 5 1.0 18-25 8 5 190 
1 12.1 8 1.6 18-25 8 5 190 
Table 10: Reaction conditions for isotopic exchange reactions in the Advion NenoTek 
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Effect of flow rate 
For each reaction condition (Table 11, No. 1 - 2) it was found a lower flow rate 
produced the highest RCY (Figure 12). 
Effect of flow rate on RCY for isotopic exchange reactions performed in the Advion NanoTek
Flow rate (uL/ml)
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Figure 12: Mean RCY for isotopic exchange reactions performed in the Advion NanoTek at 
a range of flow rates (µL/min). Values are mean ±sem, n = 8 (5 µL/min), n = 5 (10 µL/min), 
n = 3 (15 µL/min), n = 4 (20 µL/min), n = 3 (25 µL/min), n = 4 (30 µL/min). Reaction 
conditions No. 2 from Table 9. 
 
No. 
Flow rate 
(µL/min) 
Mean 
RCY 
n sem 
Precursor 
(mg) 
Reactor 
Length 
(m) 
Stoich 
iometry 
Reactor 
Temperature 
(⁰C) 
1 
5 15.9 10 3.2 18-25 4 1 190 
10 21.2 1 NA 18-25 4 1 190 
30 0.0 6 0.0 18-25 4 1 190 
         
2 
5 12.1 8 1.6 18-25 8 1 190 
10 4.8 5 0.4 18-25 8 1 190 
15 4.8 3 0.4 18-25 8 1 190 
20 8.2 4 2.9 18-25 8 1 190 
25 4.2 3 0.1 18-25 8 1 190 
30 7.5 4 2.2 18-25 8 1 190 
Table 11: Reaction conditions for isotopic exchange reactions in the Advion NanoTek 
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Fluorodenitration reactions: 
9 of 26 fluorodenitration reactions produced 4-[18F]MPPF, with a mean RCY of 
14.6 ±3.1% (range; 5.0 – 31.0%) (Appendix C). 
 
Effect of precursor concentration 
All reactions were performed using 10 mg/mL 4-MPPNO2 precursor, therefore 
the effect of precursor concentration could not be examined. 
 
Effect of reaction temperature 
At the reaction conditions shown in Table 12 it was found increasing the 
reaction temperature from 170 to 200 ⁰C increased the RCY from 8.4 to 25.6% 
(Figure 13). 
 
Effect of reaction temperature on RCY for fluorodenitration reactions performed in the Advion NanoTek
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Figure 13: Mean RCY for fluorodenitration reactions performed in the Avion NanoTek at a 
range of reaction temperatures (⁰C). Values are mean ±sem, n = 1 (170 ⁰C), n = 5 (190 ⁰C), 
n = 3 (200 ⁰C). 
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No. 
Reactor 
Temperature 
(⁰C) 
Mean 
RCY 
n sem 
Precursor 
(mg) 
Reactor 
Length 
(m) 
Flow 
rate 
(µL/min) 
Stoich- 
iometry 
1 
170 8.4 1 0.0 10 8 5 1 
190 9.3 5 2.2 10 8 5 1 
200 25.6 3 2.9 10 8 5 1 
Table 12:Reaction conditions for fluorodenitration reactions in the Advion NanoTek 
 
Effect of reactor length 
Insufficient data was collected to make a direct comparison of the effect of 
reactor length on the productions of radiolabeled product.  However it should be 
noted that 4-[18F]MPPF was only produced using a fluorodenitration reaction 
using an 8 m reactor. 
 
Effect of stoichiometry 
Insufficient data was collected to make a direct comparison of the effect of 
stoichiometry on the production of radiolabeled product. 
 
Effect of flow rate 
At the reaction conditions shown in Table 13 it was found only a flow rate of 5 
µL/min gave product. 
No. 
Flow rate 
(µL/min) 
Mean 
RCY 
n sem 
Precursor 
(mg) 
Reactor 
Length 
(m) 
Stoic-
hiometry 
Reactor 
Temperature 
(⁰C) 
1 
 
5.0 9.3 5 2.2 10.0 8 1 190 
30.0 0.0 5 0.0 10.0 8 1 190 
Table 13: Reaction conditions for fluorodenitration reactions in the Advion NanoTek 
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3.3.2 Eckert and Ziegler ModularLab radiosynthesis  
 
Reaction optimisation  
Initially the fluorodenitration reaction using the Eckert and Ziegler ModularLab 
produced low RCY’s, so a number of steps were taken to improve the RCY of 
the crude product produced by microwave heating in the ModularLab. 
Firstly the reaction solvent was changed from DMF to DMSO to allow higher 
reaction temperatures (DMF b.p. = 153⁰C, DMSO b.p. = 189⁰C).  An Al2O3 SPE 
cartridge was used to remove possible fluoride ion contamination from the 
precursor (4-MPPNO2) and reaction solvent (DMSO), which could reduce the 
specific activity of the product.  Lastly the microwave settings (temperature, 
power, time) were investigated to produce a sufficiently high RCY in the 
shortest time.  In addition, reaction solvent volume was reduced from 1.0 mL to 
0.5 mL to reduce HPLC load time. 
RCY increased from a mean of 4.7 ±0.2% (3.7 – 5.5%, n=10) under initial 
conditions to a mean of 33.5 ±3.0% (0.8 - 59.5%, n = 36) under optimised 
conditions (Appendix D) 
 
Effect of repeating microwave heating  
At the reaction conditions shown in Table 14 it was found repetitive microwave 
heating increased the RCY from 5.9 to 21.3% (Figure 14). 
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Effect of repeating microwave heating on RCY for fluorodenitration reactions
 performed on the Eckert and Ziegler Modular Lab
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Figure 14: Mean RCY for fluorodenitration reactions performed on the Eckert and Ziegler 
Modular Lab with repeat microwave heating. Values are mean ±sem, n = 1 (No. 1), n = 3 
(No. 2), n = 3 (No. 3). 
 
No. 
Mean 
RCY 
n sem 
Solvent 
Volume 
(mL) 
Microwave 
settings; Time 
(s) 
Microwave 
settings; 
Power (W) 
Microwave 
settings; 
Temperature 
(⁰C) 
1 5.9 1 NA 0.5 100 70 165 
2 14.8 3 3.6 0.5 100,100 70,100 165, 165 
3 21.3 3 4.0 0.5 
100, 100, 100, 
100, 100, 100 
70,70,70,100, 
100,100 
165, 165, 
165, 165, 
165, 165 
Table 14: Reaction conditions for fluorodenitration reactions on the Eckert and Ziegler 
ModularLab 
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Effect of increasing microwave reactor temperature and reducing heating 
repetition 
At the reaction conditions shown in Table 15 it was found increasing the 
reaction temperature from 165 ⁰C to 175 ⁰C and reducing microwave heating 
repetitions, increased the RCY from 21.3 to 33.5%. 
No. 
Mean 
RCY 
n sem 
Solvent 
Volume (mL) 
Microwave 
settings; 
Time (s) 
Microwave 
settings; 
Power (W) 
Microwave 
settings; 
Temperature 
(⁰C) 
4 21.3 3 4.0 0.5 
100, 100, 
100, 100, 
100, 100 
70, 70, 70, 
100, 100, 
100 
165, 165, 
165, 165, 
165, 165 
5 22.3 3 1.8 0.5 
100, 100, 
100, 100 
100, 100, 
70, 70 
175, 175, 
170, 170 
6 33.5 36 3.0 0.5 
100, 100, 
100, 100 
100, 100, 
70, 70 
175, 175, 
175, 175 
Table 15: Reaction conditions for fluorodenitration reactions on the Eckert and Ziegler 
ModularLab 
 
 
UV HPLC and volume optimisation/C-18 Sep-Pak SPE cartridge 
formulation 
Initially the HPLC mobile phase (EtOH and H2O (0.1% formic acid)) was chosen 
so that it was suitable for in vivo injection. Working initially at small scale (150 x 
4.6 mm analytical column, 20 µL injection crude reaction mixture) this solvent 
system adequately separated 4-[18F]MPPF from the precursor 4-MPPNO2 
(Figure 11).  However, to produce sufficient activity for in vivo PET scanning 
and ex vivo autoradiography a 500 µL injection volume was necessary, 
therefore a semi-preparative HPLC column was used (150 x 10 mm column, 
500 µL injection volume, 4 mL/min).  However, at the larger scale there was 
poor HPLC separation of the product and precursor (Figure 15).  Secondly the 
product eluted in a large volume of mobile phase (~20 mL), so that the volume 
to activity ratio was too low to be used in vivo.  
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To address these issues the solvent system, recommended by the published 
study examining the separation of 4-[18F]MPPF from 4-MPPNO2 , greatly 
improved the separation of the product and precursor (45% THF/MeOH (40:60), 
55% 0.05M NaOAC (aq)) (Koivula et al., 2010), (Figures 16 and 17), allowing 
collection of product from the HPLC without precursor contamination.  Secondly 
a protocol for solid phase extraction (SPE) was developed based on a 
published method (Vandecapelle et al., 2004), to remove the toxic HPLC 
solvents and elute 4-[18F]MPPF in a small volume of non-toxic solvent. The 
formulated product was eluted in ethanol giving a final volume of 0.3 mL.  The 
formulated product was further analysed by HPLC and Radio-TLC (Figures 18 
and 19). 
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Figure 15: Example UV HPLC trace of 4-[
18
F]MPPF and 4-MPPNO2 eluting using EtOH: 
water (0.1 % formic acid) 30:70% solvent system with Ace-5 phenyl column (150 x 10 mm), 
RT, 500 µL injection volume.  No separation between product and precursor can be seen. 
 
 
Figure 16: Example UV HPLC trace of 4-[18F]MPPF and 4-MPPNO2 eluting using 
THF/MeOH (40:60):  0.05M NaOAC (aq) 45 : 55), Ace-5 phenyl column (150 x 10 
mm), RT, 20 µL injection volume . 
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Figure 17: Example radio (top) and UV (bottom) HPLC traces of 4-[18F]MPPF and 
4-MPPNO2 in crude reaction mixture eluting using THF/MeOH (40:60):  0.05M 
NaOAC (aq) 45 : 55), Ace-5 phenyl column (150 x 10 mm), RT, 500 µL injection 
volume . It can be seen that 4-[18F]MPPF has eluted (radiotrace) when 4-MPPNO2 
starts to elute (UV trace) 
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Figure 18: Example of radioTLC for formulated 4-[
18
F]MPPF showing 100% radiopurity with 
an Rf of 0.356. 
 
 
Figure 19: Example of UV and radio HPLC of formulated 4-[
18
F]MPPF THF/MeOH (40:60):  
0.05M NaOAC (aq) 45 : 55), Ace-5 phenyl column (150 x 10 mm), RT, 20 µL injection 
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Production of PET ligand for in vivo PET scanning and ex vivo 
autoradiography 
Radiosynthesis on the Eckert and Ziegler ModularLab produced 4-[18F]MPPF 
for PET scanning or ex vivo autoradiography with a final radioactivity of 5.2 to 
251.0 MBq (mean radioactivity 84.5 ±12.1 MBq, n = 36) in ethanol (0.3 mL), 
with a total synthesis time of 60 min.  RCY’s were between 0.8 - 59.5% (mean 
RCY 33.5 ±3.0%, n = 36).  Radiopurities were between 72.4 and 100.0%, 
(mean radiopurity 95.8 ±1.3%, n = 28. One data point (3/7/13) with a radiopurity 
of 56.2% was excluded from final analysis.  Specific activities were between 0.1 
– 17.8 GBq/µmol (mean spec. ac. 4.3 ±0.7 GBq/µmol, n = 35). Using the 4-
MPPF HPLC calibration curve (section 3.2.8), the following equation was used 
to calculate the specific activity (GBq/µmol); 
4-[18F]MPPF HPLC UV absorption (mAU) = µmol x 133852   
 
Analysis of 4-[18F]MPPF analytical data 
 
Correlation between the initial activity of the fluorine-18 and the specific activity 
of 4-[18F]MPPF 
A Pearson’s correlation coefficient was calculated to reveal there was a 
significant correlation between the initial activity of the fluorine-18 and the 
specific activity (GBq/µmol) of the 4-[18F]MPPF produced; r =0.51,  p =0.002, 
n=35 (Figure 20). 
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Effect of fluorine-18 activity on specific activity of 4-[
18
F]MPPF
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Figure 20: Effect of fluorine-18 activity on 4-[
18
F]MPPF specific activity (GBq/µmol).  Values 
are plotted with a linear regression best fit curve, n = 35.* p < 0.05. 
 
Correlation between 4-[18F]MPPF radiochemical yield and specific activity 
A Pearson’s correlation coefficient was calculated to reveal there was a 
significant correlation between the RCY and specific activity (GBq/µmol) of the 
4-[18F]MPPF  produced; r = 0.57, p = <0.01, n=35 (Figure 21). 
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Corrolation between 4-[
18
F]MPPF specific activity and RCY
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Figure 21: Correlation between 4-[
18
F]MPPF RCY and specific activity(GBq/µmol).  Values 
are plotted with a linear regression best fit curve, n = 35.* p < 0.01. 
 
3.4 Discussion  
 
3.4.1 Advion NanoTek summary 
Initial radiosynthesis to produce 4-[18F]MPPF was performed on the Advion 
NanoTek microfluidic reactor as this provided an advantage over a traditional 
batch process equipment, such as the Eckert and Ziegler ModularLab.  The 
Advion NanoTek can perform multiple reactions using a single batch of 
radioisotope and precursor, allowing for rapid reaction assessment and 
optimisation (Chun et al., 2010).  In addition, the Advion NanoTek has an 
integrated HPLC system allowing radiosynthesis, product identification, 
determination of RCY and isolation of product to be completed on one piece of 
kit without handling.   
Two reaction routes were available for investigation; 19F/[18F] isotopic exchange 
(Scheme 2) and NO2/[
18F] nucleophilic aromatic substitution in the form of a 
fluorodenitration reaction (Scheme 1).  As a comprehensive optimisation study 
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was not performed it was not possible to definitively compare the effect of each 
variable.  However some trends were observed. 
Overall, for isotopic exchange reactions, the RCY’s were low (maximum mean 
RCY=19.2%) and the production of 4-[18F]MPPF was inconsistent, often failing 
to produce any product at conditions that had previously been successful.  
However, it appeared a lower flow rate (5-10 µL/min) combined with the longer 
reactor length (8 m), gave the most consistent results.  As a precursor 
concentration of 10 mg/mL did not produce any 4-[18F]MPPF at any condition it 
may be that this reaction requires a higher concentration.  However, there did 
not appear to be any benefit to concentrations greater than 18 mg/mL.   
Reaction stoichiometry did not appear to affect the RCY and insufficient data 
was collected to reveal a trend in the effect of temperature. 
Fluorodenitration reactions also produced low RCY’s (maximum mean 
RCY=25.6%).  However the production of 4-[18F]MPPF was more consistent 
than isotopic exchange reactions within a given set of variables, with the 
reaction favouring a low flow rate (5 µL/min) and high temperature (200 ⁰C).  
Insufficient data was collected to comment on the effect of other variables. 
Typically nucleophilic aromatic substitution reactions require a high temperature 
and relatively long reaction time.  Due to the design of the NanoTek the 
maximum reaction time (~13 min) and maximum temperature (200°C) was not 
sufficient to produce the RCY’s required using a fluorodenitration reaction.  To 
make production of 4-[18F]MPPF on the NanoTek viable for use as a PET 
ligand, it would require one or both of these variables to be exceeded. 
 
3.4.2 Eckert and Ziegler ModularLab summary 
The ModularLab is a batch process platform. Therefore, only one radiosynthesis 
reaction can be performed per batch of radioisotope, so method development 
required considerable time.  Reliable radiosynthesis of 4-[18F]MPPF was quickly 
achieved using a combination of the ModularLab and microwave heating via a 
fluorodenitration reaction.  However, in order to make 4-[18F]MPPF batches 
suitable for use in vivo, there was a need to increase the activity and reduce the 
final solvent volume.  Therefore preliminary optimisation of the reaction 
conditions was undertaken, which greatly improved radiochemical yields.  In 
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addition, the HPLC method was altered (Koivula et al., 2010) to accommodate 
the greater volume of crude reaction mixture injected onto the HPLC in the latter 
ModularLab experiments.  Following this, an SPE cartridge (Vandecapelle et al., 
2004) was employed to remove toxic solvents used in HPLC separation and 
elute the product into a small volume of solvent.  This resulted in a reliable 
method to produce batches of 4-[18F]MPPF suitable for use in pre-clinical PET 
scanning and autoradiography.  The 4-[18F]MPPF produced for PET and 
autoradiography studies had a mean RCY of 33.5 ± 3.0 %, a mean radioactivity 
of 84.5 ± 12.1 MBq, a mean radio-purity of 95.8 ±1.3%, with a total synthesis 
time of 60 minutes.  This is an improvement on the standard procedure set out 
by Bars et al.(Bars et al., 1998) which had an RCY of 25% and a synthesis time 
of 70 minutes.  However, the mean specific activity of 4.3 ±0.7 GBq/µmol, is 
below that reported in the literature for 4-[18F]MPPF  PET studies, which report 
30 – 185 GBq/µmol (Bars et al., 1998, Aznavour, 2009, Bartmann et al., 2010, 
Moulin-Sallanon et al., 2009).  A significant correlation was found between the 
initial fluoride activity and 4-[18F]MPPF specific activity.  Therefore future 
productions would benefit from higher [18F]fluoride activity.  However, the 
fluorine-18 activity is limited due to either off site delivery time or the 
specifications of the on site cyclotron, so to get a higher starting activity would 
require a higher powered on site cyclotron. 
 
3.5 Conclusion 
In summary, it has been shown that, given the constraints of a maximum 
temperature (200⁰C) and available reactor length (8 m) a 4-[18F]MPPF PET 
ligand cannot be reliably produced on the Advion NanoTek using either an 
19F/[18F] isotopic exchange or an NO2/[
18F] nucleophilic aromatic substitution. 
It has also been shown for the first time (to my knowledge) that a 4-[18F]MPPF 
PET ligand, for use in pre-clinical PET and autoradiography, can be reliably 
produced using a combination of the Eckert and Ziegler ModularLab and a 
Resonance Instruments microwave reactor via a nucleophilic substitution 
reaction, starting with a low activity.
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Chapter 4. Microdialysis 
 
4.1 Introduction 
Microdialysis is a technique that can be used to sample extracellular fluid in the 
brain, giving quantitative data on neurotransmitters.  It is performed by inserting 
a probe into the brain area of interest in order to collect a representative sample 
of the extracellular fluid.  This relies on diffusion of the extracellular fluid across 
the semi-permeable dialysis membrane, located at the end of the probe, into the 
perfusion medium (aCSF) passing through the probe’s internal void.  The 
perfusion medium, containing the diffused extracellular fluid, passes to a 
collection vessel for analysis.  This is the dialysate sample (Chefer et al., 2009, 
Sharp and Hjorth, 1990).   
Microdialysis has a number of advantages over other methods of measuring 5-
HT in vivo such as voltammetry, as well as perfusion techniques such as the 
cortical cup.  The advantages include factors such as, the perfusion medium is 
not directly exposed to the brain tissue, the microdialysis probes are relatively 
small and the semipermeable membrane is a barrier to substances with large 
molecular weights, keeping the dialysate relatively ‘clean’ (Stamford, 1992). 
5-HT, as measured by microdialysis, has been shown to originate from 
functioning neurons rather than other sources such as blood or damaged 
neurons.  For example, 5-HT dialysate levels have been shown to be calcium 
dependant, sensitive to pharmacological challenges and sensitive to changes in 
neuronal activity (Stamford, 1992). 
This chapter firstly describes the in vitro assessment of microdialysis probes 
and secondly in vivo experiments to quantify the concentration of 5-HT in the rat 
hippocampus, before and after administration of fenfluramine.  Fenfluramine is 
a 5-HT releasing agent which interacts with vesicular monoamine transporters 
inside the neuron to liberate the 5-HT held within.  This is then released into the 
extracellular space by reversing the serotonin transporter function and exiting 
the neuron (Jain, 2002).[ 
There is disagreement in the literature as to whether the 4-[18F]MPPF is 
displaceable by endogenous 5-HT . Furthermore, in the rat 4-[18F]MPPF has 
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been shown to be a substrate of the p-glycoprotein transporter, so blocking the 
p-glycoprotein pump (with cyclosporine) increases uptake of 4-[18F]MPPF into 
the brain (Laćan et al., 2008, Passchier et al., 2000).   
Chapter 5 describes 4-[18F]MPPF PET using both cylcosporine and the 5-HT 
releasing agent fenfluramine in the protocol.  Therefore, the aims of the present 
chapter are to use microdiaysis to determine quantitative data on the amount of 
endogenous 5-HT released by fenfluramine (with and without a pretreatment of 
cyclosporine) and ultimately determine an optimum fenfluramine challenge 
protocol to use in subsequent PET studies.   
More specifically the aims of this part of the study are to; 
 Determine the percent recovery, precision and temporal resolution of 
microdialysis probes. 
 Characterise the effect of different doses of fenfluramine on the 
extracellular levels of 5-HT in the rat brain 
 Investigate whether the p-glycoprotein pump inhibitor, cyclosporine, has 
any effect on the fenfluramine induced release of 5-HT  
 
 
4.2  Methods 
 
4.2.1 Probe construction 
Concentric microdialysis probes were constructed with a 5.0 mm dialysing 
window.  Three pieces of stainless steel tubing (Goodfellow, Cambridge, UK; 
internal diameter 0.38 mm, external diameter 0.5 mm) were cut to size to make 
the Y-shaped frame.  Two lengths of silica glass tubing (SGE Ltd, Milton 
Keynes, UK; outer diameter 170 µm) were passed through one piece of 
stainless steel tubing (19 mm) with a length of stainless steel (9 mm) placed on 
the end of each glass tube.  One silica glass tube was retracted (~ 10 mm) into 
the stainless steel tubing and the three stainless steel tubes were fixed with 
epoxy resin (Araldite, Simid Ltd., UK) at their intersection.  The silica glass 
tubing still extending from the bottom of the Y-shaped frame was cut (4 mm) 
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and dialysing membrane (polyacrylonitrile/ sodium methyl sulphonate co-
polymer, internal diameter 0.22 mm, external diameter 0.31 mm, 20 kDA 
molecular weight cut off, AN 69, Hospal, Bologna, Italy) was placed over it and 
pushed inside the stainless steel tubing.  The dialysing membrane was trimmed 
to extend past the silica glass tube by ~1 mm.  Epoxy resin was then introduced 
to the end of the dialysing membrane and to the intersection with the stainless 
steel tube producing a dialysing window of 4.5 mm.  The probes were made in 
batches of 4 – 6 and stored in cool, dry area (Figure 22). 
 
Figure 22: Microdialysis probe construction 
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4.2.2 Artificial cerebrospinal fluid (aCSF) preparation 
aCSF was used as the probe perfusion medium during the microdialysis 
procedure.  A stock solution (minus CaCl2 or glucose) was prepared at the start 
of the study and refrigerated (4⁰C), with CaCl2 and glucose being added to the 
experimental quantity of aCSF on the day of an experiment.   
 
aCSF composition; 
140 mM NaCl  
3.0 mM KCl 
0.96 mM Na2HPO4 
0.24 mM NaH2PO4 
1.0 mM MgCl2 
2.4 mM CaCl2.6H20 
7.2 mM C6H12O6 (D-(+)-glucose)  
 
4.2.3 In vitro microdialysis probe set up 
A microcentrifuge tube (0.2 mL, TreffLab, Switzerland) was placed in a heated 
tube holder (37 ⁰C, monitored with thermometer in adjacent cell.) and three 
quarters filled with aCSF.  Using a stereotaxic frame, a microdialysis probe was 
suspended in the centre of the microcentrifuge tube so that the dialysate 
window was fully submerged in the solution (Figure 23). 
aCSF was perfused through the microdialysis probe (2.3 µL/min; Harvard PHD 
2000 infusion pump, Harvard Apparatus LtD, UK) for 20 min, then the probe 
was transferred to an adjacent microdialysis tube containing the lowest 
standard 5-HT solution concentration, which had been allowed to equilibrate to 
37 ⁰C.  Dialysate samples were collected in an inverted polythene tube for 
HPLC analysis (one per 20 minutes (50 µL dialysate) for 60 min).  Once 
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samples for one concentration of 5-HT were collected, the microdialysis probe 
was quickly moved to an adjacent tube containing a higher concentration.  Once 
all samples were collected the probe was submerged and rinsed out in distilled 
water for storage. 
 
 
Figure 23: Schematic of in vitro microdialysis set- up 
 
 
4.2.4 High Performance Liquid Chromatography (HPLC) assay 
Dialysate samples were analysed for 5-HT concentration using high 
performance liquid chromatography (HPLC) with an electrochemical detection 
cell. 
Mobile phase (127 mM NaH2PO4.H2O, 1.2 mM, ethylenediamine tetraacetic 
acid, 74 µM 1-octane sulphonic acid) was prepared in deionised water, vacuum 
filtered (0.22 µm filter paper, Whatman, UK) and pH adjusted using 
orthophosphoric acid (pH 3.8).  MeOH was added to this solution (85 % 
NaH2PO4 buffer, 15 % MeOH) to complete the mobile phase and degassed for 
30 minutes via sonication. 
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The mobile phase was pumped through the HPLC system (1 mL/min, Gilson 
302 HPLC pump/manometric module), being oxidised on a guard cell (ESA 
model 5020, 350 mV) to remove any electroactive impurities. 
Dialysates (50 µL) were loaded using a manual injection system (Rheodyne 
model 7125, USA with a 50 µL loop, Anachem Ltd, UK), passed through a 
separating column (4.6 x 100 mm Microsorb 100-3 C18 column, Varian 
analytical instruments, USA) and oxidised on a coulometric sensor comprising 
of two electrochemical cells set at 120 mV and 250 mV respectively (ESA, 
Analytical LtD, UK).  Changes in current were detected by an electrochemical 
detector (Coulochem II 5100A, ESA, Analytical Ltd, UK) and plotted on an 
integrator (Waters 746 data module).  
Dialysate 5-HT concentrations were calculated from peak height compared to a 
fresh 5-HT standard (1 x 10-9 M 5-HT in mobile phase, prepared from a stock 
solution (10 mM 5-HT in 0.1 M perchloric acid)).   
Standards of 5-HIAA and DOPAC (1 x 10-9 M 5HIAA or DOPAC in mobile 
phase, prepared from a stock solution (1 x 10-2 mM 5HIAA or DOPAC in 0.1 M 
perchloric acid)) were prepared to differentiate from the 5-HT peak.   
All standard peaks were determined at the start of the day of each experiment. 
The linear relationship between peak height and concentration for 5-HT , 5-
HIAA and DOPAC was shown using a set of standard concentrations (1 x 10-7 
M, 1 x 10-8 M, 1 x 10-9 M). 
 
4.2.5 In vitro microdialysis probe calibration  
Measurement of the external solution standard 5-HT content (fmol) vs. 
microdialysis probe dialysate 5-HT content (fmol) by HPLC assay yielded a 
calibration graph with the straight line equation Y = 0.0986X + 8.5715, R2 = 
0.5799.  However, to obtain a straight line equation to convert measured 
dialysate 5-HT concentrations to external 5- HT concentrations, the intercept 
was set to (0,0).  This resulted in the straight line equation Y = 0.1233x with R2 
= 0.5224 (Figure 24) 
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Microdialysis probe calibration curve
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Figure 24: Microdialysis probe calibration curve using linear regression with intercept 
set to (0,0). 
 
4.2.6 In vivo microdialysis surgery 
Untreated male Lister Hooded rats (Charles River UK, 265 – 322 g) were 
anaesthetised in an induction box (Harvard Apparatus Ltd, UK; 5% isofluorane, 
1.5 L/min O2) then transferred to an anaesthetic mask (3% isofluorane, 1.5 
L/min O2) and fitted in to a stereotaxic frame (David Kopf Instruments, USA; 
incisor bar set 3.3 mm below the interaural line (flat skull position)).  A 
thermostatically controlled heating blanket (Harvard Apparatus Ltd, UK) 
attached to a rectal probe maintained body temperature at ~36 °C.  Isofluorane 
was adjusted as necessary to achieve a stable breathing pattern then 
readjusted for surgery (2.5 – 3 % isofluorane, 1.5 L/min O2). 
A longitudinal incision was made in the scalp with bregma exposed and a 
trephine hole (2 mm diameter) was drilled in the skull (co-ordinates relative to 
bregma: anterior – posterior  -5.2,  medial – lateral - 4.8).  An indentation was 
drilled into the skull into which a screw was fixed (Hilco Ltd, UK; 1.2 mm 
diameter, 2.6 mm length; screw ~3 mm anterior to trephine hole) to aid 
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purchase of the later applied dental cement.  The exposed dura was pierced 
and a microdialyis probe lowered into the hippocampus using a stereotaxic 
manipulator (coordinates from bregma; anterior – posterior -5.2 mm, medio – 
lateral -4.8 mm, dorso – ventral -7.8 mm). Dental cement (Kemdent Simplex 
Rapid powder) was applied on the skull, around the probe and screw, to fix the 
probe in place. 
aCSF was perfused through the microdialysis probe (2.3 µL/min; Harvard PHD 
2000 infusion pump, Harvard Apparatus LtD, UK) and 20 minutes (46 µL) 
dialysate was collected in an inverted polythene tube for HPLC analysis. 
 
4.2.7 In vivo microdialysis probe location 
Animals were given an overdose of sodium pentobarbital i.p. at the end of each 
experiment.  The brain was removed and sectioned through the hippocampal 
region using a cryostat (30 µM sections, Microm HM500OM, Walldorf, 
Germany).  Sections were mounted on glass slides, stained (see protocol 
below) and examined under a microscope (Leica MZ6, Image J software) to 
reveal linear tissue damage caused by probe implantation. Probe placement 
location was confirmed by comparison to the Paxinos and Watson rat brain 
atlas (Paxinos and Watson, 1998). 
Cresyl violet staining protocol; 
 Submerge slides in cresyl violet aqueous solution (3.1 mM cresyl violet 
(C18H15N3O3), 43 mM AcOH, 45 mins) 
 Wash (70 % EtOH, 30 % H2O) 
 Wash (95% EtOH, 5% H2O) 
 Submerge slides in EtOH (100%, 3 mins) 
 Submerge slides in EtOH (100%, 3 mins) 
 Submerge slides in Histoclear (Histoclear, National Diagnostics, UK, 
100%, 3 mins) 
 Submerge slides in Histoclear (Histoclear, National Diagnostics, UK, 
100%, 3 mins) 
 Coverslip (Eukitt mounting medium, Sigma Aldrich, Germany, #1 
coverslips, Ultima) 
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4.2.8 In vivo microdialysis drug administration 
5-HT levels, assessed via HPLC assay of the dialysate, were allowed to 
stabilise before drug administration.   
Drugs were administered via i.p. injection.  Cyclosporine (50 mg/kg) or saline 
vehicle were injected after 5-HT stabilisation. Fenfluramine (1 or 3 mg/kg) was 
administered one hour later (Figure 26).  N.B. Five of nine experiments did not 
receive a saline vehicle injection one hour before fenfluramine administration 
(Figure 25).  Anaesthesia was maintained throughout the procedure 
(isofluorane 1.5 – 2%, O2 1.5 L/min) 
 
Samples collected every 20 min     
                          Time                                  
5-HT stabilisation      2 Hrs      
Probe implantation            fenfluramine (3 mg/kg, i.p.)      
 
Figure 25: Timeline; Nil saline vehicle 3 mg/kg fenfluramine experiments.  (Note; In these 
experiments no saline vehicle was administered before fenfluramine.  These data were 
combined with saline vehicle pretreatment/3 mg/kg fenfluramine data, as shown in Figure 
26, for data analysis)  
 
 
    Samples collected every 20 min  
            Time 
        5-HT stabilisation   1 Hr      2 Hrs    
Probe implantation       saline/cyclosporine    fenfluramine  
(50 mg/kg, i.p)         (1 or 3 mg/kg, i.p.) 
 
Figure 26: Timeline; Saline vehicle/cyclosporine pretreatment combined with 1 or 3 mg/kg 
fenfluramine experiments. 
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4.2.9 In vitro microdialysis data analysis 
The percent recovery and variability of microdialysis probes was examined by 
comparing 5-HT concentration of the standard solutions to the dialysate 5-HT 
concentration.  
To create a calibration graph for microdialysis probes the measured standard 5-
HT solution concentration (fmols/50 µL) was plotted against the measured 
dialysate concentration for every standard solution concentration (fmols/50 µL), 
probe (A – G) and day.  A trend line was plotted through the data and the 
intercept set to (0,0) to give a straight line equation. 
For all other analysis the external 5-HT solution concentrations were corrected 
so that all data were equal at each concentration (50, 100, 200 or 400 fmol/50 
µL).  The dialysate concentrations were corrected by the same factor.  Only the 
last of three dialysate sample 5-HT concentrations per experiment was used in 
data analysis, so that the concentration nearest equilibrium was used.   
 
4.2.10 In vivo microdialysis data analysis 
The effect of fenfluramine on 5-HT release in the hippocampus was examined 
using 5-HT dialysate content, percentage and absolute change in 5-HT content 
after drug administration. 
To examine the effect of cyclosporine on fenfluramine induced 5-HT release in 
the hippocampus a two-way repeated measures ANOVA was performed.  Nil 
cyclosporine data excluding a vehicle was combined with nil cyclosporine data 
including the saline vehicle. 
The effect of 1mg/kg vs. 3mg/kg fenfluramine induced release of 5-HT in the 
hippocampus with 50 mg/kg cyclosporine pre-treatment was examined by 
performing a two-way repeated measures ANOVA. 
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4.3  Results 
 
4.3.1 Microdialysis probe dialysate 5-HT content  vs. external solution 5-
HT content for probes at all 5-HT levels 
Individual probe dialysates had a mean percentage recovery range of 4.7 to 
31.0% of the external 5-HT content.  The mean percentage dialysate 5-HT 
content, for all probes, was 15.7 ± 0.8% the external 5-HT content, (across all 5-
HT concentrations) 
 
4.3.2 Variability between microdialysis probe recovery at a range of 
concentrations  
For an external solution 5-HT concentration of 50 fmol/50 µL, the mean 
dialysate 5-HT concentration was 8.8 ±0.8 fmol/50 µL for probes A – G.  At 100 
fmols/50 µL external solution 5-HT the mean dialysate 5-HT concentration was 
16.9 ±1.5 fmols/50 µL, at 200 fmols/50 µL the mean dialysate 5-HT 
concentration was 28.9 ±2.7 fmols/50 µL and at 400 fmols/50 µL the mean 
dialysate 5-HT concentration was 54.1 ±4.9 fmols/50 µL for probes A – G 
(Figure 27).  
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Variablity between probe dialysate recovery at each external solution 5-HT content
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Figure 27: Variability of dialysate 5-HT content recovery for probes A-G at four different 
external solution 5-HT content.  Values are mean ± sem, n = 13. 
 
4.3.3 Probe response time 
For an external solution 5-HT concentration of 50 fmols/50 µL the probe 
dialysate had not stabilised by the third sample (T = 60 min) with the 
percentage recovery continuing to fall from sample one.  There was also large 
variability in the data with sem ±6.9, 4.2 and 2.9 for samples 1-3 respectively. 
For an external solution 5-HT concentration of 100 fmols/50 µL the probe 
dialysate had not stabilised by the third sample (T = 60 min) with the 
percentage recovery continuing to rise from sample one. However the variability 
was not as large as for 50 fmol/50 µL. 
For an external solution 5-HT concentration of 200 and 400 fmols/50 µL the 
probe dialysate had stabilised by the second sample (T = 40 min), with the 
second and third samples recovery differing by only 0.1% (Figure 28).  
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Probe response time; time for probe dialysate 5-HT content to stabilise
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Figure 28: Microdialysis probe response time; time for the dialysate 5-HT content (fmol) to 
stabilise.  Values are mean percent of external solution (% recovery) ±sem, n = 12 (probes 
A – G). 
 
4.3.4 In vivo microdialysis probe location 
The location of each microdialysis probe can be seen by the tissue lesion in the 
brain slice and were all confirmed to be in the hippocampus (Figure 29) 
(Paxinos and Watson, 1998). 
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Figure 29: Miocrodialysis probe placement in the hippocampus.  Location of probe can be 
seen by tissues lesion, as indicated by ‘probe placement’. Approximate location (Bregma -
6.04 mm) indicated by comparison to a rat brain atlas (bottom right). 
 
4.3.5 Effect of cyclosporine on fenfluramine induced release of 
hippocampal 5-HT  
Hippocampal dialysate 5-HT content reached a maximum at 60 minutes after 
fenfluramine injection (3mg/kg, i.p.) for all experiments. 
When fenfluramine 3 mg/kg was administered alone (without cyclosporine pre-
treatment) 5-HT dialysates reached a maximum mean of 89.6 ± 16.9 fmols/50 
µL, representing a 1480% increase from baseline and an absolute increase of 
81.4 ± 15.7 fmols/50 µL (n = 9), (Figure 30). 
When fenfluramine 3 mg/kg was administered after pre-treatment with 
cyclosporine (50 mg/kg, T = -60 min) dialysates reached a maximum mean of 
62.5 ± 15.4 fmols/50 µL, representing a 393% increase from baseline and an 
absolute increase of 46.6 ± 15.3 fmols (n = 7), (Figure 30). 
A two-way ANOVA, examining the effect of cyclosporine on the response to 
fenfluramine 3 mg/kg, revealed a significant main effect of time (F 11,154 = 
23.7; p = < 0.05), a significant time x group interaction (F 11, 154 = 2.0; p < 
0.05), but no significant effect of group. 
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Effect of cyclosporine on fenfluramine induced release of hippocampal 5-HT 
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Figure 30: The effect of cyclosporine (50 mg/kg) on fenfluramine (3 mg/kg) induced release 
of hippocampal 5-HT .   Data are mean ± sem, n = 9 (control), n = 7 (cyclosporine). 
 
4.3.6 Effect of fenfluramine dose on hippocampal 5-HT release 
Hippocampal dialysate 5-HT concentrations reached a maximum at 80 minutes 
after a 1 mg/kg fenfluramine injection i.p. and at 60 minutes after a 3 mg/kg 
fenfluramine injection i.p (both with a 50 mg/kg 60 min pre-treatment with 
cyclosporine). 
After administration of 1 mg/kg fenfluramine  5-HT dialysates reached a 
maximum mean of 30.9 ± 9.5 fmols/50 µL, representing a 127% increase from 
baseline and an absolute increase of 17.3 ± 8.8 fmols (n = 4), (Figure 31).  
A two-way ANOVA, examining 1 mg/kg vs. 3 mg/kg fenfluramine groups, 
revealed a significant main effect of time (F 12, 108 = 5.9; p = < 0.05) but no 
significant effect of group or time x group.  
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Effect of fenfluramine dose on hippocampal 5-HT release
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Figure 31: The effect of fenfluramine dose (1 vs.3 mg/kg) on hippocampal 5-HT release.   
Data are mean ± sem, n = 4 (1 mg/kg fenfluramine), n = 7 (3 mg/kg fenfluramine). 
 
4.3.7 Endogenous 5-HT content in the rat hippocampus after 
administration of cyclosporine (50 mg/kg) and fenfluramine (3 
mg/kg) 
The mean dialysate 5-HT concentration after cyclosporine (50 mg/kg) but 
before fenfluramine injection was 15.9 fmols/50 µL.  After fenfluramine (3 
mg/kg) injection it reached a maximum of 62.5 fmols/50 µL 60 min post 
injection.  
From the data presented thus far estimates of dialysate hippocampal 5-HT level 
can be estimated from the dialysate 5-HT concentration taking into account the 
in vitro probe calibration data (section 4.2.5).  From these data, it appears that 
the mean basal (pre-fenfluramine) hippocampal 5-HT level in cyclosporine pre-
treated rats was estimated to be 129.0 ± 26.8 fmols/50 µL (approx 2.6 x 10-9 M) 
and that fenfluramine (3 mg/kg) administration, with cyclosporine (50 mg/kg) 
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pre-treatment, caused a maximum hippocampal 5-HT concentrations of 506.9 
±124.9 fmols/50 µL (approx 1 x 10-8 M) 
 
4.4 Discussion 
Microdialysis probes were found to have a mean recovery of 15.7 ± 0.8% of the 
external 5-HT content highlighting the need to produce a calibration curve for 
probes so that the true value can be calculated.  It was also found that the 
variability between probes increased at higher external 5-HT concentrations.  In 
addition it was shown that the dialysate measurements had stabilised at T = 40 
min for external 5-HT concentrations of 200 and 400 fmol/50 µL.  However, at 
lower concentrations of 50 and 100 fmol/50 µL, it appears the dialysate had not 
stabilised by the last measurement at T = 60 min.  It should be noted that there 
was large variability in these measurements which may be masking the 
possibility that stability was achieved.  It is likely that the greater variability at 
lower 5-HT concentrations is the product of the contribution of HPLC baseline 
noise, which will affect smaller measurements of concentration proportionally 
more than higher concentrations.  
As cyclosporine pre-treatment is required to perform PET scans with 4-
[18F]MPPF in this project in order to slow down clearance in the brain, it was 
necessary to ascertain any effect this had on the fenfluramine induced 5-HT 
release.  Cyclosporine pre-treatment did not have a significant effect on 
fenfluramine induced 5-HT release.  However, again there is large variability in 
the data, and when considering the delta (absolute change) increase in 5-HT 
after fenfluramine administration, a possible effect of cylcosporine can be seen.  
Without cyclosporine pre-treatment 5-HT delta increase is 81.4 ± 15.6 fmols, 
whereas with cyclosporine produces a delta increase of 46.6 ± 15.3.  Therefore 
this could suggest cyclosporine pre-treatment has a small attenuating effect on 
fenfluramine induced 5-HT release.  However, there is still a notable increase in 
5-HT levels in the brain with a cyclosporine pre-treatment which is suitable for 
use in PET ligand binding studies. 
No significant difference in 5-HT release was found between 1 mg/kg and 3 
mg/kg fenfluramine administration.  However again there is a large amount of 
variability in the data.  When considering the delta increase it can be seen that 1 
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mg/kg fenfluramine produces a delta increase of 17.3 ± 8.8 fmols/50 µL 
whereas 3 mg/kg results in 46.6 ± 15.3 fmols/50 µL.  From the delta increased 
data it could be suggested that 3 mg/kg fenfluramine causes a greater increase 
in 5-HT release compared to 1 mg/kg. 
Due to the variability in both datasets it could be suggested that the in vivo 
microdialysis studies require higher repetitions to acquire more accurate results. 
In the present study our 506.9 ±124.9 fmols/50 µL 5-HT released by 
fenfluramine 3 mg/kg translates to approximately 400 % increase from baseline 
in 5-HT levels.  Several published studies have conducted microdialysis 
experiments in tandem with PET or β-probe studies of 4-[18F]MPPF.  One study 
by Zimmer et al. (Zimmer et al., 2002a) found a 20% increase in 5-HT in the rat 
hippocampus for 1 mg/kg fenfluramine and 50% for 2 mg/kg.  Another study 
looking at 5 mg/kg fenfluramine (Udo De Haes et al., 2006) found a 2000% 
increase in endogenous 5-HT in the monkey frontal cortex.  Other studies have 
been equally inconsistent.  Of those that used a higher dose of fenfluramine (10 
mg/kg) an increase of 170% was found in the rat DRN (Zimmer et al., 2002b) 
and 1500 to 3000% increase in the rat hippocampus (Zimmer et al., 2002a, Udo 
de Haes, 2005).  It can be seen that pharmacologically induced 5-HT release is 
inconsistent between studies, highlighting the importance of microdialysis 
studies to assess 5-HT concentrations using the same study protocol. 
This study has shown the hippocampal brain concentrations of endogenous 5-
HT  can be approximated to be 506.9 ±124.9 fmols/50 µL (approx 1 x 10-8 M) at 
the time of 4-[18F]MPPF injection for PET scans and ex vivo autoradiography 
studies to be performed in Chapter 5. 
 
4.5 Conclusion 
It has been shown that endogenous 5-HT can be increased by a maximum of 
400% from baseline in the rat hippocampus by administration of fenfluramine (3 
mg/kg) with the addition of cyclosporine pretreatment (50 mg/kg).  Using this 
drug treatment the hippocampal 5-HT concentration of 5-HT at T=60 min has 
been found to be approximately 1 x 10-8 M.  The drug treatments (cyclosporine 
(50 mg/kg)/fenfluramine (3 mg/kg) and timing protocols will be followed in the 
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PET scans and ex vivo autoradiography studies to be performed as described 
in the following chapter.
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Chapter 5. PET and autoradiography 
 
5.1 Introduction  
The underlying theory of this thesis is that receptor specific PET ligands can be 
displaced by endogenous neurotransmitters and this can give a route to examining 
dysfunction of neurotransmitter systems at the biochemical level. 
Previous work, using in vivo PET imaging, β microprobes and ex vivo 
autoradiography, has suggested the 5-HT 1A receptor PET ligand 4-[
18F]MPPF can 
be displaced from 5-HT 1A receptor rich brain areas by endogenous 5-HT , 
stimulated by pharmacological intervention (Zimmer et al., 2002b, Zimmer et al., 
2002a, Aznavour et al., 2006, Riad et al., 2004, Udo de Haes, 2005, Rbah et al., 
2003, Zimmer et al., 2003).  If 4-[18F]MPPF possesses this characteristic, it would 
make a valuable tool in the characterisation and diagnosis of disorders involving 
the 5-HT system, such as depression and anxiety.  However, not all studies 
suggest 4-[18F]MPPF is displaceable (Udo De Haes et al., 2006, Riad, 2008, 
Moulin-Sallanon et al., 2009, Riad et al., 2004, Ginovart et al., 2000, Plenevaux et 
al., 2000), so there remains a lack of agreement in the current literature. 
Chapter 2 and 3 describe the precursor synthesis and subsequent radiosynthesis 
of 4-[18F]MPPF which was used for experiments in this chapter. Chapter 4 
describes microdialysis studies characterising the release of endogenous 5-HT by 
the releasing agent fenfluramine, and the effect of the p-glycoprotein transport 
inhibitor cyclosporine.  The protocol used in the in vivo microdialysis experiments 
have been replicated for experiments in this chapter, so that 4-[18F]MPPF is 
administered at the time of maximum 5-HT release.   
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Therefore, the aims of this chapter are to:  
 Characterise the specific binding of 4-[18F]MPPF, in ex vivo autoradiography 
and 4-[3H]MPPF, in vitro autoradiography, in brain areas with a high density 
of 5-HT 1A receptors. 
 Determine the concentration of 5-HT which will displace 4-[3H]MPPF from 
brain areas with a high density of 5-HT 1A receptors, using in vitro 
autoradiography. 
 Characterise the uptake, washout and distribution of 4-[18F]MPPF in the 
brain using ex vivo autoradiography and PET.  
 Determine whether 4-[18F]MPPF can be displaced by endogenous 5-HT 
using ex vivo autoradiography and PET. 
 To compare PET and autoradiography as methods for studying 4-[18F]MPPF 
receptor binding. 
 
As the radioisotope has no effect on the binding profile of the ligand, it is 
advantageous to choose the one most practical for the proposed experiment.  For 
this reason the present study used a tritiated version of 4-MPPF, 4-[3H]MPPF for in 
vitro autoradiography studies.  The advantages of tritium over fluorine-18 are as 
follows; 
 Longer half life (12.3 years for tritium vs 110 min for fluorine-18) allows for 
longer experimental procedures to be performed such as in vitro competition 
studies, which typically are performed over approx. 6 – 8 hours. 
 Can be readily commercially purchased and subsequently stored for use 
over many years. 
 The lower energy of tritium results in better resolution autoradiographs. 
 4-[3H]MPPF can be compared to previously published in vitro 
autoradiography experiments, including those using different ligands, which 
typically use the tritium isotope. 
 Greater ease of safe handling of beta emitting isotopes vs. gamma emitters.  
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Methods 
 
5.1.1 Animal supply, housing and experimentation  
Animal procedures were performed under the UK home office requirements, set 
out in the Animal (Scientific Procedures) Act 1986.   
Male Lister hooded rats were purchased from Charles River (Margate, Kent) and 
were housed in groups of three or four per cage (56 x 38 x 20 cm) with water and 
food available ad libitum.  Animals were left at least three days to acclimatise to the 
surrounding before use in experimentation, only being disturbed to allow for cage 
cleaning and food and water replenishment.  Animals were kept in controlled 
conditions consisting of a 12 hr light, 12 hr dark, light cycle (lights on at 7am GMT) 
at a constant temperature (21 ±2 ⁰C) and humidity (~40%).  
 
5.1.2 PET ligand 
4-[18F]MPPF in ethanol (0.3 mL), was prepared and delivered to the PET scanner 
room on the morning of use.  The ligand was diluted in sterilised water (1.2 mL, 
Braun Medical Ltd, UK) to give a total volume of 1.5 mL containing 20% ethanol.   
 
5.1.3 General PET protocol 
On the day of the experiment, animals were transferred to separate cages (one 
animal per cage) in the PET scanner room, and treated with cyclosporine (50 mg/ 
kg, i.p., SANDIMMUN, Novartis Pharmaceuticals Ltd, UK).   
 
5.1.4 Specific binding of 4-[18F]MPPF in different brain regions 
As described in Figure 32, animals were anaesthetised (5% isoflurane induction, 1-
2% isoflurane maintainance via a facemask, anaesthetic station VTS VetTech 
Solutions Ltd, UK with active scavenging unit (#6238) and Cardiff absorber (Shirley 
Aldred & Co. LtD, UK).) and placed on a heated pad).  Cold 4-MPPF (10 mg/kg, 
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i.p, dissolved in a drop of conc. HCl and made up to volume in sterilised water to 
pH 3 - 4) or acidified water vehicle control was administered to the animal at T-30 
minutes before the PET study.  A tail vein was cannulated (19 mm I.V. catheters, 
Abbott Laboratories, China) at approximately T -15 min before the start of the PET 
study.  Post tail cannulation the animal was moved to the PET scanner Minerve 
tube (Patent PCT/FR2006/001218, Bioscan by Minerve), which maintained 
anaesthesia for the duration of the scan (0.5 – 1.5 % isofluorane, 1 L/min O2, 
scavenger (Halosorb), heating (URT Multipostes 06170030) and pump unit (PCA 
Multipostes 08220027), Isofluorane tank (NS 07010392), Equipment Veterinaire 
Minerve, Esternay.), then placed into the PET scanner.  The head was positioned 
using two wedges of oasis foam placed either side of the head and the head and 
body were fixed in place with tape. 
The animal was positioned in the scanner so that the laser positioning cross hairs 
were approximately over the centre of the brain.  At the start of the PET scan (T = 
0 min) 4-[18F]MPPF was injected (i.v. tail vein, over approximately 30 seconds).  
Radioactivity of the syringe containing 4-[18F]MPPF was measured before and after 
injection so that exact injected activity could be calculated. 
Each animal was subjected to a single PET or autoradiography experiment then 
euthanized by anaesthetic overdose. 
 
5.1.5 Effects of endogenous 5-HT release on 4-[18F]MPPF binding 
Essentially the same protocol was used as for the study described above (section 
5.2.4).  However, as described in Figure 33, fenfluramine (3 mg/kg @ 1mL/kg, i.p) 
or saline vehicle control (1 mL/kg i.p.) was administered before induction of 
anaesthesia at T - 60 min.  
 
5.1.6 PET system description 
PET studies were performed on a Philips MOSAIC HP preclinical PET system 
(Phillips Health Care, Netherlands).  The scanner uses 14,456 lutetium-yttrium 
orthosilicate (LYSO) crystals (2 x 2 x 10 mm, Photonic materials Ltd., Scotland) 
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arranged in 52 rings each containing 278 crystals.  The signal from the crystals is 
read out by a hexagonal array of 288 photomultiplier tubes (19 mm diameter).  The 
detector ring diameter is 19.7 cm and a bore size of 18 cm.  The system scans 
exclusively in 3-D mode, has an axial field of view of 11.9 cm and a spatial 
resolution of 1.9 mm full width half maximum (FWHM) (Huisman et al., 2007, Surti 
et al., 2005). 
The system quality control checks consisted of system initialization, baseline 
correction, energy tests and PMT gain tests.  This is followed by a short emission 
QC where a sinogram is generated and observed to see if there are any missing or 
weak line segments.  This was performed at the start of each day with a 22Na point 
source (2.5 cm disc, 100 µCi, Eckert and Ziegler, California) which was placed in a 
cradle and centred in the transaxial and axial FOVs. 
The scanner is controlled by in-built dedicated Philips Mosaic software running on 
Sun Microsystems hardware.  30 minute dynamic scans (5 x 1 min, 3 x 5 min and 1 
x 10 min) were conducted with the animal weight and an approximate injected 
radioactivity entered into the software prior to scanning.  Raw data from dynamic 
scans were stored in sinogram format.  Each sinogram was corrected for injected 
activity after scan completion and reconstructed to give images with a voxel size of 
1 mm3. The reconstruction was a 3D RAMLA emission algorithm, which was decay 
corrected and contains 128 slices.  There was no attenuation correction, no scatter 
correction and no random subtraction. 
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Figure 32:  PET imaging experiments timeline; to reveal specific binding of 4-[
18
F]MPPF by 
pre-treatment with cold 4-MPPF. 
Figure 33: PET imaging experiments timeline; to test effect of pharmacologically induced 
endogenous 5-HT release (using fenfluramine) on 4-[
18
F]MPPF binding. 
 
5.1.7 PET data analysis 
To create an MRI template, MRI images were taken from 12 untreated male Lister 
hooded rats.  The images were corrected for an artefact and resized to a voxel size 
of 1 mm3 using MRIcro (v. 1.40 build 1).  The images were co-registered to a single 
arbitrary MRI image using FSL (v. 5.0), to create a single summed MRI image.  
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The MRI template was created by Dr. David Cousins, from MRI images produced 
by Dr. Richard McQuade and Dr. David Cousins. 
The MRI template and reconstructed PET image DICOM files were uploaded to 
Imalytics software (3.0 Rev 3974 (64)) for analysis.  Volumes of interest (VOI’s) for 
the prefrontal cortex (PFC), hippocampus, dorsal raphe nucleus (DRN) and the 
cerebellum were drawn manually on the MRI template, using a rat brain atlas for 
reference (Paxinos and Watson, 1998).  PET images were manually co-registered 
to the MRI image using the eye socket as an anatomical reference and voxel sizes 
for each VOI was recorded for each PET image (Figure 34).  Time-activity curves 
(TAC) were calculated for each VOI by the Imalytics software and plotted as mean 
standard uptake value (SUV) over time (s).  
 
SUV   =  tissue radioactive concentration (MBq) (t) / 
(injected activity (MBq) (t)/ body weight (g)) 
 
Non-specific binding was defined as the SUV in the cerebellum and specific 
binding was calculated by subtracting the cerebellum SUV from that of each brain 
area.  The magnitude of ligand binding was inferred from specific binding at any 
given time point in each VOI.   
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Figure 34: Example of a PET image from a single coronal slice of the whole rat head and neck.  
Approximate Bregma location (Paxinos and Watson, 1998) for the brain is highlighted in purple 
and the hippocampal region of interest (ROI) in pink.  The region of interest (ROI) in the 
hippocampus which was used for PET analysis in this slice is outlined in white. 
 
To statistically analyse whether specific binding occurred in the cerebellum, the 
raw SUV data was used.  For all other statistical analysis specific binding data was 
used and weighted in accordance with the time period it represented.  For 
example, an SUV taken from a 5 minute window was multiplied by five, with 
comparable treatment given to the 1 and 10 minute window data.  The effect of 
cold 4-MPPF or fenfluramine on the binding profile of 4-[18F]MPPF in the 
hippocampus, DRN or PFC was examined using a two-way (time and pre-
treatment) repeated measures ANOVA followed by a post-hoc independent 
samples t-test.  
 
5.1.8 Ex vivo 4-[18F]MPPF autoradiography protocol 
Here, the protocol was identical to the in vivo PET protocol (sections 5.2.3-5). 
however, the animal was not placed in the PET scanner and was killed by an 
overdose of anaesthesia 5 min after administration of 4-[18F]MPPF (Figures 35 and 
36).  After the animal had been killed the brain was rapidly removed and flash 
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frozen in a bath of iso-pentane (VWR, France) submerged in dry ice.  Brain 
sections were collected (50 µm, hippocampus, DRN, PFC and cerebellum, Microm 
HM 500 OM cryostat, Germany) and mounted on glass slides before being 
exposed overnight to autoradiography film (Amersham Hyperfilm M.P, 24 x 30 cm, 
GE Healthcare Ltd, UK).  The individual experiments were designed such that a 
vehicle and a drug challenge were paired and performed on the same day.  Brain 
sections from each paired experiment were laid down on film after the same 
interval post 4-[18F]MPPF injection (approx. 1 hr). 
 
 
Figure 35: Ex vivo autoradiography experiments timeline; to reveal specific binding of 4-
[
18
F]MPPF by pre-treatment with cold 4-MPPF. 
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Figure 36: Ex vivo autoradiography experiments timeline; to test effect of pharmacologically 
induced endogenous 5-HT release (using fenfluramine) on 4-[
18
F]MPPF binding. 
 
5.1.9 Fluorine-18 autoradiography standards and calibration curve 
To create a fluorine-18 autoradiography standard, forebrain tissue from 6 male 
Lister hooded rats was homogenised using a pestle and mortar then divided into 
eight 1.0 mL Eppendorfs (0.4g per tube, Kartell Spa, Noviglio (MI)).  [18F]FDG (20 
µL, 4.8 – 160 Bq) was added to each Eppendorf and vortexed (1 min) to distribute 
the radioactivity evenly throughout the brain tissue, creating 8 radioactive 
concentration standards.  The activity of each Eppendorf was measured after 
vortexing.  A small amount of tissue (approx. 0.05 – 0.1 mg) from each standard 
was placed in a well, formed within a block of frozen Tissue-Tek O.C.T compound 
(Sakura Finetek, USA).  The block was mounted in a cryostat (Microm HM 500 OM 
cryostat, Germany) and sections (50 µm) were taken to be laid on autoradiographic 
film (24 hr, Amersham Hyperfilm M.P, 24 x 30 cm, GE Healthcare Ltd, UK).  All 
radioactive standards were laid onto film simultaneously.  To create a 4-[18F]MPPF 
standard calibration curve the mean optical density of 14 standard samples, at 
each of the 8 activities, was measured using ImageJ (v. 1.46 r) and the 
background subtracted.  The mean optical densities were then plotted against the 
known activity/g (MBq/g) and cubic polynomial regression analysis was performed 
 98 
 
to give a correction equation; Y = 41.882x3 - 139.89x2 + 195.3x - 6.4636, R² = 
0.977 (Figure 37, Table 16). 
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Figure 37:  [
18
F]FDG autoradiography calibration curve, with 3
rd 
order polynomial regression 
curve. Values are mean ±sem. 
 
MBq/g 
Mean 
optical 
denisty n 
Standard 
deviation sem 
1.2 98.8 14 3.5 0.9 
0.6 68.4 14 4.4 1.2 
0.6 64.0 14 6.2 1.6 
0.3 33.2 14 4.4 1.2 
0.2 34.0 16 4.7 1.2 
0.2 31.4 16 2.6 0.6 
0.1 0.6 16 2.2 0.6 
0.0 0.5 16 1.9 0.5 
 
Table 16: [
18
F]FDG autoradiography calibration curve data 
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5.1.10 In vitro 4-[3H]MPPF autoradiography protocol 
For each experiment a solution of 4-[3H]MPPF (0.14, 1.4 or 10 nM) was made up in 
Tris buffer solution (50mM, Trizma pre-set crystals pH 7.6, Sigma, USA. pH to 7.4 
using conc. HCl). Solutions for non-specific binding, using (±) 8-OH-DPAT (0.07 
nM (±) 8-hydroxy-2(di-n-propylamino)tetralin hydrobromide, Aldrich, UK) and 
displacement  studies, using 5-HT (1 x 10-13 to 2 x 10-6 mM 5-hydroxytryptamine 
hydrochloride, 99%, Alfa Aesar Ltd, UK) were made up in the 4-[18F]MPPF 
solution. 
Four male Lister hooded rats (245 - 373g) were killed by decapitation and the 
brains removed and flash frozen in a bath of iso-pentane submerged in dry ice.  
Sections (20 µM) were collected from four brain areas; hippocampus, DRN, PFC 
and cerebellum and mounted on glass slides.  After initial pre-incubated in buffer 
(30 min, R.T, 50mM Tris HCl (pH 7.4), 2 mM MgCl2), the slides were incubated for 
2 hr at room temperature in their respective solutions containing 4-[3H]MPPF and 
5-HT or (±) 8-OH-DPAT (Table 17).  Following this incubation the sections were 
rinsed in buffer solution for 15 min.  Buffer was washed off by dipping in ice cold 
distilled water and sections were allowed to dry before being exposed to 
autoradiographic (Amersham HyperfilmMP) film for 3 months along with 
autoradiographic [3H] microscales (Amersham, UK). 
 
Labelling solution 4-[
3
H]MPPF concentration 
0.14 nM 1.4 nM 10.0 nM 
4-[
3
H]MPPF    
8-OH DPAT (0.07 nM)    
1 x 10
-13
 mM 5-HT     
2 x 10
-13
 mM 5-HT     
5 x 10
-13
 mM 5-HT     
2 x 10
-12
 mM 5-HT     
2 x 10
-11
 mM 5-HT     
2 x 10
-10
 mM 5-HT     
2 x 10
-9
 mM 5-HT     
2 x 10
-8
 mM 5-HT     
2 x 10
-6
 mM 5-HT     
Table 17:  Labelling solutions for 4-[
3
H]MPPF in vitro autoradiography studies 
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5.1.11 Autoradiographic film development 
After the desired exposure time had elapsed the film was transferred to a dark 
room and submerged in developer solution (5 min with agitation, RG Universal 
ready to use X-ray developer, Champion, UK.), washed in water containing wetting 
agent (20 s, ILFORD wetting agent, Herman Technology Ltd., UK), submerged in 
fixer (5 min with agitation, Amfix high speed fixer, Champion, UK) then thoroughly 
washed in water containing wetting agent (3 min, ILFORD wetting agent, Herman 
Technology Ltd., UK), before hanging to dry. 
 
5.1.12 [3H] autoradiography calibration curve 
To create a calibration curve the optical density from a [3H] Amersham microscale 
standard was measured using ImageJ (v. 1.46 r) and the background subtracted.  
The optical densities were plotted against the known activity/g (Bq/mg) and cubic 
polynomial regression analysis was performed to give a correction equation. A 
calibration curve was constructed for each film.  An example calibration curve is 
shown in Figure 38. 
Regression equation; Y = 0.2314x3 - 8.9648x2 + 163.21x + 298.99, R² = 0.9958 
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Figure 38. Example of a [
3
H] autoradiography calibration curve (for film 6/6) with 3
rd
 order 
polynomial regression. 
 
bq/mg 
Optical 
density 
4107.0 32.6 
2405.0 24.7 
1457.8 15.4 
865.8 3.7 
510.6 0.6 
314.5 0.1 
185.0 0.3 
Table 18: [
3
H] autoradiography calibration curve data 
 
5.1.13 Autoradiography data analysis 
For both ex vivo and in vitro autoradiography brain sections were stained after 
exposure to the autoradiographic film (Cresyl violet protocol Chapter 4, section 
4.2.7) and digital images taken of stained sections as well as the corresponding 
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autoradiographic brain sections images, (Scion Image software (Beta 4.0.2), Leica 
M26 microscope with Leica 10445930 1.0 x camera).  Microscope manual zoom 
and focus were kept constant throughout data analysis.  Using image J (v. 1.46 r), 
the brain region of interest (ROI) was manually highlighted on the stained brain 
section image.  ImageJ software was then used to redirect the ROI onto the 
corresponding autoradiograph image and the optical density of that area was 
recorded.  Measurements were recorded from three brain sections per brain area 
(hippocampus, DRN, PFC and cerebellum) and the optical density of the 
background was also recorded to control for any differences in optical density 
across the film.   
The magnitude of ligand binding was calculated from the optical density calibrated 
to commercial [3H] microscales standards for the 4-[3H]MPPF autoradiography, and 
in house [18F]FDG standards for the 4-[18F]MPPF autoradiography.  Non-specific 
binding was defined as the mean optical density in the cerebellum and specific 
binding was calculated by subtracting the mean cerebellum optical density from the 
mean optical density of each brain area.   
The effect of cold 4-MPPF or fenfluramine on the binding profile of 4-[18F]MPPF in 
the hippocampus, DRN and PFC was examined using two tailed paired t-test.  
The effect of 5-HT on 4-[3H]MPPF binding was examined using a one way ANOVA 
with a post-hoc Dunnetts test. 
 
 
5.2 Results 
 
5.2.1 4-[3H]MPPF Autoradiography  
Distribution of 4-[3H]MPPF in controls 
A dense signal was observed in the dorsal and ventral hippocampus (CA1,CA2 & 
CA3),  entorhinal cortex and the dorsal raphe nucleus.  A less dense signal was 
observed in the PFC, dentate gyrus, median raphe nucleus, agranular insular, 
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parietal, occipital, temporal, perihinal, piriform, cingulate and frontal cortex as well 
as the entorhinal cortex inferior colliculus and dorsal, lateral and ventral central 
gray.  The cerebellum and caudate putamen showed a very low signal (Figures 39 
– 42). 
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Figure 39: Cerebellum; Top 4-[
3
H]MPPF 
only, middle 4-[
3
H]MPPF + 0.07 nM (±) 8-
OH-DPAT, bottom 4-[
3
H]MPPF + 2 x 10
-6
 
M 5-HT  
 
 
 
 
 
 
 
 
 
Figure 40: Hippocampus; Top 4-
[
3
H]MPPF only, middle 4-[
3
H]MPPF + 
0.07 nM (±) 8-OH-DPAT, bottom 4-
[
3
H]MPPF + 2 x 10
-6
 M 5-HT  
 
 
 105 
 
   
 
 
Figure 41: DRN; Top 4-[
3
H]MPPF only, 
middle 4-[
3
H]MPPF + 0.07 nM (±) 8-OH-
DPAT, bottom 4-[
3
H]MPPF + 2 x 10
-6
 M 
5-HT  
 
 
 
 
 
Figure 42: PFC; Top 4-[
3
H]MPPF only, 
middle 4-[
3
H]MPPF + 0.07 nM (±) 8-OH-
DPAT, bottom 4-[
3
H]MPPF + 2 x 10
-6
 M 
5-HT  
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Effect of 0.07 nM (±) 8-OH-DPAT on binding of 4-[3H]MPPF in different 
brain regions 
The 5-HT 1A agonist (±) 8-OH-DPAT was used to displace specific 4-[
3H]MPPF 
binding in order to determine of non-specific binding of the ligand.  However in 
this experiment the concentration of (±) 8-OH-DPAT used (0.07 nM) had little or 
no effect on 4-[3H]MPPF in the hippocampus or DRN in any of the brain areas 
studied (Table 19).  This is discussed further later in this thesis. 
 
 10.0 nM 4-[3H]MPPF Specific activity (bq/mg) 
  hippocampus DRN PFC 
4-[3H]MPPF 
1439.5 1208.2 919.0 
4-[3H]MPPF + 0.07nM 
DPAT 
1567.6 1200.1 846.0 
 % control binding 
108.9 99.3 92.1 
Table 19: Effect of 0.07 nM (±) 8-OH-DPAT on binding of 4-[
3
H]MPPF in different brain 
regions 
 
Effect of 5-HT on specific binding of 4-[3H]MPPF in different brain regions 
To determine the concentrations of 5-HT that would cause displacement of 4-
[3H]MPPF in the hippocampus, DRN and PFC,  brain sections were incubated 
with 4-[3H]MPPF and increasing concentrations of 5-HT (Table 20). 
A one way ANOVA with post-hoc Dunnetts test comparing 4-[3H]MPPF specific 
binding incubated with 5-HT vs. control (no 5-HT ) revealed there was no 
significant reduction in binding at any 5-HT concentration in the hippocampus.  
However there was significant reduction in binding vs. control in the DRN and 
PFC at a 5-HT concentration of 2 x 10-6 M 5-HT (DRN and PFC: p= < 0.05) 
(Figures 43 – 45).   
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  10 nM 4-
[3H]MPPF  
Hippocampus 
(bq/mg) 
% 
control  
DRN 
(bq/mg) 
% 
control  
PFC 
(bq/mg) 
% 
control  
5-HT 0 M 1499.0   1209.1   926.1   
5-HT 2 x 10-6 M 480.7 32.1 216.0 17.9 106.9 11.5 
5-HT 2 x 10-8 M 1173.6 78.3 1020.5 84.4 790.6 85.4 
5-HT 2 x 10-9 M 1317.5 87.9 1225.3 101.3 685.6 74.0 
5-HT 2 x 10-10 M 1201.0 80.1 1104.8 91.4 738.1 79.7 
5-HT 2 x 10-11 M 1438.3 96.0 1237.3 102.3 657.1 71.0 
5-HT 2 x 10-12 M 1164.6 77.7 1117.2 92.4 738.6 79.8 
5-HT 5 x 10-13 M 1591.2 106.1 1501.3 124.2 1187.8 128.3 
5-HT 2 x 10-13 M 1728.0 115.3 1585.5 131.1 1291.1 139.4 
Table 20: Effect of 5-HT on specific binding of 4-[
3
H]MPPF in different brain regions 
 
Effect of 5-HT concentration on 4-[
3
H]MPPF specific binding in the hippocampus
5-HT concentration (M)
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Figure 43:  4-[
3
H]MPPF (10 nM) specific binding in the hippocampus; effect of 5-HT (2 x 10
-
13
 to 2 x 10
-6
 M). Values are optical density of the hippocampus (n=3) with the optical 
density of the cerebellum (n=3) subtracted. 
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Effect of 5-HT concentration on 4-[
3
H]MPPF specific binding in the DRN
5-HT concentration (M)
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Figure 44:. 4-[
3
H]MPPF (10 nM) specific binding in the DRN; effect of 5-HT (2 x 10
-13
 to 2 x 
10
-6
 M). Values are mean optical density of the DRN (n=3) with the mean optical density of 
the cerebellum (n=3) subtracted. * p = < 0.01 relative to control. 
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Effect of 5-HT concentration on 4-[
3
H]MPPF specific binding in the PFC
5-HT concentration (M)
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Figure 45:.4 -[
3
H]MPPF (10 nM) specific binding in the PFC; effect of 5-HT (2 x 10
-13
 to 2 x 
10
-6
 M). Values are mean optical density of the PFC (n=3) with the mean optical density of 
the cerebellum (n=3) subtracted. * p = <0.01 relative to control. 
 
5-HT displacement of MPPF at relevant hippocampal 5-HT levels for in 
vivo 4-[18F]MPPF PET and autoradiography  
It was found using in vivo microdialysis (Chapter 4) that hippocampal 5-HT 
increased from 129.0 ± 26.8 fmol/50 µL pre-fenfluramine administration, to 
506.9 ±124.9 fmol/50 µL, 1 hour after 3 mg/kg fenfluramine administration.  This 
drug treatment was used to increase endogenous 5-HT in this chapter for in 
vivo autoradiography and PET studies experiments, to examine its effect on 4-
[18F]MPPF specific binding.  Using the microdialysis probe calibration curve, it 
could be estimated that actual hippocampal 5-HT concentration before 
fenfluramine administration was 2.6 x 10-9 ± 0.5 x 10-9 M and the actual 
hippocampal 5-HT concentration after fenfluramine administration was 1.0 x 10-
8 ± 0.3 x 10-8 M 
From the autoradiography studies described above it appears that there is only 
partial hippocampal displacement (approx. 78% of control) of 4-[3H]MPPF at 1.0 
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x 10-8 M 5-HT .  These are the predicted in vivo hippocampal conditions for the 
PET and autoradiographic examination of the effect of increased endogenous 
5-HT on 4-[18F]MPPF specific binding. 
 
0.14 and 1.4 nM 4-[3H]MPPF autoradiography 
Experiments using 0.14 nM and 1.4 nM 4-[3H]MPPF concentrations resulted in 
low optical densities, which resulted in negative calibrated specific activities for 
two reasons;  
 The signal was close to the autoradiographic film background optical 
density, resulting in high signal to noise ratio 
 The range of optical densities making up the calibration curves was 
above that needed to calibrate this data. 
For these reasons these data were excluded from examination. 
 
5.2.2 [18F] Autoradiography Results 
 
Distribution of 4-[18F]MPPF in controls  
A dense signal was observed in the dorsal and ventral hippocampus (CA1,CA2 
& CA3), the dorsal raphe nucleus, lateral septal nucleus and entorhinal cortex.  
A less dense signal was observed in the agranular insular, parietal, occipital, 
temporal, perihinal, cingulate, piriform and prefrontal cortex as well as the 
median raphe nuclus, dentate gyrus, external cortex inferior colliculus and the 
pontine reticular nucleus, oral.  The cerebellum and caudate putamen showed a 
very low signal (Figure 46). 
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Figure 46: 4-[
18
F]MPPF  binding in the rat brain; Top left cerebellum, top right hippocampus, 
bottom left DRN, bottom right septal nucleus. An artefact can be seen at the top of the 
caudate putamen highlighted by the black square. 
 
Specific binding of 4-[18F]MPPF in different brain regions 
 
4-[18F]MPPF binding in the cerebellum (non-specific binding) 
Pre-treatment with cold 4-MPPF was used to reveal the non-specific binding of 
4-[18F]MPPF.  10 mg/kg 4-MPPF pre-treatment did not affect the binding of 4-
[18F]MPPF in the cerebellum, an area reported to be essentially devoid of 5-HT 
1A receptors.  The mean optical density for the cerebellum with cold 4-MPPF 
pretreatment was 2.65 ±0.06 MBq/g and 2.74 ± 0.06 MBq/g for control. A 2-
tailed paired t-test revealed there was no significant difference between vehicle 
and 4-MPPF pre-treated binding in the cerebellum, (p = 0.75, n = 4) (Figure 47). 
These data indicate that there is minimal specific binding of 4-[18F]MPPF in the 
cerebellum, and on the basis of these data 4-[18F]MPPF binding (optical 
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density) in the cerebellum was used as a measure of non-specific binding in the 
brain.   
   
Figure 47: 4-[
18
F]MPPF  binding in the cerebellum; Left control, right cold 4-MPPF (10 
mg/kg) pre-treatment 
 
4-[18F]MPPF specific binding in the hippocampus 
4-MPPF pre-treatment had no significant effect on the specific binding of 4-
[18F]MPPF in the hippocampus.  The mean optical density for the hippocampus 
with cold 4-MPPF pretreatment was 0.067 ±0.002 MBq/g and for control was 
0.078 ± 0.008 MBq/g.  A two-tailed t-test examining cold 4-MPPF pre-treatment 
vs. water vehicle found no significance difference in optical density in the 
hippocampus (p = 0.17, n = 5) (Figure 48).   
   
Figure 48: 4-[
18
F]MPPF binding in the hippocampus; Left control, right cold 4-MPPF (10 
mg/kg) pre-treatment 
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4-[18F]MPPF binding in the DRN 
4-MPPF pre-treatment had a possible effect on the specific binding of 4-
[18F]MPPF in the DRN. The mean optical density for the DRN with cold 4-MPPF 
pretreatment was 0.066 ±0.003 MBq/g and for control was 0.076 ± 0.004 
MBq/g. A two-tailed t-test examining 10 mg/kg 4-MPPF pre-treatment vs. water 
vehicle found a strong trend in optical density in the DRN (p = 0.059, n = 4) 
(Figure 49).   
   
Figure 49: 4-[
18
F]MPPF  binding in the DRN; Left control, right cold 4-MPPF(10 mg/kg) pre-
treatment 
 
4-[18F]MPPF specific binding in the PFC 
4-MPPF pre-treatment had a significant effect the specific binding of 4-
[18F]MPPF in the PFC.  The mean optical density for the PFC with cold 4-MPPF 
pretreatment 0.064 ±0.002 MBq/g was and for control was 0.072 ± 0.002 
MBq/g. A two-tailed t-test examining 10 mg/kg 4-MPPF pre-treatment vs. water 
vehicle found a significance difference in optical density in the PFC (p = 0.041, 
n = 4) (Figure 50).   
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Figure 50: 4-[
18
F]MPPF  binding in the PFC; Left control, right cold 4-MPPF.  (10 mg/kg) 
pre-treatment.  Artefacts are highlighted in black squares. 
 
Effects of endogenous 5-HT release on 4-[18F]MPPF specific binding 
Here pre-treatment with the 5-HT releasing agent fenfluramine was used to 
examine the effect of raised levels of endogenous 5-HT on 4-[18F]MPPF specific 
binding in different brain areas. 
 
Effect of fenfluramine pre-treatment on the specific binding of 4-[18F]MPPF 
in the hippocampus 
Pre-treatment with fenfluramine (3 mg/kg) had no effect on the specific binding 
of 4-[18F]MPPF in the hippocampus. The mean optical density for the 
hippocampus with fenfluramine pretreatment was 0.091 ±0.005 MBq/g and for 
control was 0.15 ± 0.03 MBq/g. A two-tailed t-test examining 3 mg/kg 
fenfluramine pre-treatment vs. saline vehicle found no significance difference in 
optical density in the hippocampus (p = 0.090, n = 6) (Figure 51).   
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Figure 51: 4-[
18
F]MPPF  binding in the hippocampus; Left control, right fenfluramine (3 
mg/kg) pre-treatment 
 
Effect of fenfluramine pre-treatment on the specific binding of 4-[18F]MPPF 
in the DRN 
Pre-treatment with fenfluramine (3 mg/kg) had no effect on the specific binding 
of 4-[18F]MPPF in the DRN. The mean optical density for the DRN with 
fenfluramine pretreatment was 0.080 ±0.006 MBq/g and for control was 0.12 ± 
0.02 MBq/g.  A two-tailed t-test examining 3 mg/kg fenfluramine pre-treatment 
vs. saline vehicle found no significant difference in optical density in the DRN (p 
= 0.065, n = 6) (Figure 52).   
   
Figure 52: 4-[
18
F]MPPF  binding in the DRN; Left control, right fenfluramine (3 mg/kg) pre-
treatment. 
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Effect of fenfluramine pre-treatment on the specific binding of 4-[18F]MPPF 
in the PFC/ septal nucleus 
Pre-treatment with fenfluramine (3 mg/kg) had no effect on the specific binding 
of 4-[18F]MPPF in the PFC/ septal nucleus.  The mean optical density for the 
PFC with fenfluramine pretreatment was 0.076 ±0.005 MBq/g and for control 
was 0.090 ± 0.01 MBq/g. A two-tailed t-test examining 3 mg/kg fenfluramine 
pre-treatment vs. saline vehicle found no significance difference in ligand 
binding in the PFC (p = 0.146, n = 5) (Figure 53).   
   
Figure 53: 4-[
18
F]MPPF  binding in the septal nucleus; Left control, right fenfluramine (3 
mg/kg) pre-treatment. Artefact highlighted in a black square. 
 
Effect of 4-[18F]MPPF quantity injected and radio-purity on ligand kinetics 
(specific binding ) 
Pearson’s correlation coefficients were calculated to determine any relationship 
between both the quantity (µmol/kg) and radio-purity (%) of 4-[18F]MPPF 
injected and the specific binding (optical density (MBq/g)).  2-tailed bivariate 
correlation analysis was performed, with water and saline vehicles combined.  
10mg/ kg 4-MPPF and 3 mg/kg fenfluramine pre-treatments were examined 
separately.   
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Correlation of quantity injected and specific binding 
As shown in Table 21 there was no significant correlation between quantity of 4-
[18F]MPPF injected and the specific binding in any brain area, for any of the 
treatment groups. 
 Hippocampus DRN PFC 
Pearson 
correlation 
p (2-
tailed) 
n Pearson 
correlation 
p (2-
tailed) 
n Pearson 
correlation 
p (2-
tailed) 
n 
Vehicle 0.32 0.92 12 -0.091 0.80 11 -0.027 0.94 10 
4-MPPF 
pratment 
-0.65 0.16 6 -0.36 0.56 5 -0.56 0.44 4 
Fenfluramine -0.53 0.29 6 -0.45 0.37 6 0.24 0.70 5 
Table 21: Correlation between specific binding (optical density (MBq/g)) and quantity of 4-
[
18
F]MPPF injected (µmol/Kg).  Data based on specific activity obtained from crude HPLC 
measurement. 
 
Correlation of radio-purity and specific binding 
As shown in Table 22 there was no significant correlation between radiopurity of 
the 4-[18F]MPPF injected and the specific binding in the vehicle group (all brain 
areas).  Whilst there did appear to be a significant correlation between 
radiopurity and specific binding in the 4-MPPF treatment group (PFC) there was 
an insufficient range to provide a reliable correlation, as both data points were 
almost the same value.   
 
 Hippocampus DRN PFC 
Pearson 
correlatio
n 
p (2-
tailed) 
n Pearson 
correlation 
p (2-
tailed) 
n Pearson 
correlation 
p (2-
tailed) 
n 
Vehicle 0.32 0.44 8 0.32 0.44 8 0.46 0.26 8 
4-MPPF 
pratment 
0.20 0.82 4 -0.51 0.50 4 1* - 2 
Fenfluramine 
e-
treatment 
** ** ** ** ** ** ** ** ** 
Table 22: Correlation between specific binding (optical density (MBq/g)) and radio-purity (%) 
of 4-[
18
F]MPPF injected (µmol/Kg) * Insufficient range of data points to provide correlation 
(both data points almost same values).** Cannot be calculated as radio-purity was constant 
(100%) for all fenfluramine pre-treatment experiments. 
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5.2.3 PET results 
 
Uptake and distribution of 4-[18F]MPPF in controls  
4-[18F]MPPF rapidly accumulated in the brain after i.v. injection, with the 
greatest uptake in the second minute.  This was followed by fast washout, with 
a mean of 48.7% (range of 27.3 – 58.4%) of the maximum SUV remaining after 
5 mins across all brain areas.  The washout rate was fastest in the DRN, with all 
other brain areas having an approximately equal washout rate (Figure 54). 
The maximum ratio of hippocampus/DRN/PFC:cerebellum SUV uptake 
occurred at 3 min; 1.7 for the hippocampus and DRN and 1.8 for the PFC.  In 
agreement with previous PET studies using  4-[18F]MPPF to study 5-HT 1A 
receptor density in the rat brain, the uptake was lowest in the cerebellum and 
greatest in the 5-HT 1A receptor rich areas; the hippocampus, DRN and PFC for 
all experiments (Udo De Haes et al., 2006, Kung et al., 1995, Sijbesma et al., 
1991, Khawaja, 1995). 
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4-[18F]MPPF uptake and washout in all brain areas
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Figure 54: Mean 4-[
18
F]MPPF uptake and washout in four brain regions; the cerebellum, 
hippocampus, DRN and PFC.  Values are mean ±sem, n = 12. 
 
PET image resolution (voxel/region of interest) 
The mean number of voxels within the different regions of interest were as 
follows: cerebellum- 87.7 voxels (78 – 91 voxels)), hippocampus- 98.5 voxels 
(86 – 99 voxels), DRN- 2.5 voxels (1-5 voxels), PFC- 13.9 voxels (10-15 voxels)  
 
Specific binding of 4-[18F]MPPF in different brain regions 
4-[18F]MPPF binding in the cerebellum (non-specific binding) 
Pre-treatment with cold 4-MPPF was used to reveal the non-specific binding of 
4-[18F]MPPF.  10 mg/kg 4-MPPF pre-treatment did not affect the binding of 4-
[18F]MPPF in the cerebellum, an area reported to be essentially devoid of 5-HT 
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1A receptors.  Thus a two-way ANOVA, examining water vehicle vs. 10 mg/kg 4-
MPPF pre-treatment, revealed a significant main effect of time (F 8, 80 = 27.4; p 
= < 0.001), but no significant time x pre-treatment interaction (F 8, 80 = 0.3; p = 
0.973), and no significant effect of pre-treatment (F1,10 = 0.4; p = 0.521).  
These data indicate that there is minimal specific binding of 4-[18F]MPPF in the 
cerebellum, and on the basis of these data 4-[18F]MPPF binding (SUV) in the 
cerebellum was used as a measure of non-specific binding in the brain (Figure 
55).   
 
Effect of cold 4-MPPF (10 mg/kg) pre-treatment on 4-[18F]MPPF binding in the cerebellum 
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Figure 55: Mean 4-[
18
F]MPPF uptake and washout in the cerebellum; effect of cold 4-MPPF 
(10 mg/kg) pre-treatment. Values are mean ±sem, n = 5 (water) and n = 7 (4-MPPF). 
 
4-[18F]MPPF binding in the hippocampus 
4-[18F]MPPF accumulated rapidly in the hippocampus within the first minute 
followed by a fast washout, nearing equilibrium within 10 minutes.  4-MPPF pre-
treatment decreased the specific binding of 4-[18F]MPPF in the hippocampus by 
83.4% at 5 min. Thus, a two-way ANOVA, examining the effect of 10 mg/kg 4-
MPPF pre-treatment revealed a significant main effect of time (F 8, 80 = 3.9; p = 
0.001), a significant time x pre-treatment interaction (F 8, 80 = 6.1; p = < 0.001), 
and a significant effect of pre-treatment (F1,10 = 15.6; p = 0.003). A post-hoc t-
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test revealed a significant effect of 4-MPPF pre-treatment at time points 
between t = 3 – 30 min (p = 0.002 – 0.038) (Figure 56). 
 
Effect of cold 4-MPPF (10 mg/kg) pre-treatment on 4-[18F]MPPF 
specific binding in the hippocampus
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Figure 56: Mean 4-[
18
F]MPPF specific binding in the hippocampus; effect of cold 4-MPPF 
(10 mg/kg) pre-treatment. Values are mean ±sem, n = 5 (water) and n = 7 (4-MPPF).    * p < 
0.05 (post-hoc t-test.). 
 
4-[18F]MPPF binding in the DRN 
4-[18F]MPPF accumulated rapidly in the DRN within the first minute followed by 
a fast washout, nearing equilibrium within 5 minutes.  4-MPPF pre-treatment 
increased the specific binding of 4-[18F]MPPF in the DRN by 300% at 5 min. 
However, a two-way ANOVA, examining 10 mg/kg 4-MPPF pre-treatment vs. 
water vehicle, revealed a significant main effect of time (F 8, 80 = 5.4; p = < 
0.001), but no significant effect of time x pre-treatment (F 8, 80 = 4.7; p = 
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0.875), and no significant effect of pre-treatment (F1,10 = 0.1; p = 0.263) 
(Figure 57).  
Effect of cold 4-MPPF (10 mg/kg) pre-treatment on 4-[18F]MPPF
 specific binding in the DRN
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Figure 57: Mean 4-[
18
F]MPPF specific binding in the DRN; effect of cold 4-MPPF (10 mg/kg) 
pre-treatment. Values are mean ±sem, n = 5 (water) and n = 7 (4-MPPF). 
 
 4-[18F]MPPF binding in the PFC 
4-[18F]MPPF accumulated rapidly in the PFC within the first minute followed by 
a fast washout, nearing equilibrium within 10 minutes.  4-MPPF pre-treatment 
decreased the specific binding of 4-[18F]MPPF in the PFC by 71.4% at 5 min. 
Thus, A two-way ANOVA, examining 10 mg/kg 4-MPPF pre-treatment vs. water 
vehicle, revealed a significant main effect of time (F 8, 80 = 4.0; p = 0.001), a 
significant time x pre-treatment interaction (F 8, 80 = 5.1; p = < 0.001), and a 
significant effect of pre-treatment (F1,10 = 7.0; p = 0.024). A post-hoc t-test 
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revealed a significant difference of 4-MPPF pre-treatment at time points 
between t = 6 – 30 min (p = 0.01 – 0.02) (Figure 58). 
 
Effect of cold 4-MPPF (10 mg/kg) pre-treatment on 4-[18F]MPPF
 specific binding in the PFC
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Figure 58: Mean 4-[
18
F]MPPF specific binding in the PFC; effect of cold 4-MPPF (10 mg/kg) 
pre-treatment. Values are mean ±sem, n = 5 (water) and n = 7 (4-MPPF).  * p < 0.05 (post-
hoc t-test.). 
 
Effects of endogenous 5-HT release on 4-[18F]MPPF binding 
Here pre-treatment with the 5-HT releasing agent fenfluramine was used to 
examine the effect of raised levels of endogenous 5-HT on 4-[18F]MPPF specific 
binding in different brain areas. 
 
 124 
 
Effect of fenfluramine pre-treatment on the binding of 4-[18F]MPPF in the 
hippocampus 
Pre-treatment with fenfluramine (3 mg/kg) had no effect on the specific binding 
of 4-[18F]MPPF in the hippocampus.  Thus, a two-way ANOVA, examining 
effects of 3 mg/kg fenfluramine pre-treatment vs. saline vehicle, revealed a 
significant main effect of time (F 8, 80 = 5.1; p = < 0.001), but no significant time 
x fenfluramine interaction (F 8, 80 = 0.7; p = 0.658), and no significant effect of 
fenfluramine (F1,10 = 0.1; p = 0.741) (Figure 59).  
 
Effect of fenfluramine (3 mg/kg) pre-treatment on 4-[18F]MPPF
 specific binding in the hippocampus
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Figure 59: Mean 4-[
18
F]MPPF specific binding in the hippocampus; effect of fenfluramine (3 
mg/kg) pre-treatment. Values are mean ±sem, n = 7 (saline) and n = 5 (fenfluramine).   
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Effect of fenfluramine pre-treatment on the binding of 4-[18F]MPPF in the 
DRN. 
Pre-treatment with fenfluramine (3 mg/kg) had no effect on the specific binding 
of 4-[18F]MPPF in the DRN.  Thus, a two-way ANOVA, examining 3 mg/kg 
fenfluramine pre-treatment vs. saline vehicle, revealed a significant main effect 
of time (F 8, 80 = 12.1; p = < 0.001), but no significant time x fenfluramine 
interaction (F 8, 80 = 1.3; p = 0.246) and no significant effect of fenfluramine 
(F1,10 = 0.2; p = 0.653) (Figure 60).  
 
Effect of fenfluramine (3 mg/kg) pre-treatment on 4-[18F]MPPF
 specific binding in the DRN
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Figure 60: Mean 4-[
18
F]MPPF specific binding in the DRN; effect of fenfluramine (3 mg/kg) 
pre-treatment. Values are mean ±sem, n = 7 (saline) and n = 5 (fenfluramine).   
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Effect of fenfluramine pre-treatment on the binding of 4-[18F]MPPF in the 
PFC 
Pre-treatment with fenfluramine (3 mg/kg) had no effect on the specific binding 
of 4-[18F]MPPF in the PFC.  Thus, a two-way ANOVA, examining 3 mg/kg 
fenfluramine pre-treatment vs. saline vehicle, revealed a significant main effect 
of time (F 8, 80 = 3.4; p = 0.002), but no significant time x fenfluramine 
interaction (F 8, 80 = 0.3; p = 0.952), and no significant effect of fenfluramine 
(F1,10 = 0.5;p = 0.486) (Figure 61).  
 
Effect of fenfluramine (3 mg/kg) pre-treatment on 4-[18F]MPPF
 specific binding in the PFC
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Figure 61: Mean 4-[
18
F]MPPF specific binding in the PFC; effect of fenfluramine (3 mg/kg) 
pre-treatment. Values are mean ±sem, n = 7 (saline) and n = 5 (fenfluramine).   
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Effect of 4-[18F]MPPF quantity injected and radio-purity on ligand kinetics 
(specific binding and washout) 
Pearson’s correlation coefficients were calculated to determine any relationship 
between both the quantity (µmol/kg) and radio-purity (%) of 4-[18F]MPPF 
injected and the maximum specific binding (SUV) and washout in each brain 
area.    
 
Correlation of quantity injected and maximum specific binding 
As shown in Table 23 there was no significant correlation between quantity of 4-
[18F]MPPF injected and the maximal specific binding in any brain area, for any 
of the treatment groups. 
 
 Hippocampus DRN PFC 
Pearson 
correlati
on 
p (2-
tailed) 
n Pearson 
correlation 
p (2-tailed)) n Pearson 
correlation 
p (2-
tailed) 
n 
Vehicle -0.263 0.410 12 -0.021 0.949 
. 
12 -0.303 0.338 12 
4-MPPF  -0.389 0.388 7 -0.391 0.386 7 -0.274 0.552 7 
Fenfluramine 0.790 0.112 5 -0.714 0.176 5 0.817 0.091 5 
Table 23: Correlation between maximum specific binding (SUV) and quantity of 4-
[
18
F]MPPF injected (µmol/Kg).  Data based on specific activity obtained from crude HPLC 
measurement. 
 
Correlation of radiopurity and maximum specific binding 
As shown in Table 24 there was no significant correlation between radiopurity of 
the 4-[18F]MPPF injected and the maximal specific binding in the vehicle group 
(all brain areas).  Whilst there did appear to be a significant correlation between 
radiopurity and maximal specific binding in fenfluramine treatment group 
(hippocampus and PFC), all data points had a radio-purity of 100% except for 
one, which was 93.1%.  As only one data point differed it may have resulted in a 
skewed significance. 
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 Hippocampus DRN PFC 
Pearson 
correlati
on 
p (2-
tailed) 
n Pearson 
correlati
on 
p (2-
tailed) 
n Pearson 
correlation 
p (2-
tailed) 
n 
Vehicle 0.129 0.761 8 -0.245 0.559 8 0.080 0.851 8 
4-MPPF  ** ** ** ** ** ** ** ** ** 
Fenfluramine -0.959 0.010 5 0.421 0.480 5 -0.932 0.021 5 
Table 24: Correlation between maximum specific binding (SUV) and radio-purity (%) of 4-
[
18
F]MPPF injected (µmol/Kg).  ** insufficient data for analysis. 
 
Correlation of quantity injected on washout 
As shown in Table 25 there was no significant correlation between quantity of 4-
[18F]MPPF injected and the washout rate in any brain area, for any of the 
treatment groups. 
 
 Hippocampus DRN PFC 
Pearson 
correlation 
p (2-
tailed) 
n Pearson 
correlation 
p (2-tailed) n Pearson 
correlation 
p (2-tailed) n 
Vehicle 0.042 0.897 12 0.021 0.949 12 -0.104 0.749 12 
4-MPPF  -0.336 0.461 7 -0.210 0.651 7 0.119 0.8 7 
Fenfluramine 0.614 0.271 5 -0.721 0.169 5 0.727 0.164 5 
Table 25: Correlation between brain area ligand washout (SUV) and 4-[
18
F]MPPF injected 
(µmol/Kg).  Data based on specific activity obtained from crude HPLC measurement 
 
Correlation of radiopurity on washout 
As shown in Table 26 there was no significant correlation between radiopurity of 
the 4-[18F]MPPF injected and the washout rate in the vehicle group (all brain 
areas).  Whilst there did appear to be a significant correlation between 
radiopurity and washout rate in fenfluramine treatment group (hippocampus and 
PFC), all data points had a radiopurity of 100% except for one, which was 
93.1%.  As only one data point differed it may have resulted in a skewed 
significance. 
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 Hippocampus DRN PFC 
Pearson 
correlation 
p (2-tailed) n Pearson 
correlation 
p (2-
tailed) 
n Pearson 
correlation 
p (2-tailed) n 
Vehicle -0.256 0.541 8 -0.307 0.459 8 -0.136 0.748 8 
4-MPPF  ** ** ** ** ** ** ** ** ** 
Fenfluramine -0.910 0.032 5 0.624 0.261 5 -0.939 0.018 5 
Table 26: Correlation between ligand washout (SUV) and radio-purity (%) of 4-[
18
F]MPPF 
injected (µmol/Kg).  ** insufficient data for analysis. 
 
5.3 Discussion 
 
4-[13H]MPPF in vitro autoradiography  
Brain distribution of 4-[3H]MPPF 
The brain distribution of 4-[3H]MPPF binding was similar to areas shown to be 
high in 5-HT 1A receptor sites in studies labelling with the selective 5-HT 1A 
receptor agonist (±)-8-OH-DPAT and selective antagonist WAY100635 
(Sijbesma et al., 1991, Khawaja, 1995, Plenevaux et al., 2000). The distribution 
is also in agreement with previous studies examining the autoradiographic 
profile of 4-[18F]MPPF (Plenevaux et al., 2000, Moulin-Sallanon et al., 2009, 
Riad et al., 2004, Udo de Haes, 2005, Zimmer et al., 2002b, Desbree et al., 
2008).  The cerebellum showed a very low level of labelling in agreement with 
that seen in tissue incubated in the presence of 10µM (±)-8-OH-DPAT or 
WAY100635 (Kung et al., 1995, Riad et al., 2004, Duncan and Hensler, 2002) 
which is generally taken to indicate non-specific binding in the literature.  
 
Effect of (±)-8-OH-DPAT on the binding of 4-[3H]MPPF in different brain 
areas 
This study found 0.07 nM (±)-8-OH-DPAT had negligible effect on the binding of 
4-[3H]MPPF, with only the PFC showing a reduction in binding to 92.1% vs. 
control.  It had been intended to use this as a measure of non-specific binding, 
as (±)-8-OH-DPAT is a 5-HT 1A receptor agonist and therefore competes with 4-
MPPF binding at the 5-HT 1A receptor.  However, to obtain a measure of non-
specific binding the 4-[3H]MPPF must be fully displaced.  However, it appears a 
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concentration of 0.07 nM is not sufficient to fully displace 4-[3H]MPPF.  Other 
studies have used 10 µM (±)-8-OH-DPAT or WAY100635-HT to fully displace 4-
[18F]MPPF (Duncan and Hensler, 2002, Kung et al., 1995, Riad et al., 2004) 
which appears to be a more suitable concentration. 
 
Effect of 5-HT on specific binding of 4-[3H]MPPF in different brain regions 
In chapter 4 the microdialysis study found that fenfluramine (3 mg/kg) 
administration increased the hippocampal 5-HT concentration to 1 x 10-8 M.  
Therefore, it is of interest to examine the reduction in binding of 4-[3H]MPPF in 
vitro to assess the impact of 1 x 10-8 M 5-HT on specific binding, as this will be 
the predicted hippocampal 5-HT concentration in the PET and ex vivo 
autoradiography studies in this thesis.  
In this study 4-[3H]MPPF specific binding was reduced to 78.3 – 85.4% of 
control in the hippocampus, DRN and PFC when incubated with 5-HT at a 
concentration of 2 x 10-8 M.  This is in conflict with one report, examining 4-
[125I]MPPF in the rat hippocampus, which reports a reduction in binding to 25% 
control at this 5-HT concentration (Kung et al., 1995).   
In this study a significant reduction in binding was found when 4-[3H]MPPF was 
incubated with the higher concentration of 5-HT of 2 x 10-6 M in the DRN and 
PFC.  Binding was reduced to 11.5% control for the PFC, 17.9% for the DRN 
but only 32.1% for the hippocampus. Other studies have reported binding 
reduced to 10% or 60% control in the hippocampus at the same 5-HT 
concentration (Kung et al., 1995, Moulin-Sallanon et al., 2009).  Therefore it 
appears there is considerable variability in the reports.  In fact our present study 
adds to the variability. 
Displacement curves, as those shown in Figures 43 – 45, should fit a sigmoidal 
curve with a slope of 1 if binding to only one site.  However, insufficient data at 
the high 5-HT concentrations precluded the fitting of such a curve to the present 
data, so evidence of the number of binding sites could not be shown. 
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0.14 and 1.4 nM 4-[3H]MPPF autoradiography 
In contrast to the 10nM concentration, it was found that 0.14 nM and 1.4 nM 
concentrations of 4-[3H]MPPF gave a very weak signal compared to the 
background optical density of the autoradiographic film.  Due to this, a high 
signal to noise ratio was observed.  In addition, the scale of the calibration 
curves was above the range required to calibrate the low optical density values 
from these experiments resulting in many of the calibrated measurements 
having negative activities. 
One study examining the autoradiographic profile of 4-[3H]MPPF in the rat 
hippocampus and PFC used a concentration of 2 nM 4-[3H]MPPF (Landry and 
Di Paolo, 2003) and found this to provide adequate images.  This study used 
the same autoradiographic film and had a similar ligand specific activity (66.2 
Ci/µmol vs. 75 Ci/µmol in this study), and used a shorter exposure time than 
this study (6 weeks vs.3 months used in this study).   
 
 
4-[18F]MPPF ex vivo autoradiography  
 
Brain distribution of 4-[18F]MPPF 
As with the 4-[3H]MPPF binding, the brain distribution of 4-[18F]MPPF binding 
was similar to areas shown to be high in 5-HT 1A receptor sites in studies 
labelling with the selective 5-HT 1A receptor agonist (±)-8-OH-DPAT and 
selective antagonist WAY100635 (Sijbesma et al., 1991, Khawaja, 1995, 
Plenevaux et al., 2000). The distribution is also in agreement with previous 
studies examining the autoradiographic profile of 4-[18F]MPPF (Plenevaux et al., 
2000, Moulin-Sallanon et al., 2009, Riad et al., 2004, Udo de Haes, 2005, 
Zimmer et al., 2002b, Desbree et al., 2008).  The cerebellum showed a very low 
level of labelling in agreement with that seen in tissue incubated in the presence 
of 10µM (±)-8-OH-DPAT or WAY100635 (Kung et al., 1995, Riad et al., 2004, 
Duncan and Hensler, 2002) which is generally taken to indicate non-specific 
binding in the literature.  
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Specific binding of 4-[18F]MPPF in different brain regions 
In this study a pre-treatment with cold 4-MPPF was used to block the binding of 
4-[18F]MPPF with a view to differentiating regions of specific and non-specific 
binding.  The specific binding of 4-[18F]MPPF was examined in four brain 
regions, three 5-HT 1A receptor rich areas; hippocampus, DRN and PFC, and 
one where 5-HT 1A receptors are sparse; the cerebellum.   
Pre-treatment with 4-MPPF did not affect the binding in the cerebellum, 
suggesting there was no specific binding of 4-[18F]MPPF in this region.  This 
conclusion supports the use of the cerebellum as a region of non-specific 
binding in this study, which is in line with the protocol used in previous 4-
[18F]MPPF ex vivo autoradiographic studies (Moulin-Sallanon et al., 2009, Udo 
de Haes, 2005). 
In this study, 4-MPPF (10 mg/kg) pre-treatment had no significant effect on the 
specific binding 4-[18F]MPPF in the hippocampus (p = 0.17).  However there 
was a possible effect seen in the DRN (p = 0.059) and the specific binding was 
significantly reduced in the PFC (p = 0.041).  This suggests 4-[18F]MPPF was 
specifically bound in the PFC and strongly indicates this was also the case in 
the DRN.  Unexpectedly no effect was seen in the hippocampus.   
Using a YAP-(S)PET scanner, a scanner which combines the PET and SPECT 
techniques (YAP-(S)PET), one study demonstrated that a dose of 0.5 mg/kg 4-
MPPF caused complete displacement of 4-[18F]MPPF in the hippocampus, 
raphe nucleus and frontal cortex of the rat (Millet et al., 2008), suggesting the 
dose used in this study (10 mg/kg) is sufficient to cause complete displacement 
of 4-[18F]MPPF.  The present findings are in agreement with the reported study 
when considering the PFC and are strongly suggestive that this is also the case 
in the DRN. However this is not the case in the hippocampus in this study.  This 
may be due to experimental error resulting from intra-hippocampal differences 
in 5-HT 1A receptor density.  Sub-regions of the hippocampus do have 
differences in 5-HT 1A receptor density whilst the DRN and the PFC appear to 
have a more homogenous distribution of 5-HT 1A receptors.  Given only three 
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random samples were examined from each area, the large variance in the 
hippocampal measurements may explain the lack of statistical significance. 
 
Effects of endogenous 5-HT release on 4-[18F]MPPF binding in the 
Hippocampus, DRN and PFC 
This study found pre-treatment with the 5-HT releasing agent fenfluramine (3 
mg/kg) did not have a significant effect on the binding of 4- [18F]MPPF in any 
brain region.  This is in conflict with one study examining the effect of 
fenfluramine (10 mg/kg) on 4-[18F]MPPF using ex vivo autoradiography, which 
found a significant reduction in binding in the frontal cortex, hippocampus and 
DRN of the rat in the fenfluramine treated group (Udo de Haes, 2005).  The 
difference could be explained by the higher dose of fenfluramine used in the 
study.  Two further studies examined the effect of fluoxetine (2 or 10 mg/kg) 
(Plenevaux et al., 2000, Riad et al., 2004) on 4-[18F]MPPF binding in the rat 
brain.  In agreement with this study no significant effect on binding was 
observed in the hippocampus, DRN or frontal cortex.  Other studies have 
examined the effects of citalopram (0.5 mg/kg) or combined 
citalopram/ketanserin (10 µmol/kg / 100 nmol/kg) using ex vivo autoradiography 
in the rat brain (Moulin-Sallanon et al., 2009, Udo de Haes, 2005).  Significant 
decrease in binding was only found in one study in the DRN after 
citalopram/ketanserin (10 µmol/kg / 100 nmol/kg) treatment (Udo de Haes, 
2005).  However it is difficult to interpret the results of some of these earlier 
studies as it is unclear what the consequences of acute SSRI’s were on 
extracellular 5-HT levels, and furthermore any changes in extracellular 5-HT 
were not quantified. 
 
Effect of 4-[18F]MPPF quantity injected and radio-purity on ligand kinetics 
(specific binding and washout) 
This study found no correlation between the maximum specific binding or 
washout of 4-[18F]MPPF and the quantity administered or radiopurity. This will 
be further discussed and compared to the PET results in the PET discussion  
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PET imaging  
 
Uptake kinetics and brain distribution of 4-[18F]MPPF in the rat (controls) 
In accordance with the literature, uptake of 4-[18F]MPPF (in control groups) was 
highest in the 5-HT 1A receptor rich areas of the hippocampus, DRN and PFC 
and lowest in the 5-HT 1A receptor poor cerebellum (Sijbesma et al., 1991, 
Khawaja, 1995, Passchier et al., 2000, Plenevaux et al., 2000, Aznavour and 
Zimmer, 2007).   
Whilst the literature to date reports that  uptake is highest in areas known to be 
rich in 5-HT 1A receptors, it also reports that washout is slowest in these areas 
(Bars et al., 1998, Shiue et al., 1997, Aznavour and Zimmer, 2007, Plenevaux 
et al., 2000, Kung et al., 1996b, Passchier et al., 2000, Sijbesma et al., 1991, 
Khawaja, 1995, Millet et al., 2008).  However, in contrast to published data, in 
this study we found that the washout rate was fastest in the DRN, an area rich 
in 5-HT 1A receptors, and the hippocampus, PFC and cerebellum had 
approximately equal washout rates.   
Previous in vivo PET and β-microprobe studies have demonstrated a rapid 
initial uptake of [18F]4-MPPF in the rat brain within the first 10 – 15 minutes, with 
the maximum uptake (hippocampal to cerebellum ratio) occurring at around 20 - 
30 mins, followed by a fast washout up to around 60 - 70 min (Plenevaux et al., 
2000, Shiue et al., 1997, Zimmer et al., 2003, Wu et al., 2004) with one study 
showing only 0.03% activity remaining at 60 min (Shiue et al., 1997).  However 
other studies using a β-microprobe have shown activity remaining up to 3 hours 
post injection (Zimmer et al., 2002a, Zimmer et al., 2002b).  
In the present study it was found the washout rate of 4-[18F]MPPF was 
considerably faster than reported in the literature, with maximum 
hippocampus/DRN/PFC:cerebellum ratio occurring at 3 minutes, in contrast with 
20 minutes in the literature (Shiue et al., 1997, Plenevaux et al., 2000, Zimmer 
et al., 2003, Wu et al., 2004).  In addition, a cerebellum to brain area ratio of 1.7 
– 1.8 was obtained in these experiments, in contrast with 5.6 at 30 minutes in 
one study (Shiue et al., 1997).  This could indicate there was less specific 
binding in our experiments compared to the literature.  This would be consistent 
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with the lower specific activity used, being between 0.1 – 17.8 GBq/µmol in 
comparison to between 30 – 185 GBq/µmol in the literature, as specific activity 
has an effect on radioligand specific binding and washout profiles (Bars et al., 
1998, Aznavour, 2009, Bartmann et al., 2010, Moulin-Sallanon et al., 2009). 
In the present study, in order to increase the uptake and reduce the washout 
time of the 4-[18F]MPPF, animals were pre-treated with cyclosporine (50 mg/kg).  
Cyclosporine (50 mg/kg) pre-treatment has been shown increase in 4-
[18F]MPPF uptake by 200 -1000% (Passchier et al., 2000, Elsinga et al., 2005 , 
Laćan et al., 2008).  In addition cyclosporine has been shown not to have an 
effect on the brain distribution of 4-[18F]MPPF, correlating to the binding of 
methoxy-[3H]WAY100635 (Passchier et al., 2000).  Therefore, cyclosporine pre-
treatment should provide the positive effect of slowing the washout time, without 
affecting actual 4-[18F]MPPF binding.  
 
Specific binding of 4-[18F]MPPF in different brain regions 
In this study pre-treatment with cold 4-MPPF was used to block the binding of 4-
[18F]MPPF with a view to identifying regions of specific binding.  A dose of 10 
mg/kg was chosen in line with previous studies (Thielen and Frazer, 1995, 
Thielen, 1996).  In a later YAP-(S)PET study it was shown a dose of 0.5 mg/kg 
4-MPPF caused complete displacement of 4-[18F]MPPF in the hippocampus, 
raphe and frontal cortex of the rat (Millet et al., 2008), confirming that the dose 
used in this study is sufficient to cause complete displacement. 
The specific binding of 4-[18F]MPPF was examined in four brain regions, three 
5-HT 1A receptor rich areas; hippocampus, DRN and PFC, and one where 5-HT 
1A receptors are sparse; the cerebellum.   
Pre-treatment with 4-MPPF did not affect the binding in the cerebellum, 
suggesting there was no specific binding of 4-[18F]MPPF in this region.  This 
conclusion supports the use of the cerebellum as a region of non-specific 
binding in this study, which is in line with the protocol in previous 4-[18F]MPPF 
PET studies (Aznavour et al., 2006, Udo De Haes et al., 2006, Ginovart et al., 
2000). 
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In this study, the binding of 4-[18F]MPPF was significantly reduced in the 
hippocampus and PFC with a pre-treatment of 4-MPPF.  This suggests 4-
[18F]MPPF was specifically bound in these areas.   
However, in this study pre-treatment with 4-MPPF did not significantly affect the 
binding of 4-[18F]MPPF in the DRN.  This is in conflict with the literature which 
reports a significant decrease in binding using a lower dose of 1 mg /kg 4-MPPF 
post treatment (Zimmer et al., 2002b) and a total displacement using 0.5 mg/kg 
post treatment in the raphe of the rat (Millet et al., 2008).   
However there are issues related to the spatial resolution for the Phillips Mosaic 
PET scanner which is reported to be between 1.9 – 2.7 mm (FWHM) (Surti et 
al., 2005, Huisman et al., 2007, Yao et al., 2012).  The hippocampus, 
cerebellum and PFC are relatively large brain areas, so the volume of interest 
for each area contained a sufficient number of voxels to assume it was above 
the level of the scanner resolution.  However, the DRN is a comparatively small 
brain area, (2 mm anterior – posterior, 1 – 2.6 mm medo-lateral, 1 – 5.1 mm 
dorsal – ventral) with the VOI containing a mean of 2.5 voxels (1- 5 voxels).  
Although it is difficult to make a general comment on the impact of the size of 
the VOI with regards to the PET scanner spatial resolution, especially as the 
shape of the VOI and the number of voxels it contains will change for each 
image due to the co-registration process, it can be assumed that a VOI 
containing only a few voxels will be near the limit of the detector resolution.  
This fact, coupled with the low sample numbers (n = 5 – 7), it can be concluded 
that the SUV data from the DRN will be less accurate than those from the larger 
brain areas.  Therefore, the inconsistency in this study could be explained by 
the small size of the DRN and subsequent potential for variability in the results. 
 
Effects of endogenous 5-HT release on 4-[18F]MPPF binding in the 
hippocampus, DRN and PFC 
The classic receptor occupancy model suggests a correlation between the 
levels of endogenous neurotransmitters and the amount of in vivo binding of 
competing radiolabelled ligands (Aznavour and Zimmer, 2007).  In the case of 
4-[18F]MPPF an increase of endogenous 5-HT could therefore compete for 
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binding sites at the 5-HT 1A receptor resulting in reduced binding of 4-
[18F]MPPF.  Inversely a reduction in endogenous 5-HT could leave more 
binding sites free for 4- [18F]MPPF therefore increasing its overall binding. 
Drug challenges have been used in many studies to examine the relationship 
between endogenous 5-HT levels and 4-[18F]MPPF binding in the brain, but 
there are inconsistencies in the reported characteristics of 4-[18F]MPPF in the 
presence of a drug induced increase of endogenous 5-HT .  Some studies 
report 4-[18F]MPPF binding is reduced by an increased level of 5-HT , indicating 
it is displaceable by 5-HT and consistent with the occupancy model (Aznavour 
et al., 2006, Rbah et al., 2003, Riad et al., 2004, Zimmer et al., 2002b, Zimmer 
et al., 2002a, Zimmer et al., 2003).  However, other studies report no such 
change in binding during the drug challenge (Aznavour et al., 2006, Ginovart et 
al., 2000, Moulin-Sallanon et al., 2009, Riad et al., 2004, Riad, 2008, Udo De 
Haes et al., 2006). 
The present study found pre-treatment with the 5-HT releasing agent 
fenfluramine (3 mg/kg) did not have a significant effect on the binding of 4- 
[18F]MPPF in any brain region.  As the microdialysis study performed in chapter 
3 revealed the 5-HT concentration at the time of 4-[18F]MPPF injection would be 
1 x 10-8 M, the PET result would suggest 4- [18F]MPPF is not displaceable by 1 
x 10-8 M endogenous 5-HT.  This is consistent with the in vitro 4-[3H]MPPF 
study performed in this chapter, which showed no significant reduction in 
binding in any brain area when incubated with 2 x 10-8 M 5-HT .  However in the 
in vitro study, 2 x 10-6 M 5-HT caused significant displacement in all brain areas.  
Therefore it would be of interest to repeat our PET study at a higher dose of 
fenfluramine which replicated an endogenous 5-HT concentration of 2 x 10-6 M 
or above, to assess whether this would displace 4- [18F]MPPF in vivo.   
However, one issue that needs to be raised is that part of the aim of the present 
study was not only to use a characterised (w.r.t. 5-HT release) dose of 
fenfluramine, but also attempt to use the dose of fenfluramine that could be 
translated in human studies.  Whilst it is not easy to compare rodent and human 
doses, the fenfluramine dose used here (3 mg/kg) was still double that of the 
maximum daily dose of 1.7 mg /kg of fenfluramine used in published human 
studies (Lewis et al., 1971).  Therefore increasing to higher dosages in this pre-
clinical studies may not represent conditions possible for clinical studies. 
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In conflict with the present study, five PET or β microprobe studies have 
reported significantly decreased 4-[18F]MPPF binding in the hippocampus, DRN 
or frontal cortex of the rat (Rbah et al., 2003, Riad et al., 2004, Zimmer et al., 
2002b, Zimmer et al., 2002a, Zimmer et al., 2003), and in the cat (Aznavour et 
al., 2006) with pharmacologically induced increased endogenous 5-HT .  
Furthermore, one has shown significantly increased binding in the hippocampus 
of the rat with decreased 5-HT.  These results suggest 4-[18F]MPPF is sensitive 
and to changes in endogenous 5-HT and displaceable.  In contrast, six studies 
performed in monkey, cat and rat have not shown any effect of increased 
endogenous 5-HT on the binding of 4-[18F]MPPF in the same areas (Aznavour 
et al., 2006, Ginovart et al., 2000, Moulin-Sallanon et al., 2009, Riad et al., 
2004, Riad, 2008, Udo De Haes et al., 2006). 
The different reports can possibly be explained by several factors which are not 
consistent between the experimental protocols.   
Firstly there are variable reports as to the concentration of endogenous 5-HT 
examined in the displacement experiments.  In this study a pre-treatment of 
fenfluramine (3 mg/kg) (in combination with cyclosporine) was found by 
microdialysis study in chapter 3 to produce a maximum 400% increase in 
endogenous 5-HT in the hippocampus.  As the PET protocol was under the 
same conditions as the microdialysis experiment, it can be predicted that the 
endogenous 5-HT in the hippocampus of the rat at the time of 4-[18F]MPPF 
administration was at this maximum value of 1 x 10-8 M.  However other studies 
have used doses of fenfuramine ranging from 1-10 mg/kg in a range of different 
species (e.g cat, monkey, rat) and using different time courses. 
There is also the state of the 5-HT 1A receptor to take into consideration, which 
can exist in a high or low affinity state (Gozlan et al., 1995, Khawaja, 1995, 
Nenonene et al., 1994, Udo De Haes et al., 2006, Watson et al., 2000).  
Receptor antagonists, such as 4-[18F]MPPF bind equally to both affinity states, 
whereas agonists, such as 5-HT , will bind preferentially to the high affinity state 
(Gozlan et al., 1995, Khawaja, 1995, Nenonene et al., 1994, Udo De Haes et 
al., 2006, Watson et al., 2000).  Therefore it is possible that changes in 5-HT 
will only effect the 4-[18F]MPPF that is bound to high affinity state receptors.  If 
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the proportion of high to low affinity state 5-HT 1A receptors is different between 
studies this could affect the resultant binding profiles.    
Lastly the brain area examined differs between studies and it could be 
concluded that binding characteristics for a particular PET ligand will not be 
consistent in different areas (Udo De Haes et al., 2006). 
In this thesis the experimental protocol was designed such that variables such 
as anaesthesia, 4-[18F]MPPF administration vs. max 5-HT concentrations, brain 
areas examined and animal type were all kept constant.  It is clear that any 
future PET studies with 4-[18F]MPPF will need to take into account the many 
variables discussed above and design the experimental protocol to minimise 
such differences.   
 
Clinical studies 
4-[18F]MPPF has been used in a number of clinical PET studies.  The binding, 
distribution and test to test variability have been characterised in several studies 
and found to be suitable for clinical PET studies of the 5-HT system (Costes et 
al., 2005, Costes, 2007, Passchier, 2000, Sanabria-Bohórquez et al., 2002).  In 
addition 4-[18F]MPPF has been examined in variety of CNS diseases and 
disorders including; temporal lobe epilepsy, depression, narcolepsy, 
Alzheimer’s, dementia, anorexia nervosa, migraine, Parkinsons and 
schizophrenia (Ballanger et al., 2012, Demarquay et al., 2011, Derry et al., 
2006, Didelot et al., 2008, Galusca et al., 2008, Kepe et al., 2006, Lerond et al., 
2013, Lothe et al., 2008a, Lothe et al., 2008b, Lothe et al., 2012, Merlet et al., 
2004, Merlet, 2004, Truchot et al., 2008, Truchot et al., 2007).  In addition 4-
[18F]MPPF has been used in combination with drug challenges in the humans, 
(Lerond et al., 2013, Lothe et al., 2012, Passchier, 2000, Udo De Haes et al., 
2002a, Passchier et al., 2001, Sibon et al., 2008).  Two of these studies are of 
particular interest to the present study.  In the first study a reduction in binding 
of 4-[18F]MPPF was found in the DRN after administration with fluoxetine (20 
mg, 0.3 mg/kg).  This suggests 4-[18F]MPPF is sensitive to increases in 
endogenous 5-HT in the human brain.  This is of interest to compare to pre-
clinical studies with fluoxetine (10 mg/kg) where two studies found reduced 
binding in the DRN (Aznavour et al., 2006, Riad et al., 2004) but a further four 
studies found no change in binding in the cortex, hippocampus and DRN 
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(Aznavour et al., 2006, Ginovart et al., 2000, Riad et al., 2004, Riad, 2008).  
This suggests that pre-clinical studies, at present, do not always predict the 
clinical outcome.  In a second study there was no change in binding of 4-
[18F]MPPF in the cortex and raphe nucleus after tryptophan depletion 
suggesting it is not sensitive to a reduction in endogenous 5-HT (Udo De Haes 
et al., 2002b).  It is clear that further work is needed to find accurate and 
reproducible methods. 
 
Effect of 4-[18F]MPPF quantity injected and radio-purity on ligand kinetics 
(specific binding and washout) 
The quantity of 4-[18F]MPPF injected into each animal was based on 
radioactivity, therefore the molar quantity of hot vs. cold 4-MPPF injected varied 
across experiments, as the specific activity of each batch varied.  In addition the 
radiopurity was not the same between experiments, so that the amount of 4-
[18F]MPPF vs. a radioactive side product varied. 
Therefore, it was hypothesized that these variations may have an effect on the 
maximum uptake and washout rate of 4-[18F]MPPF.  However, this study found 
no correlation between the maximum specific binding or washout of 4-
[18F]MPPF and the quantity administered or radiopurity.   
This may be due to the small range of values examined, as quantity injected 
ranged from 0.003 -0.02 µmol/kg and the radiopurity ranged from 83.9 – 100%, 
with only 4 of 14 not being 100%.  If larger ranges or datasets were examined a 
correlation may be seen.  There were two apparent correlations for radiopurity, 
but in these instances only one data point differed from the group, so these 
were assumed to have skewed the correlation. 
 
Comparison of PET and ex vivo autoradiography methods for examination 
of 4-[18F]MPPF ligand binding 
Autoradiography typically has a spatial resolution approximately an order of 
magnitude higher than that of PET, being in the range of a few hundreds 
microns compared to  around 1-2 mm with PET (Schmidt and Smith, 2005).  
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Therefore it would be expected autoradiography would be more accurate when 
looking for change in ligand binding in small structures, such as are found in the 
rat brain.  However, PET has the advantage that ligand binding can be 
assessed over time in an entire brain region, whereas autoradiography may 
only study a few sections in each brain area at one time point.   
In this study the distribution and changes in 4-[18F]MPPF specific binding, 
revealed by PET and ex vivo autroradiographic studies following the same 
protocols, were generally in agreement.  However, in one instance a significant 
reduction in binding was found in PET where no significance was found in 
autoradiography, which was with a 4-MPPF pre-treatment in the hippocampus.   
Several studies have compared PET and autoradiography methods, for a 
variety of PET ligands, and found good consensus in the results (Toyama et al., 
2004, Strome et al., 2006, Mizuma et al., 2010).  One study compared PET and 
autoradiography for the PET ligand [18F]FDG (Prieto et al., 2011).  The study 
employed the same Philips MOSAIC PET scanner as the present study but, in 
difference to this study, performed 3-D autoradiography where complete brain 
regions were sectioned as usual then stacked into 3-D volumes and co-
registered with an MRI image for analysis.  This study concluded that PET and 
autoradiography are generally in good agreement in detecting changes in the 
rodent brain though admit PET may have difficultly detecting changes in small 
brain areas which are detectable by autoradiography (Toyama et al., 2004, 
Strome et al., 2006, Mizuma et al., 2010). 
One last consideration when comparing PET to autoradiography is the 
difference between the resolutions on autoradiographic film resulting from 
different isotopes.  A low energy β emitter such as tritium (max. 18.5 KeV) 
produces sharper images on autoradiographic film than a high energy positron 
emitter (511 KeV) such as fluorine-18 (Rogers, 1979).  Therefore comparisons 
between PET and autoradiography in small brain areas may also be affected by 
the radioisotope used.  Although examination of the absolute differences was 
beyond the scope of this study, a visual comparison can be seen in Figure 62 
and is in agreement with radioisotope image comparisons seen in the literature 
(Plenevaux et al., 2000). 
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Figure 62: Comparison of the autoradiographic resolution given by fluorine-18 (left) and 
tritium (right) with an 4-MPPF ligand in the hippocampus of the rat brain. 
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Chapter 6. General Discussion 
 
There is evidence that dysfunction of the 5-HT 1A receptor plays a role in 
affective disorders such as anxiety and depression (Didelot et al., 2008, Drevets 
et al., 2000, Hirvonen et al., 2008, Sargent et al., 2000, Shively et al., 2006, 
Savitz et al., 2009, Arango et al., 1995, Detke et al., 1995, Haddjeri et al., 1998, 
Matsubara et al., 1991, Neff et al., 2009, Stockmeier et al., 1998, Szewczyk et 
al., 2009, Zhang et al., 2009) and it has been proposed that altered 5-HT levels 
in the brain are also associated with these disorders (Ruhé et al., 2007, Asberg 
et al., 1976, Traskman-Bendz et al., 1984).  Therefore it is of interest to study 
both changes in receptor density and distribution as well as pre-synaptic 
neurotransmitter release. 
The underlying hypothesis of this thesis is that 5-HT receptor specific PET 
ligands can be displaced by endogenous neurotransmitters and this can give a 
route to examining dysfunction of neurotransmitter systems at the biochemical 
level.  However, although there are currently 5-HT 1A ligands suitable to 
examine receptor density and distribution, the challenge taken on by this study 
was to find a 5-HT 1A ligand sensitive to changes in synaptic levels of 5-HT .  
Thus, the present study aimed to chemically synthesise and biologically 
characterise 4-[18F]MPPF to determine its suitability to examine pre-synaptic 
changes in the 5-HT system using PET and autoradiography. 
In chapter two alternative precursors to 4-[18F]MPPF, 4-MPPF and 4-MPPNO2 
were successfully synthesised via the published route and fully characterised.  
In chapter three the development of a routine radiosynthesis of 4-[18F]MPPF 
was achieved using a combination of the Eckert and Zielgler ModularLab and a 
microwave reactor via a fluorodenitration reaction of 4-MPPNO2 with fluorine-18.   
4-[18F]MPPF with a radiochemical yield of 33.5%, mean specific  activity of. 4.3 
±0.7 GBq/µmol, mean radioactivity of 84.5 ± 12.1 MBq and a mean radiopurity 
of 95.8 ± 1.3% was produced with a total synthesis time of 60 minutes.  The 4-
[18F]MPPF synthesised was then used in the following PET and ex vivo 
autoradiographic studies (chapter five). 
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In chapter four and five PET and ex vivo/in vitro autoradiography studies in rats 
revealed that 4-[18F]MPPF specifically bound in areas rich in 5-HT 1A receptors 
and binding could be blocked by pre-treatment with cold 4-MPPF.  The 5-HT 
releasing agent fenfluramine was used to increase the concentration of 
endogenous 5-HT in the brain in parallel PET, autoradiography, and 
microdialysis studies.  The microdialysis studies revealed that fenfluramine 3 
mg/kg increased 5-HT levels to approximately 400% of basal levels, reaching a 
maximum concentration of 1 x 10-8 M 5-HT in the rat hippocampus.  However, 
the present PET and autoradiography studies indicated that 4-[18F]MPPF was 
not displaced by fenfluramine induced 5-HT release at this dose. 
 
6.1 Strengths of the study 
There are a number of strengths to the present study.  Firstly, this study 
successfully performed chemical synthesis of two precursors, 4-MPPF and 4-
MPPNO2.  This was followed by the development of a routine production method 
for 4-[18F]MPPF starting with low levels of activity.  The final activity and high 
radiopurity of the 4-[18F]MPPF produced made it suitable for in vivo PET 
imaging. 
Secondly this study performed parallel microdialysis, PET and autoradiographic 
studies, maintaining the same protocol throughout.  Unlike 4-[18F]MPPF PET 
studies in the literature, the present study determined the endogenous 5-HT 
concentration in the hippocampus at the time of ligand administration in PET 
and ex vivo autoradiography studies.  Therefore we were able to directly 
compare ligand binding with a specific 5-HT concentration.  It was also shown 
that 3 mg/kg fenfluramine does not produce sufficient 5-HT release to displace 
4-[18F]MPPF in the rat brain. 
Thirdly a direct comparison of PET and autoradiography methods was 
performed to characterise the distribution and displacement of 4-[18F]MPPF.  
Although here, the results of the two experimental methods were not always 
consistent with each other. 
Lastly, the present study was the first PET neuroimaging performed at 
Newcastle University.  Therefore a protocol for the development of radioligand 
synthesis starting with a low fluorine-18 activity, followed by PET imaging has 
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now been laid down for future studies.  In addition, software for PET data 
analysis was adapted for neuroimaging specifically for this project, and now 
includes a co-registration function.  This is now available for future studies. 
 
6.2 Limitations of the study 
A number of limitations were found in the present study.  Firstly, due to the low 
starting activity of the fluorine-18, the specific activity of the 4-[18F]MPPF 
produced was lower than commonly reported in the literature, which is likely to 
affect the binding and washout profile.  However, It should be noted that no 
correlation between quantity 4-[18F]MPPF injected (a factor dependent on 
specific activity and radioactivity) and specific binding was found.  This is likely 
due to the limited range of specific activity and radioactivities examined.  In 
relation to the limitation above, in the present study we administered lower 
activities (11 ±1 MBq) compared to published 4-[18F]MPPF PET studies (37 -
510 MBq) which may have affected the accuracy of detection by the PET 
scanner (Aznavour et al., 2006, Ginovart et al., 2000, Moulin-Sallanon et al., 
2009, Rbah et al., 2003, Riad, 2008, Udo De Haes et al., 2006, Zimmer et al., 
2002b, Zimmer et al., 2002a, Zimmer et al., 2003).   
In addition the present study had low group sizes which had an effect on the 
data for two reasons; due to the small volume of interest (VOI) being examined, 
particularly in the DRN, it was found that the area being examined was close to 
the PET scanner resolution.  To improve the accuracy of these results would 
require performing additional experiments to increase the group size.  The small 
group size may also have affected the comparison of PET and ex vivo 
autoradiography methods.  In general these two methods were in agreement, 
but significant change in binding was found in PET in one experiment where it 
was not in ex vivo autoradiography. 
 
6.3 Translation of this study to human studies 
When considering translating the present study to clinical studies, a number of 
factors should be considered.  Firstly, due to the larger size of the human brain, 
the spatial resolution will be less of an issue, even when differences in 
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resolution of human and small animal PET scanners are taken into 
consideration (Yao et al., 2012). 
Secondly, small animal PET studies must be performed under anaesthesia, 
which is likely to have an effect on 5-HT function.  Clinical studies can be 
performed without the use of anaesthesia so this complication is avoided.  
Finally, even though fenfluramine induced release of endogenous 5-HT was 
directly measured in the present study, it is difficult to predict how much release 
this would produce in humans. 
This said, the finding that 4-[18F]MPPF was not displaced by endogenous 5-HT 
could be exploited to some degree.  For example, should a clinical study reveal 
a change in 4-[18F]MPPF binding, it could be concluded that this change is due 
to a difference in receptor number/binding capacity and not a difference in 
endogenous 5-HT levels.  Thus, 4-[18F]MPPF could still be added to the 
research armamentarium of biological psychiatrist. 
 
6.4 Future directions 
To date only the 4- regioisomer of MPPF has been radiolabelled for PET 
imaging because a method for radiolabelling the 2- and 3- regioisomers has not 
been available until recently.  A limitation of the direct aromatic nucleophilic 
substitution reaction used in the present study is its inability to label electron 
rich arenes.  In addition, obtaining adequate yields from nucleophilic substitution 
reactions are limited to the 2- or 4- position.  However, novel diaryliodonium salt 
or copper mediated nucleophilic fluorination reactions can now be used for the 
fluorine-18 labelling of both electron rich and electron deficient arenes at any 
position on the aryl ring (Carroll and Wood, 2007, Tredwell et al., 2014). 
Therefore, these novel reactions could be used to label sites which are not 
favoured by nucleophilic substitution (Cai et al., 2008, Chun et al., 2010). 
It is hypothesised that the 3- regioisomer, and possibly to a lesser extent the 2-  
regioisomer, will be less susceptible to metabolism of the fluoride atom in vivo 
and therefore provide improved PET imaging resolution compared to 4-MPPF.  
It could also be speculated that 2- and 3- regioisomers may also demonstrate 
other properties conducive to 5-HT 1A PET imaging which are not available 
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using 4-MPPF.  Therefore future studies following from the present study will 
examine the regioisomers of [18F]MPPF with respects to PET characteristics.  In 
addition, future PET neuroimaging studies at Newcastle University now have a 
routine protocol for radiosynthesis and PET imaging in place. 
As the majority of PET ligands under study are antagonists, another vital 
avenue for future PET imaging research is to find suitable agonist ligands in 
order to exploit their particular characteristics.   
This is of particular interest in the search for a ligand that can be displaced by 5-
HT, as an agonist may be more sensitive to changes in endogenous 5-HT.  It is 
known that 5-HT agonists preferentially bind to receptors that are coupled to G-
proteins (i.e. in the high affinity state) and therefore endogenous 5-HT could 
fully displace this ligand which is competing for binding at the same population 
of receptors (Zimmer and Le Bars, 2013, Billard et al., 2014).  5-HT antagonists 
bind to both high and low affinity state receptors, so endogenous 5-HT would 
not in theory displace the antagonist ligand bound to low affinity state receptors, 
resulting in a less sensitive measurement. 
In addition there is recent evidence that the state of the G-protein receptor 
coupling is linked with the pathogenesis of mood disorders (Schreiber and 
Avissar, 2007, Thathiah and De Strooper, 2011), making new agonist ligands, in 
combination with current antagonist ligands, a vital tool to differentiate between 
high and low affinity state receptors. 
 
6.5 Conclusion 
These studies demonstrate that a combination of the Eckert and Zielgler 
ModularLab with a microwave reactor is an effective production method, when 
starting with low activity, for the synthesis of 4-[18F]MPPF for use in PET.  This 
study has also shown that 4-[18F]MPPF is a suitable PET ligand for the 
examination of the distribution of 5-HT 1A receptors in the rat brain.  However, 
this study suggests that 4-[18F]MPPF may not be suitable for use in examining 
possible changes in 5-HT in the brain in affective disorders.   
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Appendix 
Appendix: A  X-ray crystal structure data for 4-MPPF 
 
Table 1.  Crystal data and structure refinement for mac104. 
 
Identification code  mac104 
Chemical formula (moiety) C25H27FN4O2 
Chemical formula (total) C25H27FN4O2 
Formula weight  434.51 
Temperature  150(2) K 
Radiation, wavelength   
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 13.7504(9) Å  
 b = 14.5099(10) Å  
 c = 16.8016(12) Å  
Cell volume 3327.0(4) Å3 
Z 6 
Calculated density  1.301 g/cm3 
 0.090 mm1 
F(000) 1380 
Reflections for cell refinement  
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-  
 2.8 to 25.0° 
Index ranges h 16 to 16, k 17 to 16, l 19 to 19 
 99.9 %  
Reflections collected 39547 
Independent reflections 11694 (Rint = 0.0479) 
Reflections with F2  3301 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.84833 and 1.00000 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0816, 0.0000 
Data / restraints / parameters 11694 / 0 / 869 
Final R indices [F2  R1 = 0.0551, wR2 = 0.1529 
R indices (all data) R1 = 0.1529, wR2 = 0.2238 
Goodness-of-fit on F2 0.984 
Extinction coefficient 0.0009(3) 
Largest and mean shift/su 0.397 and 0.076 
Largest diff. peak and hole 0.27 and 0.20 e Å3 
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Table 2.  Atomic coordinates and equivalent isotropic displacement parameters 
(Å2) 
for mac104.  Ueq is defined as one third of the trace of the orthogonalized U
ij 
tensor. 
 
      x      y      z      Ueq 
 
O(1) 0.4841(2) 0.7217(2) 0.47322(18) 0.0323(8) 
O(2) 0.0303(3) 0.6880(2) 0.79602(19) 0.0347(9) 
N(1) 0.3344(3) 0.6176(3) 0.5132(2) 0.0221(9) 
N(2) 0.2803(3) 0.5879(3) 0.6711(2) 0.0260(9) 
N(3) 0.1396(3) 0.6058(3) 0.8605(2) 0.0263(9) 
N(4) 0.2046(3) 0.4969(3) 0.9360(2) 0.0297(10) 
C(1) 0.5508(3) 0.7887(4) 0.4511(3) 0.0369(13) 
C(2) 0.4412(3) 0.6641(3) 0.4120(3) 0.0273(12) 
C(3) 0.4675(4) 0.6587(4) 0.3317(3) 0.0348(13) 
C(4) 0.4176(4) 0.6030(4) 0.2728(3) 0.0393(14) 
C(5) 0.3396(4) 0.5519(4) 0.2926(3) 0.0444(15) 
C(6) 0.3136(4) 0.5544(4) 0.3714(3) 0.0372(13) 
C(7) 0.3619(4) 0.6101(3) 0.4320(3) 0.0264(11) 
C(8) 0.2367(3) 0.5869(3) 0.5281(3) 0.0302(12) 
C(9) 0.2125(3) 0.6224(3) 0.6134(3) 0.0228(11) 
C(10) 0.3792(3) 0.6156(3) 0.6538(3) 0.0284(12) 
C(11) 0.4041(3) 0.5813(3) 0.5686(3) 0.0274(11) 
C(12) 0.2556(3) 0.6235(3) 0.7531(3) 0.0300(12) 
C(13) 0.1766(4) 0.5646(3) 0.7834(3) 0.0285(12) 
C(14) 0.0622(3) 0.6642(3) 0.8590(3) 0.0256(11) 
C(15) 0.0150(3) 0.6994(3) 0.9360(3) 0.0205(10) 
C(16)  0.0081(3) 0.6423(3) 0.9932(3) 0.0276(12) 
C(17)  0.0527(4) 0.6785(4) 1.0631(3) 0.0373(13) 
C(18)  0.0707(4) 0.7712(4) 1.0736(3) 0.0398(15) 
C(19)  0.0503(4) 0.8298(4) 1.0185(3) 0.0376(14) 
C(20)  0.0086(3) 0.7925(3) 0.9487(3) 0.0278(12) 
C(21) 0.1900(3) 0.5873(3) 0.9314(3) 0.0234(11) 
C(22) 0.2230(3) 0.6569(4) 0.9891(3) 0.0302(12) 
C(23) 0.2694(3) 0.6310(4) 1.0568(3) 0.0377(14) 
C(24) 0.2838(4) 0.5381(4) 1.0628(3) 0.0353(13) 
C(25) 0.2511(4) 0.4735(4) 1.0014(3) 0.0347(13) 
F(1)  0.1104(2) 0.8082(2) 1.14503(19) 0.0601(10) 
F(2)  0.1107(2) 0.4750(2) 0.81126(19) 0.0608(10) 
F(3) 1.1109(2) 0.8579(2)  0.47831(19) 0.0628(10) 
O(3) 0.4837(2) 0.3884(2) 0.13914(19) 0.0332(8) 
O(4) 0.0307(3) 0.3551(2) 0.46235(19) 0.0352(9) 
N(5) 0.3353(3) 0.2841(3) 0.1799(2) 0.0237(9) 
N(6) 0.2800(3) 0.2535(3) 0.3377(2) 0.0242(9) 
N(7) 0.1392(3) 0.2728(3) 0.5267(2) 0.0247(9) 
N(8) 0.2054(3) 0.1627(3) 0.6025(2) 0.0264(9) 
C(26) 0.5500(4) 0.4559(4) 0.1175(3) 0.0385(13) 
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C(27) 0.4403(3) 0.3303(3) 0.0774(3) 0.0278(12) 
C(28) 0.4683(4) 0.3259(3)  0.0001(3) 0.0328(13) 
C(29) 0.4176(4) 0.2685(4)  0.0595(3) 0.0399(14) 
C(30) 0.3400(4) 0.2180(4)  0.0412(3) 0.0427(14) 
C(31) 0.3132(4) 0.2215(3) 0.0386(3) 0.0366(13) 
C(32) 0.3626(3) 0.2764(3) 0.0996(3) 0.0260(11) 
C(33) 0.2362(3) 0.2526(3) 0.1961(3) 0.0274(11) 
C(34) 0.2125(3) 0.2894(3) 0.2802(3) 0.0304(12) 
C(35) 0.4050(3) 0.2476(4) 0.2351(3) 0.0313(12) 
C(36) 0.3794(3) 0.2818(4) 0.3204(3) 0.0313(12) 
C(37) 0.2545(3) 0.2898(4) 0.4197(3) 0.0288(12) 
C(38) 0.1756(3) 0.2304(3) 0.4498(3) 0.0245(11) 
C(39) 0.0612(3) 0.3315(3) 0.5257(3) 0.0241(11) 
C(40) 0.0157(3) 0.3658(3) 0.6021(3) 0.0241(11) 
C(41)  0.0086(4) 0.3091(4) 0.6612(3) 0.0353(13) 
C(42)  0.0531(4) 0.3448(4) 0.7296(3) 0.0406(14) 
C(43)  0.0711(3) 0.4384(4) 0.7414(3) 0.0387(14) 
C(44)  0.0495(4) 0.4976(4) 0.6849(3) 0.0364(13) 
C(45)  0.0079(3) 0.4598(3) 0.6152(3) 0.0259(11) 
C(46) 0.1898(3) 0.2530(3) 0.5970(3) 0.0234(11) 
C(47) 0.2235(3) 0.3227(3) 0.6551(3) 0.0301(12) 
C(48) 0.2700(4) 0.2976(4) 0.7228(3) 0.0418(14) 
C(49) 0.2835(4) 0.2048(4) 0.7286(3) 0.0396(14) 
C(50) 0.2524(4) 0.1409(4) 0.6677(3) 0.0355(13) 
O(5) 0.5163(2) 0.9449(2) 0.19395(19) 0.0351(9) 
O(6) 0.9688(2) 0.9789(2)  0.12901(19) 0.0340(8) 
N(9) 0.6659(3) 1.0490(3) 0.1537(2) 0.0256(9) 
N(10) 0.7195(3) 1.0791(3)  0.0044(2) 0.0264(9) 
N(11) 0.8606(3) 1.0613(2)  0.1942(2) 0.0224(9) 
N(12) 0.7952(3) 1.1703(3)  0.2689(2) 0.0295(10) 
C(51) 0.4495(3) 0.8777(4) 0.2152(3) 0.0368(13) 
C(52) 0.5587(3) 1.0025(3) 0.2559(3) 0.0269(11) 
C(53) 0.5312(4) 1.0065(4) 0.3331(3) 0.0337(13) 
C(54) 0.5819(4) 1.0630(4) 0.3932(3) 0.0427(15) 
C(55) 0.6599(4) 1.1151(4) 0.3741(3) 0.0419(14) 
C(56) 0.6874(4) 1.1114(3) 0.2955(3) 0.0328(12) 
C(57) 0.6373(3) 1.0566(3) 0.2339(3) 0.0239(11) 
C(58) 0.7641(3) 1.0792(3) 0.1384(3) 0.0256(11) 
C(59) 0.7873(3) 1.0451(3) 0.0524(3) 0.0258(11) 
C(60) 0.6196(3) 1.0516(4) 0.0129(3) 0.0304(12) 
C(61) 0.5965(3) 1.0862(3) 0.0981(3) 0.0276(12) 
C(62) 0.7454(3) 1.0431(3)  0.0855(3) 0.0308(12) 
C(63) 0.8241(4) 1.1030(3)  0.1166(3) 0.0300(12) 
C(64) 0.9376(4) 1.0020(3)  0.1930(3) 0.0254(11) 
C(65) 0.9839(3) 0.9673(3)  0.2708(3) 0.0259(11) 
C(66) 1.0087(3) 0.8750(3)  0.2818(3) 0.0286(12) 
C(67) 1.0511(3) 0.8380(3)  0.3518(3) 0.0308(12) 
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C(68) 1.0703(3) 0.8956(4)  0.4081(3) 0.0360(13) 
C(69) 1.0515(4) 0.9876(4)  0.3964(3) 0.0398(14) 
C(70) 1.0080(4) 1.0244(4)  0.3266(3) 0.0333(12) 
C(71) 0.8093(3) 1.0809(3)  0.2648(3) 0.0222(11) 
C(72) 0.7768(3) 1.0114(3)  0.3218(3) 0.0288(12) 
C(73) 0.7307(4) 1.0370(4)  0.3898(3) 0.0358(13) 
C(74) 0.7159(4) 1.1292(4)  0.3972(3) 0.0372(13) 
C(75) 0.7481(4) 1.1930(4)  0.3346(3) 0.0370(14) 
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Table 3.   Bond lengths [Å] and angles [°] for mac104. 
 
O(1)–C(1)  1.421(6) O(1)–C(2)  1.366(6) 
O(2)–C(14)  1.224(5) N(1)–C(7)  1.416(5) 
N(1)–C(8)  1.451(5) N(1)–C(11)  1.463(6) 
N(2)–C(9)  1.462(6) N(2)–C(10)  1.462(6) 
N(2)–C(12)  1.461(5) N(3)–C(13)  1.464(5) 
N(3)–C(14)  1.365(6) N(3)–C(21)  1.419(6) 
N(4)–C(21)  1.339(6) N(4)–C(25)  1.337(6) 
C(1)–H(1A)  0.980 C(1)–H(1B)  0.980 
C(1)–H(1C)  0.980 C(2)–C(3)  1.399(6) 
C(2)–C(7)  1.410(6) C(3)–H(3A)  0.950 
C(3)–C(4)  1.370(7) C(4)–H(4A)  0.950 
C(4)–C(5)  1.372(7) C(5)–H(5A)  0.950 
C(5)–C(6)  1.374(7) C(6)–H(6A)  0.950 
C(6)–C(7)  1.378(7) C(8)–H(8A)  0.990 
C(8)–H(8B)  0.990 C(8)–C(9)  1.509(6) 
C(9)–H(9A)  0.990 C(9)–H(9B)  0.990 
C(10)–H(10A)  0.990 C(10)–H(10B)  0.990 
C(10)–C(11)  1.505(6) C(11)–H(11A)  0.990 
C(11)–H(11B)  0.990 C(12)–H(12A)  0.990 
C(12)–H(12B)  0.990 C(12)–C(13)  1.514(6) 
C(13)–H(13A)  0.990 C(13)–H(13B)  0.990 
C(14)–C(15)  1.496(6) C(15)–C(16)  1.384(6) 
C(15)–C(20)  1.383(6) C(16)–H(16A)  0.950 
C(16)–C(17)  1.385(6) C(17)–H(17A)  0.950 
C(17)–C(18)  1.359(7) C(18)–C(19)  1.364(7) 
C(18)–F(1)  1.381(5) C(19)–H(19A)  0.950 
C(19)–C(20)  1.370(6) C(20)–H(20A)  0.950 
C(21)–C(22)  1.380(7) C(22)–H(22A)  0.950 
C(22)–C(23)  1.382(7) C(23)–H(23A)  0.950 
C(23)–C(24)  1.379(7) C(24)–H(24A)  0.950 
C(24)–C(25)  1.374(7) C(25)–H(25A)  0.950 
F(2)–C(43)  1.356(5) F(3)–C(68)  1.372(6) 
O(3)–C(26)  1.421(5) O(3)–C(27)  1.378(6) 
O(4)–C(39)  1.222(5) N(5)–C(32)  1.400(5) 
N(5)–C(33)  1.477(5) N(5)–C(35)  1.462(6) 
N(6)–C(34)  1.465(6) N(6)–C(36)  1.472(6) 
N(6)–C(37)  1.465(5) N(7)–C(38)  1.464(5) 
N(7)–C(39)  1.374(6) N(7)–C(46)  1.416(6) 
N(8)–C(46)  1.343(6) N(8)–C(50)  1.330(6) 
C(26)–H(26A)  0.980 C(26)–H(26B)  0.980 
C(26)–H(26C)  0.980 C(27)–C(28)  1.362(6) 
C(27)–C(32)  1.406(6) C(28)–H(28A)  0.950 
C(28)–C(29)  1.391(7) C(29)–H(29A)  0.950 
C(29)–C(30)  1.354(7) C(30)–H(30A)  0.950 
C(30)–C(31)  1.395(6) C(31)–H(31A)  0.950 
C(31)–C(32)  1.384(7) C(33)–H(33A)  0.990 
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C(33)–H(33B)  0.990 C(33)–C(34)  1.493(6) 
C(34)–H(34A)  0.990 C(34)–H(34B)  0.990 
C(35)–H(35A)  0.990 C(35)–H(35B)  0.990 
C(35)–C(36)  1.509(6) C(36)–H(36A)  0.990 
C(36)–H(36B)  0.990 C(37)–H(37A)  0.990 
C(37)–H(37B)  0.990 C(37)–C(38)  1.517(6) 
C(38)–H(38A)  0.990 C(38)–H(38B)  0.990 
C(39)–C(40)  1.476(6) C(40)–C(41)  1.408(6) 
C(40)–C(45)  1.396(6) C(41)–H(41A)  0.950 
C(41)–C(42)  1.363(7) C(42)–H(42A)  0.950 
C(42)–C(43)  1.373(7) C(43)–C(44)  1.390(7) 
C(44)–H(44A)  0.950 C(44)–C(45)  1.371(6) 
C(45)–H(45A)  0.950 C(46)–C(47)  1.388(7) 
C(47)–H(47A)  0.950 C(47)–C(48)  1.379(7) 
C(48)–H(48A)  0.950 C(48)–C(49)  1.375(7) 
C(49)–H(49A)  0.950 C(49)–C(50)  1.356(7) 
C(50)–H(50A)  0.950 O(5)–C(51)  1.420(5) 
O(5)–C(52)  1.370(6) O(6)–C(64)  1.232(5) 
N(9)–C(57)  1.405(5) N(9)–C(58)  1.456(5) 
N(9)–C(61)  1.469(6) N(10)–C(59)  1.449(6) 
N(10)–C(60)  1.475(5) N(10)–C(62)  1.454(5) 
N(11)–C(63)  1.471(5) N(11)–C(64)  1.368(6) 
N(11)–C(71)  1.424(6) N(12)–C(71)  1.322(6) 
N(12)–C(75)  1.342(6) C(51)–H(51A)  0.980 
C(51)–H(51B)  0.980 C(51)–H(51C)  0.980 
C(52)–C(53)  1.354(6) C(52)–C(57)  1.416(6) 
C(53)–H(53A)  0.950 C(53)–C(54)  1.394(7) 
C(54)–H(54A)  0.950 C(54)–C(55)  1.377(7) 
C(55)–H(55A)  0.950 C(55)–C(56)  1.377(6) 
C(56)–H(56A)  0.950 C(56)–C(57)  1.394(6) 
C(58)–H(58A)  0.990 C(58)–H(58B)  0.990 
C(58)–C(59)  1.511(6) C(59)–H(59A)  0.990 
C(59)–H(59B)  0.990 C(60)–H(60A)  0.990 
C(60)–H(60B)  0.990 C(60)–C(61)  1.501(6) 
C(61)–H(61A)  0.990 C(61)–H(61B)  0.990 
C(62)–H(62A)  0.990 C(62)–H(62B)  0.990 
C(62)–C(63)  1.526(7) C(63)–H(63A)  0.990 
C(63)–H(63B)  0.990 C(64)–C(65)  1.501(6) 
C(65)–C(66)  1.375(6) C(65)–C(70)  1.369(6) 
C(66)–H(66A)  0.950 C(66)–C(67)  1.378(6) 
C(67)–H(67A)  0.950 C(67)–C(68)  1.364(7) 
C(68)–C(69)  1.352(7) C(69)–H(69A)  0.950 
C(69)–C(70)  1.381(6) C(70)–H(70A)  0.950 
C(71)–C(72)  1.370(6) C(72)–H(72A)  0.950 
C(72)–C(73)  1.383(7) C(73)–H(73A)  0.950 
C(73)–C(74)  1.374(7) C(74)–H(74A)  0.950 
C(74)–C(75)  1.378(7) C(75)–H(75A)  0.950 
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C(1)–O(1)–C(2) 116.5(4) C(7)–N(1)–C(8) 116.5(4) 
C(7)–N(1)–C(11) 115.8(3) C(8)–N(1)–C(11) 110.1(4) 
C(9)–N(2)–C(10) 109.0(3) C(9)–N(2)–C(12) 110.7(3) 
C(10)–N(2)–C(12) 110.6(4) C(13)–N(3)–C(14) 117.6(4) 
C(13)–N(3)–C(21) 118.0(4) C(14)–N(3)–C(21) 124.3(4) 
C(21)–N(4)–C(25) 117.7(4) O(1)–C(1)–H(1A) 109.5 
O(1)–C(1)–H(1B) 109.5 O(1)–C(1)–H(1C) 109.4 
H(1A)–C(1)–H(1B) 109.5 H(1A)–C(1)–H(1C) 109.5 
H(1B)–C(1)–H(1C) 109.5 O(1)–C(2)–C(3) 124.6(4) 
O(1)–C(2)–C(7) 116.6(4) C(3)–C(2)–C(7) 118.7(4) 
C(2)–C(3)–H(3A) 119.3 C(2)–C(3)–C(4) 121.4(5) 
H(3A)–C(3)–C(4) 119.3 C(3)–C(4)–H(4A) 120.3 
C(3)–C(4)–C(5) 119.5(5) H(4A)–C(4)–C(5) 120.3 
C(4)–C(5)–H(5A) 119.9 C(4)–C(5)–C(6) 120.2(5) 
H(5A)–C(5)–C(6) 119.9 C(5)–C(6)–H(6A) 119.1 
C(5)–C(6)–C(7) 121.8(5) H(6A)–C(6)–C(7) 119.1 
N(1)–C(7)–C(2) 118.3(4) N(1)–C(7)–C(6) 123.2(4) 
C(2)–C(7)–C(6) 118.4(4) N(1)–C(8)–H(8A) 110.0 
N(1)–C(8)–H(8B) 110.1 N(1)–C(8)–C(9) 108.3(4) 
H(8A)–C(8)–H(8B) 108.4 H(8A)–C(8)–C(9) 110.0 
H(8B)–C(8)–C(9) 110.1 N(2)–C(9)–C(8) 111.8(4) 
N(2)–C(9)–H(9A) 109.2 N(2)–C(9)–H(9B) 109.3 
C(8)–C(9)–H(9A) 109.2 C(8)–C(9)–H(9B) 109.3 
H(9A)–C(9)–H(9B) 107.9 N(2)–C(10)–H(10A) 109.5 
N(2)–C(10)–H(10B) 109.5 N(2)–C(10)–C(11) 110.8(4) 
H(10A)–C(10)–H(10B) 108.1 H(10A)–C(10)–C(11) 109.5 
H(10B)–C(10)–C(11) 109.5 N(1)–C(11)–C(10) 110.0(4) 
N(1)–C(11)–H(11A) 109.7 N(1)–C(11)–H(11B) 109.6 
C(10)–C(11)–H(11A) 109.7 C(10)–C(11)–H(11B) 109.6 
H(11A)–C(11)–H(11B) 108.2 N(2)–C(12)–H(12A) 109.5 
N(2)–C(12)–H(12B) 109.5 N(2)–C(12)–C(13) 110.6(4) 
H(12A)–C(12)–H(12B) 108.1 H(12A)–C(12)–C(13) 109.5 
H(12B)–C(12)–C(13) 109.5 N(3)–C(13)–C(12) 112.2(4) 
N(3)–C(13)–H(13A) 109.2 N(3)–C(13)–H(13B) 109.2 
C(12)–C(13)–H(13A) 109.1 C(12)–C(13)–H(13B) 109.2 
H(13A)–C(13)–H(13B) 107.9 O(2)–C(14)–N(3) 121.4(4) 
O(2)–C(14)–C(15) 119.4(4) N(3)–C(14)–C(15) 119.3(4) 
C(14)–C(15)–C(16) 122.8(4) C(14)–C(15)–C(20) 118.0(4) 
C(16)–C(15)–C(20) 119.2(4) C(15)–C(16)–H(16A) 119.9 
C(15)–C(16)–C(17) 120.3(4) H(16A)–C(16)–C(17) 119.9 
C(16)–C(17)–H(17A) 121.1 C(16)–C(17)–C(18) 117.8(5) 
H(17A)–C(17)–C(18) 121.1 C(17)–C(18)–C(19) 123.9(5) 
C(17)–C(18)–F(1) 117.9(5) C(19)–C(18)–F(1) 118.2(5) 
C(18)–C(19)–H(19A) 121.2 C(18)–C(19)–C(20) 117.5(5) 
H(19A)–C(19)–C(20) 121.2 C(15)–C(20)–C(19) 121.2(5) 
C(15)–C(20)–H(20A) 119.4 C(19)–C(20)–H(20A) 119.4 
N(3)–C(21)–N(4) 113.9(4) N(3)–C(21)–C(22) 122.6(4) 
N(4)–C(21)–C(22) 123.4(4) C(21)–C(22)–H(22A) 121.1 
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C(21)–C(22)–C(23) 117.8(5) H(22A)–C(22)–C(23) 121.1 
C(22)–C(23)–H(23A) 120.3 C(22)–C(23)–C(24) 119.3(5) 
H(23A)–C(23)–C(24) 120.4 C(23)–C(24)–H(24A) 120.5 
C(23)–C(24)–C(25) 119.0(5) H(24A)–C(24)–C(25) 120.5 
N(4)–C(25)–C(24) 122.7(5) N(4)–C(25)–H(25A) 118.7 
C(24)–C(25)–H(25A) 118.6 C(26)–O(3)–C(27) 116.9(4) 
C(32)–N(5)–C(33) 117.1(4) C(32)–N(5)–C(35) 115.5(3) 
C(33)–N(5)–C(35) 109.5(3) C(34)–N(6)–C(36) 108.5(4) 
C(34)–N(6)–C(37) 109.9(3) C(36)–N(6)–C(37) 110.7(4) 
C(38)–N(7)–C(39) 118.0(4) C(38)–N(7)–C(46) 117.3(4) 
C(39)–N(7)–C(46) 124.6(4) C(46)–N(8)–C(50) 117.6(4) 
O(3)–C(26)–H(26A) 109.5 O(3)–C(26)–H(26B) 109.5 
O(3)–C(26)–H(26C) 109.5 H(26A)–C(26)–H(26B) 109.5 
H(26A)–C(26)–H(26C) 109.5 H(26B)–C(26)–H(26C) 109.5 
O(3)–C(27)–C(28) 123.2(4) O(3)–C(27)–C(32) 115.2(4) 
C(28)–C(27)–C(32) 121.6(5) C(27)–C(28)–H(28A) 120.2 
C(27)–C(28)–C(29) 119.6(5) H(28A)–C(28)–C(29) 120.2 
C(28)–C(29)–H(29A) 119.6 C(28)–C(29)–C(30) 120.8(5) 
H(29A)–C(29)–C(30) 119.6 C(29)–C(30)–H(30A) 120.4 
C(29)–C(30)–C(31) 119.1(5) H(30A)–C(30)–C(31) 120.5 
C(30)–C(31)–H(31A) 119.0 C(30)–C(31)–C(32) 121.9(5) 
H(31A)–C(31)–C(32) 119.1 N(5)–C(32)–C(27) 119.7(4) 
N(5)–C(32)–C(31) 123.3(4) C(27)–C(32)–C(31) 116.9(4) 
N(5)–C(33)–H(33A) 110.1 N(5)–C(33)–H(33B) 110.0 
N(5)–C(33)–C(34) 108.4(4) H(33A)–C(33)–H(33B) 108.4 
H(33A)–C(33)–C(34) 110.0 H(33B)–C(33)–C(34) 110.0 
N(6)–C(34)–C(33) 111.1(4) N(6)–C(34)–H(34A) 109.5 
N(6)–C(34)–H(34B) 109.4 C(33)–C(34)–H(34A) 109.4 
C(33)–C(34)–H(34B) 109.4 H(34A)–C(34)–H(34B) 108.0 
N(5)–C(35)–H(35A) 109.7 N(5)–C(35)–H(35B) 109.8 
N(5)–C(35)–C(36) 109.5(4) H(35A)–C(35)–H(35B) 108.2 
H(35A)–C(35)–C(36) 109.7 H(35B)–C(35)–C(36) 109.8 
N(6)–C(36)–C(35) 111.1(4) N(6)–C(36)–H(36A) 109.4 
N(6)–C(36)–H(36B) 109.4 C(35)–C(36)–H(36A) 109.4 
C(35)–C(36)–H(36B) 109.5 H(36A)–C(36)–H(36B) 108.0 
N(6)–C(37)–H(37A) 109.6 N(6)–C(37)–H(37B) 109.6 
N(6)–C(37)–C(38) 110.3(4) H(37A)–C(37)–H(37B) 108.1 
H(37A)–C(37)–C(38) 109.6 H(37B)–C(37)–C(38) 109.6 
N(7)–C(38)–C(37) 111.2(4) N(7)–C(38)–H(38A) 109.4 
N(7)–C(38)–H(38B) 109.4 C(37)–C(38)–H(38A) 109.4 
C(37)–C(38)–H(38B) 109.4 H(38A)–C(38)–H(38B) 108.0 
O(4)–C(39)–N(7) 120.3(4) O(4)–C(39)–C(40) 120.8(4) 
N(7)–C(39)–C(40) 118.9(4) C(39)–C(40)–C(41) 124.2(4) 
C(39)–C(40)–C(45) 117.7(4) C(41)–C(40)–C(45) 118.1(4) 
C(40)–C(41)–H(41A) 119.4 C(40)–C(41)–C(42) 121.2(5) 
H(41A)–C(41)–C(42) 119.4 C(41)–C(42)–H(42A) 120.7 
C(41)–C(42)–C(43) 118.6(5) H(42A)–C(42)–C(43) 120.7 
F(2)–C(43)–C(42) 118.8(5) F(2)–C(43)–C(44) 118.5(5) 
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C(42)–C(43)–C(44) 122.7(5) C(43)–C(44)–H(44A) 121.1 
C(43)–C(44)–C(45) 117.8(5) H(44A)–C(44)–C(45) 121.1 
C(40)–C(45)–C(44) 121.6(5) C(40)–C(45)–H(45A) 119.2 
C(44)–C(45)–H(45A) 119.2 N(7)–C(46)–N(8) 115.5(4) 
N(7)–C(46)–C(47) 122.1(4) N(8)–C(46)–C(47) 122.3(4) 
C(46)–C(47)–H(47A) 120.7 C(46)–C(47)–C(48) 118.6(5) 
H(47A)–C(47)–C(48) 120.7 C(47)–C(48)–H(48A) 120.7 
C(47)–C(48)–C(49) 118.5(5) H(48A)–C(48)–C(49) 120.8 
C(48)–C(49)–H(49A) 120.2 C(48)–C(49)–C(50) 119.6(5) 
H(49A)–C(49)–C(50) 120.2 N(8)–C(50)–C(49) 123.4(5) 
N(8)–C(50)–H(50A) 118.3 C(49)–C(50)–H(50A) 118.3 
C(51)–O(5)–C(52) 116.6(4) C(57)–N(9)–C(58) 117.4(4) 
C(57)–N(9)–C(61) 115.1(3) C(58)–N(9)–C(61) 109.7(4) 
C(59)–N(10)–C(60) 109.7(3) C(59)–N(10)–C(62) 109.6(3) 
C(60)–N(10)–C(62) 111.1(4) C(63)–N(11)–C(64) 117.5(4) 
C(63)–N(11)–C(71) 117.6(3) C(64)–N(11)–C(71) 124.8(4) 
C(71)–N(12)–C(75) 116.7(4) O(5)–C(51)–H(51A) 109.5 
O(5)–C(51)–H(51B) 109.5 O(5)–C(51)–H(51C) 109.5 
H(51A)–C(51)–H(51B) 109.5 H(51A)–C(51)–H(51C) 109.5 
H(51B)–C(51)–H(51C) 109.5 O(5)–C(52)–C(53) 123.8(5) 
O(5)–C(52)–C(57) 114.8(4) C(53)–C(52)–C(57) 121.3(5) 
C(52)–C(53)–H(53A) 119.9 C(52)–C(53)–C(54) 120.2(5) 
H(53A)–C(53)–C(54) 119.9 C(53)–C(54)–H(54A) 120.0 
C(53)–C(54)–C(55) 120.0(5) H(54A)–C(54)–C(55) 120.0 
C(54)–C(55)–H(55A) 120.2 C(54)–C(55)–C(56) 119.7(5) 
H(55A)–C(55)–C(56) 120.1 C(55)–C(56)–H(56A) 119.2 
C(55)–C(56)–C(57) 121.6(5) H(56A)–C(56)–C(57) 119.1 
N(9)–C(57)–C(52) 120.0(4) N(9)–C(57)–C(56) 122.7(4) 
C(52)–C(57)–C(56) 117.1(4) N(9)–C(58)–H(58A) 110.0 
N(9)–C(58)–H(58B) 110.0 N(9)–C(58)–C(59) 108.5(4) 
H(58A)–C(58)–H(58B) 108.4 H(58A)–C(58)–C(59) 110.0 
H(58B)–C(58)–C(59) 110.0 N(10)–C(59)–C(58) 112.4(4) 
N(10)–C(59)–H(59A) 109.1 N(10)–C(59)–H(59B) 109.1 
C(58)–C(59)–H(59A) 109.1 C(58)–C(59)–H(59B) 109.2 
H(59A)–C(59)–H(59B) 107.9 N(10)–C(60)–H(60A) 109.6 
N(10)–C(60)–H(60B) 109.7 N(10)–C(60)–C(61) 109.9(4) 
H(60A)–C(60)–H(60B) 108.2 H(60A)–C(60)–C(61) 109.7 
H(60B)–C(60)–C(61) 109.7 N(9)–C(61)–C(60) 110.5(4) 
N(9)–C(61)–H(61A) 109.6 N(9)–C(61)–H(61B) 109.6 
C(60)–C(61)–H(61A) 109.5 C(60)–C(61)–H(61B) 109.6 
H(61A)–C(61)–H(61B) 108.1 N(10)–C(62)–H(62A) 109.5 
N(10)–C(62)–H(62B) 109.4 N(10)–C(62)–C(63) 110.9(4) 
H(62A)–C(62)–H(62B) 108.0 H(62A)–C(62)–C(63) 109.5 
H(62B)–C(62)–C(63) 109.5 N(11)–C(63)–C(62) 111.9(4) 
N(11)–C(63)–H(63A) 109.2 N(11)–C(63)–H(63B) 109.2 
C(62)–C(63)–H(63A) 109.2 C(62)–C(63)–H(63B) 109.2 
H(63A)–C(63)–H(63B) 107.9 O(6)–C(64)–N(11) 120.3(4) 
O(6)–C(64)–C(65) 121.0(4) N(11)–C(64)–C(65) 118.7(4) 
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C(64)–C(65)–C(66) 116.8(4) C(64)–C(65)–C(70) 122.8(4) 
C(66)–C(65)–C(70) 120.2(4) C(65)–C(66)–H(66A) 119.9 
C(65)–C(66)–C(67) 120.1(5) H(66A)–C(66)–C(67) 120.0 
C(66)–C(67)–H(67A) 120.8 C(66)–C(67)–C(68) 118.4(5) 
H(67A)–C(67)–C(68) 120.8 F(3)–C(68)–C(67) 118.1(5) 
F(3)–C(68)–C(69) 119.7(5) C(67)–C(68)–C(69) 122.3(5) 
C(68)–C(69)–H(69A) 120.4 C(68)–C(69)–C(70) 119.3(5) 
H(69A)–C(69)–C(70) 120.3 C(65)–C(70)–C(69) 119.5(5) 
C(65)–C(70)–H(70A) 120.2 C(69)–C(70)–H(70A) 120.3 
N(11)–C(71)–N(12) 114.1(4) N(11)–C(71)–C(72) 121.6(4) 
N(12)–C(71)–C(72) 124.2(4) C(71)–C(72)–H(72A) 121.2 
C(71)–C(72)–C(73) 117.6(5) H(72A)–C(72)–C(73) 121.2 
C(72)–C(73)–H(73A) 120.0 C(72)–C(73)–C(74) 120.0(5) 
H(73A)–C(73)–C(74) 120.0 C(73)–C(74)–H(74A) 121.4 
C(73)–C(74)–C(75) 117.3(5) H(74A)–C(74)–C(75) 121.4 
N(12)–C(75)–C(74) 124.0(5) N(12)–C(75)–H(75A) 118.0 
C(74)–C(75)–H(75A) 118.0  
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Table 4.   Anisotropic displacement parameters (Å2) for mac104.  The anisotropic 
displacement factor exponent takes the form:  2[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U11      U22      U33      U23      U13      U12 
 
O(1) 0.0285(19)  0.043(2) 0.0249(19)  0.0046(16) 0.0030(15)   
0.0104(16) 
O(2) 0.051(2)  0.028(2) 0.027(2)  0.0100(16) 0.0005(17) 
 0.0095(17) 
N(1) 0.022(2)  0.026(2) 0.018(2)  0.0034(17) 0.0018(17) 
 0.0007(17) 
N(2) 0.023(2)  0.033(2) 0.022(2)  0.0066(18) 0.0032(18) 
 0.0033(18) 
N(3) 0.030(2)  0.027(2) 0.023(2)  0.0070(18) 0.0029(18) 
 0.0003(18) 
N(4) 0.026(2)  0.032(3) 0.033(2)  0.0109(19) 0.0025(19)   
0.0043(18) 
C(1) 0.021(3)  0.037(3) 0.054(4)  0.012(3) 0.003(2)   0.003(2) 
C(2) 0.027(3)  0.029(3) 0.026(3)  0.005(2)  0.001(2)  0.005(2) 
C(3) 0.034(3)  0.048(4) 0.026(3)  0.016(3) 0.009(2)  0.008(3) 
C(4) 0.053(4)  0.047(4) 0.017(3)  0.000(2) 0.004(3)  0.004(3) 
C(5) 0.060(4)  0.046(4) 0.027(3)  0.004(3)  0.002(3)   0.016(3) 
C(6) 0.051(3)  0.038(3) 0.024(3)  0.008(2) 0.001(3)   0.014(3) 
C(7) 0.032(3)  0.028(3) 0.020(3)  0.007(2) 0.003(2)  0.006(2) 
C(8) 0.029(3)  0.038(3) 0.025(3)  0.008(2) 0.003(2)   0.004(2) 
C(9) 0.019(2)  0.028(3) 0.023(3)  0.010(2)  0.001(2)   0.005(2) 
C(10) 0.028(3)  0.037(3) 0.020(3)  0.006(2)  0.006(2)  0.000(2) 
C(11) 0.024(3)  0.037(3) 0.023(3)  0.010(2) 0.003(2)  0.005(2) 
C(12) 0.031(3)  0.037(3) 0.022(3)  0.002(2) 0.001(2)  0.000(2) 
C(13) 0.041(3)  0.023(3) 0.020(3)   0.003(2) 0.005(2)   0.002(2) 
C(14) 0.028(3)  0.019(3) 0.031(3)  0.009(2) 0.005(2)  0.002(2) 
C(15) 0.015(2)  0.021(3) 0.026(3)  0.005(2) 0.000(2)  0.0002(19) 
C(16) 0.026(3)  0.022(3) 0.036(3)  0.006(2) 0.009(2)   0.003(2) 
C(17) 0.033(3)  0.040(4) 0.040(3)  0.009(3) 0.011(3)   0.006(3) 
C(18) 0.027(3)  0.054(4) 0.035(3)   0.008(3) 0.016(2)   0.005(3) 
C(19) 0.035(3)  0.032(3) 0.041(3)   0.013(3)  0.003(3)  0.006(2) 
C(20) 0.024(3)  0.023(3) 0.036(3)  0.005(2)  0.010(2)  0.004(2) 
C(21) 0.027(3)  0.027(3) 0.018(3)  0.009(2) 0.012(2)  0.002(2) 
C(22) 0.028(3)  0.033(3) 0.028(3)   0.004(2) 0.000(2)  0.001(2) 
C(23) 0.025(3)  0.054(4) 0.033(3)   0.002(3)  0.001(2)  0.009(3) 
C(24) 0.027(3)  0.055(4) 0.026(3)  0.015(3) 0.003(2)  0.008(3) 
C(25) 0.029(3)  0.043(3) 0.035(3)  0.016(3) 0.005(3)  0.006(3) 
F(1) 0.051(2)  0.075(3) 0.051(2)   0.0074(18) 0.0236(18) 
 0.0000(18) 
F(2) 0.051(2)  0.076(3) 0.052(2)   0.0110(18) 0.0251(18) 
 0.0011(19) 
F(3) 0.051(2)  0.080(3) 0.053(2)   0.0152(18) 0.0264(18) 
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 0.0018(19) 
O(3) 0.0294(19)  0.040(2) 0.031(2)  0.0062(17) 0.0033(16)   
0.0108(16) 
O(4) 0.047(2)  0.032(2) 0.028(2)  0.0108(16) 0.0055(17) 
 0.0062(17) 
N(5) 0.020(2)  0.031(2) 0.020(2)  0.0052(18) 0.0003(17)   
0.0012(17) 
N(6) 0.022(2)  0.033(2) 0.018(2)  0.0020(18) 0.0006(17) 
 0.0004(18) 
N(7) 0.028(2)  0.027(2) 0.019(2)  0.0050(18) 0.0008(18)   
0.0003(18) 
N(8) 0.024(2)  0.027(3) 0.030(2)  0.0107(19) 0.0032(18) 
 0.0037(18) 
C(26) 0.034(3)  0.038(3) 0.045(3)  0.012(3) 0.005(3)   0.009(3) 
C(27) 0.027(3)  0.028(3) 0.029(3)  0.004(2) 0.005(2)  0.003(2) 
C(28) 0.028(3)  0.035(3) 0.038(3)  0.013(3) 0.008(2)  0.001(2) 
C(29) 0.058(4)  0.039(3) 0.023(3)  0.000(2) 0.009(3)   0.001(3) 
C(30) 0.060(4)  0.043(4) 0.023(3)  0.000(3)  0.001(3)   0.006(3) 
C(31) 0.050(3)  0.026(3) 0.033(3)  0.003(2) 0.007(3)   0.011(3) 
C(32) 0.028(3)  0.025(3) 0.026(3)  0.006(2) 0.007(2)  0.004(2) 
C(33) 0.027(3)  0.032(3) 0.023(3)  0.006(2)  0.012(2)   0.006(2) 
C(34) 0.020(3)  0.036(3) 0.035(3)  0.001(2)  0.003(2)  0.005(2) 
C(35) 0.026(3)  0.043(3) 0.027(3)  0.014(2) 0.000(2)  0.006(2) 
C(36) 0.021(3)  0.046(3) 0.028(3)  0.010(2) 0.000(2)  0.009(2) 
C(37) 0.027(3)  0.041(3) 0.017(3)   0.003(2) 0.007(2)   0.002(2) 
C(38) 0.034(3)  0.021(3) 0.020(2)  0.002(2) 0.007(2)  0.001(2) 
C(39) 0.027(3)  0.019(3) 0.027(3)  0.003(2)  0.004(2)   0.001(2) 
C(40) 0.026(3)  0.020(3) 0.027(3)  0.006(2)  0.008(2)   0.006(2) 
C(41) 0.032(3)  0.029(3) 0.046(3)  0.005(3) 0.009(3)   0.004(2) 
C(42) 0.032(3)  0.054(4) 0.037(3)  0.008(3) 0.019(3)   0.006(3) 
C(43) 0.021(3)  0.051(4) 0.040(3)   0.014(3) 0.011(2)  0.002(3) 
C(44) 0.027(3)  0.030(3) 0.050(4)   0.002(3) 0.001(3)  0.006(2) 
C(45) 0.021(3)  0.024(3) 0.033(3)  0.004(2)  0.003(2)  0.005(2) 
C(46) 0.019(2)  0.025(3) 0.026(3)  0.006(2) 0.005(2)  0.000(2) 
C(47) 0.034(3)  0.028(3) 0.029(3)  0.004(2) 0.005(2)  0.006(2) 
C(48) 0.037(3)  0.055(4) 0.032(3)   0.003(3) 0.004(3)  0.007(3) 
C(49) 0.031(3)  0.061(4) 0.030(3)  0.019(3)  0.001(2)  0.002(3) 
C(50) 0.038(3)  0.030(3) 0.040(3)  0.011(3)  0.004(3)  0.005(2) 
O(5) 0.031(2)  0.047(2) 0.0276(19)  0.0057(17) 0.0045(16)   
0.0107(17) 
O(6) 0.045(2)  0.030(2) 0.028(2)  0.0089(16) 0.0068(17) 
 0.0013(16) 
N(9) 0.022(2)  0.035(3) 0.021(2)  0.0073(18) 0.0027(17) 
 0.0010(18) 
N(10) 0.027(2)  0.036(3) 0.017(2)  0.0040(18) 0.0017(17) 
 0.0048(19) 
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N(11) 0.026(2)  0.020(2) 0.021(2)  0.0027(17) 0.0077(18) 
 0.0060(17) 
N(12) 0.031(2)  0.027(3) 0.032(2)  0.0093(19) 0.000(2)  0.0012(19) 
C(51) 0.028(3)  0.051(4) 0.032(3)  0.008(3) 0.005(2)   0.005(3) 
C(52) 0.024(3)  0.034(3) 0.024(3)  0.010(2)  0.004(2)  0.005(2) 
C(53) 0.034(3)  0.042(3) 0.026(3)  0.006(2) 0.005(2)  0.000(3) 
C(54) 0.051(4)  0.050(4) 0.030(3)  0.013(3) 0.014(3)  0.011(3) 
C(55) 0.067(4)  0.036(3) 0.021(3)   0.004(2) 0.008(3)   0.005(3) 
C(56) 0.042(3)  0.030(3) 0.027(3)  0.005(2)  0.005(2)   0.004(2) 
C(57) 0.028(3)  0.025(3) 0.020(3)  0.007(2)  0.002(2)  0.004(2) 
C(58) 0.017(2)  0.035(3) 0.025(3)  0.006(2)  0.002(2)   0.006(2) 
C(59) 0.022(3)  0.031(3) 0.026(3)  0.007(2) 0.004(2)   0.004(2) 
C(60) 0.013(2)  0.055(4) 0.024(3)  0.011(2)  0.002(2)   0.001(2) 
C(61) 0.024(3)  0.033(3) 0.027(3)  0.010(2) 0.003(2)  0.007(2) 
C(62) 0.029(3)  0.039(3) 0.025(3)  0.008(2)  0.006(2)   0.003(2) 
C(63) 0.034(3)  0.034(3) 0.023(3)  0.007(2) 0.004(2)  0.009(2) 
C(64) 0.037(3)  0.013(3) 0.026(3)  0.008(2)  0.004(2)   0.006(2) 
C(65) 0.021(3)  0.032(3) 0.025(3)  0.005(2) 0.002(2)  0.006(2) 
C(66) 0.021(3)  0.036(3) 0.030(3)  0.006(2)  0.006(2)   0.002(2) 
C(67) 0.015(2)  0.029(3) 0.047(3)  0.001(3)  0.002(2)  0.007(2) 
C(68) 0.021(3)  0.046(4) 0.041(3)  0.001(3) 0.006(2)  0.002(2) 
C(69) 0.039(3)  0.049(4) 0.033(3)  0.010(3) 0.002(3)   0.011(3) 
C(70) 0.040(3)  0.029(3) 0.033(3)  0.008(2) 0.006(2)  0.000(2) 
C(71) 0.017(2)  0.028(3) 0.022(3)  0.008(2) 0.003(2)  0.002(2) 
C(72) 0.025(3)  0.031(3) 0.030(3)  0.003(2) 0.003(2)  0.007(2) 
C(73) 0.034(3)  0.049(4) 0.022(3)   0.005(3) 0.001(2)  0.001(3) 
C(74) 0.026(3)  0.060(4) 0.026(3)  0.007(3)  0.003(2)  0.012(3) 
C(75) 0.030(3)  0.044(4) 0.043(3)  0.028(3) 0.002(3)  0.000(3) 
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Table 5.   Hydrogen coordinates and isotropic displacement parameters (Å2) 
for mac104. 
 
      x       y       z       U 
 
H(1A) 0.5750 0.8274 0.4993 0.055 
H(1B) 0.5179 0.8278 0.4152 0.055 
H(1C) 0.6054 0.7569 0.4235 0.055 
H(3A) 0.5212 0.6945 0.3177 0.042 
H(4A) 0.4368 0.5998 0.2186 0.047 
H(5A) 0.3034 0.5146 0.2519 0.053 
H(6A) 0.2610 0.5168 0.3843 0.045 
H(8A) 0.2329 0.5183 0.5200 0.036 
H(8B) 0.1896 0.6114 0.4905 0.036 
H(9A) 0.2145 0.6911 0.6203 0.027 
H(9B) 0.1456 0.6026 0.6242 0.027 
H(10A) 0.4259 0.5898 0.6909 0.034 
H(10B) 0.3850 0.6841 0.6625 0.034 
H(11A) 0.4706 0.6019 0.5577 0.033 
H(11B) 0.4023 0.5126 0.5607 0.033 
H(12A) 0.2329 0.6884 0.7546 0.036 
H(12B) 0.3142 0.6234 0.7884 0.036 
H(13A) 0.1223 0.5567 0.7434 0.034 
H(13B) 0.2029 0.5023 0.7894 0.034 
H(16A) 0.0067 0.5781 0.9846 0.033 
H(17A)  0.0701 0.6399 1.1024 0.045 
H(19A)  0.0644 0.8942 1.0280 0.045 
H(20A) 0.0042 0.8312 0.9084 0.033 
H(22A) 0.2141 0.7204 0.9825 0.036 
H(23A) 0.2911 0.6768 1.0987 0.045 
H(24A) 0.3159 0.5191 1.1088 0.042 
H(25A) 0.2620 0.4096 1.0056 0.042 
H(26A) 0.5692 0.4983 0.1652 0.058 
H(26B) 0.5188 0.4912 0.0778 0.058 
H(26C) 0.6078 0.4248 0.0944 0.058 
H(28A) 0.5220 0.3618  0.0136 0.039 
H(29A) 0.4377 0.2648  0.1135 0.048 
H(30A) 0.3043 0.1806  0.0823 0.051 
H(31A) 0.2595 0.1851 0.0514 0.044 
H(33A) 0.2330 0.1839 0.1891 0.033 
H(33B) 0.1887 0.2758 0.1581 0.033 
H(34A) 0.2162 0.3580 0.2866 0.036 
H(34B) 0.1452 0.2712 0.2913 0.036 
H(35A) 0.4716 0.2685 0.2244 0.038 
H(35B) 0.4035 0.1789 0.2270 0.038 
H(36A) 0.4261 0.2563 0.3577 0.038 
H(36B) 0.3848 0.3503 0.3290 0.038 
H(37A) 0.2313 0.3545 0.4207 0.035 
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H(37B) 0.3129 0.2903 0.4553 0.035 
H(38A) 0.1213 0.2223 0.4098 0.029 
H(38B) 0.2021 0.1682 0.4560 0.029 
H(41A) 0.0064 0.2449 0.6533 0.042 
H(42A)  0.0714 0.3057 0.7683 0.049 
H(44A)  0.0632 0.5620 0.6943 0.044 
H(45A) 0.0052 0.4985 0.5749 0.031 
H(47A) 0.2148 0.3862 0.6483 0.036 
H(48A) 0.2923 0.3435 0.7644 0.050 
H(49A) 0.3143 0.1856 0.7750 0.048 
H(50A) 0.2648 0.0772 0.6719 0.043 
H(51A) 0.4272 0.8381 0.1668 0.055 
H(51B) 0.3936 0.9091 0.2412 0.055 
H(51C) 0.4816 0.8395 0.2522 0.055 
H(53A) 0.4773 0.9706 0.3463 0.040 
H(54A) 0.5626 1.0655 0.4473 0.051 
H(55A) 0.6947 1.1536 0.4151 0.050 
H(56A) 0.7418 1.1471 0.2830 0.039 
H(58A) 0.8112 1.0536 0.1753 0.031 
H(58B) 0.7685 1.1478 0.1474 0.031 
H(59A) 0.8539 1.0655 0.0414 0.031 
H(59B) 0.7860 0.9763 0.0450 0.031 
H(60A) 0.6133 0.9831 0.0042 0.036 
H(60B) 0.5729 1.0779  0.0240 0.036 
H(61A) 0.5994 1.1549 0.1059 0.033 
H(61B) 0.5296 1.0668 0.1095 0.033 
H(62A) 0.6870 1.0418  0.1213 0.037 
H(62B) 0.7692 0.9787  0.0862 0.037 
H(63A) 0.7972 1.1651  0.1225 0.036 
H(63B) 0.8788 1.1113  0.0769 0.036 
H(66A) 0.9966 0.8367  0.2410 0.034 
H(67A) 1.0666 0.7739  0.3608 0.037 
H(69A) 1.0681 1.0264  0.4358 0.048 
H(70A) 0.9948 1.0890  0.3173 0.040 
H(72A) 0.7857 0.9479  0.3149 0.035 
H(73A) 0.7092 0.9908  0.4315 0.043 
H(74A) 0.6847 1.1483  0.4435 0.045 
H(75A) 0.7363 1.2568  0.3382 0.044 
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Table 6.  Torsion angles [°] for mac104. 
 
C(1)–O(1)–C(2)–C(3) 8.6(7) C(1)–O(1)–C(2)–C(7)  168.2(4) 
O(1)–C(2)–C(3)–C(4)  176.2(5) C(7)–C(2)–C(3)–C(4) 0.5(7) 
C(2)–C(3)–C(4)–C(5) 0.5(8) C(3)–C(4)–C(5)–C(6)  2.0(8) 
C(4)–C(5)–C(6)–C(7) 2.4(8) C(5)–C(6)–C(7)–N(1) 177.0(5) 
C(5)–C(6)–C(7)–C(2)  1.3(8) O(1)–C(2)–C(7)–N(1)  1.5(6) 
O(1)–C(2)–C(7)–C(6) 176.9(4) C(3)–C(2)–C(7)–N(1)  178.5(4) 
C(3)–C(2)–C(7)–C(6)  0.1(7) C(8)–N(1)–C(7)–C(2) 160.3(4) 
C(8)–N(1)–C(7)–C(6)  18.0(7) C(11)–N(1)–C(7)–C(2)  67.8(5) 
C(11)–N(1)–C(7)–C(6) 113.9(5) C(7)–N(1)–C(8)–C(9)  165.7(4) 
C(11)–N(1)–C(8)–C(9) 59.8(5) C(10)–N(2)–C(9)–C(8) 57.8(5) 
C(12)–N(2)–C(9)–C(8) 179.7(4) N(1)–C(8)–C(9)–N(2)  59.7(5) 
C(9)–N(2)–C(10)–C(11)  56.4(5) C(12)–N(2)–C(10)–C(11)  
178.4(4) 
C(7)–N(1)–C(11)–C(10) 165.2(4) C(8)–N(1)–C(11)–C(10)  60.0(5) 
N(2)–C(10)–C(11)–N(1) 58.1(5) C(9)–N(2)–C(12)–C(13) 83.4(5) 
C(10)–N(2)–C(12)–C(13)  155.6(4) C(14)–N(3)–C(13)–C(12) 90.5(5) 
C(21)–N(3)–C(13)–C(12)  85.6(5) N(2)–C(12)–C(13)–N(3) 171.4(4) 
C(13)–N(3)–C(14)–O(2)  6.5(7) C(13)–N(3)–C(14)–C(15) 173.1(4) 
C(21)–N(3)–C(14)–O(2) 169.4(4) C(21)–N(3)–C(14)–C(15) 11.0(7) 
O(2)–C(14)–C(15)–C(16) 133.8(5) O(2)–C(14)–C(15)–C(20)  
44.4(6) 
N(3)–C(14)–C(15)–C(16)  45.8(7) N(3)–C(14)–C(15)–C(20) 136.0(5) 
C(14)–C(15)–C(16)–C(17)  179.3(4) C(20)–C(15)–C(16)–C(17) 1.2(7) 
C(15)–C(16)–C(17)–C(18)  1.3(7) C(16)–C(17)–C(18)–C(19) 2.2(8) 
C(16)–C(17)–C(18)–F(1)  176.7(4) C(17)–C(18)–C(19)–C(20) 0.4(8) 
F(1)–C(18)–C(19)–C(20) 178.4(4) C(18)–C(19)–C(20)–C(15) 2.2(7) 
C(14)–C(15)–C(20)–C(19)  178.7(4) C(16)–C(15)–C(20)–C(19) 3.0(7) 
C(25)–N(4)–C(21)–N(3)  179.5(4) C(25)–N(4)–C(21)–C(22) 2.1(7) 
C(13)–N(3)–C(21)–N(4)  52.1(5) C(13)–N(3)–C(21)–C(22) 126.3(5) 
C(14)–N(3)–C(21)–N(4) 132.1(5) C(14)–N(3)–C(21)–C(22) 49.5(7) 
N(3)–C(21)–C(22)–C(23) 178.6(4) N(4)–C(21)–C(22)–C(23)  3.2(7) 
C(21)–C(22)–C(23)–C(24) 2.2(7) C(22)–C(23)–C(24)–C(25) 0.3(7) 
C(21)–N(4)–C(25)–C(24)  0.1(7) C(23)–C(24)–C(25)–N(4)  0.8(8) 
C(26)–O(3)–C(27)–C(28) 9.8(7) C(26)–O(3)–C(27)–C(32)  
168.8(4) 
O(3)–C(27)–C(28)–C(29)  176.9(5) C(32)–C(27)–C(28)–C(29) 1.6(7) 
C(27)–C(28)–C(29)–C(30) 0.9(8) C(28)–C(29)–C(30)–C(31) 2.2(8) 
C(29)–C(30)–C(31)–C(32) 1.1(8) C(30)–C(31)–C(32)–N(5) 177.6(5) 
C(30)–C(31)–C(32)–C(27) 1.2(8) C(33)–N(5)–C(32)–C(27) 159.6(4) 
C(33)–N(5)–C(32)–C(31)  16.6(7) C(35)–N(5)–C(32)–C(27) 69.0(6) 
C(35)–N(5)–C(32)–C(31) 114.7(5) O(3)–C(27)–C(32)–N(5)  0.4(6) 
O(3)–C(27)–C(32)–C(31) 176.0(4) C(28)–C(27)–C(32)–N(5)  
179.1(4) 
C(28)–C(27)–C(32)–C(31)  2.6(7) C(32)–N(5)–C(33)–C(34)  
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165.0(4) 
C(35)–N(5)–C(33)–C(34) 61.0(5) C(36)–N(6)–C(34)–C(33) 59.4(5) 
C(37)–N(6)–C(34)–C(33)  179.4(4) N(5)–C(33)–C(34)–N(6)  61.5(5) 
C(32)–N(5)–C(35)–C(36) 165.6(4) C(33)–N(5)–C(35)–C(36) 59.5(5) 
C(34)–N(6)–C(36)–C(35)  57.2(5) C(37)–N(6)–C(36)–C(35)  
177.9(4) 
N(5)–C(35)–C(36)–N(6) 58.3(5) C(34)–N(6)–C(37)–C(38) 84.6(5) 
C(36)–N(6)–C(37)–C(38)  155.6(4) C(39)–N(7)–C(38)–C(37) 90.8(5) 
C(46)–N(7)–C(38)–C(37)  86.7(5) N(6)–C(37)–C(38)–N(7) 171.8(4) 
C(38)–N(7)–C(39)–O(4)  7.9(6) C(38)–N(7)–C(39)–C(40) 172.5(4) 
C(46)–N(7)–C(39)–O(4) 169.4(4) C(46)–N(7)–C(39)–C(40) 10.3(7) 
O(4)–C(39)–C(40)–C(41) 133.9(5) O(4)–C(39)–C(40)–C(45)  
43.7(6) 
N(7)–C(39)–C(40)–C(41)  46.4(7) N(7)–C(39)–C(40)–C(45) 135.9(4) 
C(39)–C(40)–C(41)–C(42)  178.1(5) C(45)–C(40)–C(41)–C(42) 0.5(7) 
C(40)–C(41)–C(42)–C(43)  2.3(8) C(41)–C(42)–C(43)–F(2)  
176.5(5) 
C(41)–C(42)–C(43)–C(44) 2.8(8) F(2)–C(43)–C(44)–C(45) 178.8(4) 
C(42)–C(43)–C(44)–C(45)  0.5(8) C(43)–C(44)–C(45)–C(40) 2.4(7) 
C(39)–C(40)–C(45)–C(44)  179.4(4) C(41)–C(40)–C(45)–C(44) 2.9(7) 
C(50)–N(8)–C(46)–N(7)  179.8(4) C(50)–N(8)–C(46)–C(47) 2.1(7) 
C(38)–N(7)–C(46)–N(8)  50.9(5) C(38)–N(7)–C(46)–C(47) 127.2(5) 
C(39)–N(7)–C(46)–N(8) 131.8(4) C(39)–N(7)–C(46)–C(47) 50.1(7) 
N(7)–C(46)–C(47)–C(48) 178.4(4) N(8)–C(46)–C(47)–C(48)  3.6(7) 
C(46)–C(47)–C(48)–C(49) 1.9(7) C(47)–C(48)–C(49)–C(50) 1.1(8) 
C(46)–N(8)–C(50)–C(49) 1.1(7) C(48)–C(49)–C(50)–N(8)  2.7(8) 
C(51)–O(5)–C(52)–C(53)  8.8(7) C(51)–O(5)–C(52)–C(57) 168.9(4) 
O(5)–C(52)–C(53)–C(54) 176.2(5) C(57)–C(52)–C(53)–C(54) 1.4(7) 
C(52)–C(53)–C(54)–C(55) 0.2(8) C(53)–C(54)–C(55)–C(56) 0.2(8) 
C(54)–C(55)–C(56)–C(57) 0.7(8) C(55)–C(56)–C(57)–N(9)  
177.6(4) 
C(55)–C(56)–C(57)–C(52)  1.9(7) C(58)–N(9)–C(57)–C(52)  
159.2(4) 
C(58)–N(9)–C(57)–C(56) 16.5(6) C(61)–N(9)–C(57)–C(52) 69.2(6) 
C(61)–N(9)–C(57)–C(56)  115.1(5) O(5)–C(52)–C(57)–N(9) 0.3(6) 
O(5)–C(52)–C(57)–C(56)  175.5(4) C(53)–C(52)–C(57)–N(9) 178.1(4) 
C(53)–C(52)–C(57)–C(56) 2.3(7) C(57)–N(9)–C(58)–C(59) 167.1(4) 
C(61)–N(9)–C(58)–C(59)  58.9(5) C(60)–N(10)–C(59)–C(58)  
57.1(5) 
C(62)–N(10)–C(59)–C(58)  179.4(4) N(9)–C(58)–C(59)–N(10) 58.6(5) 
C(59)–N(10)–C(60)–C(61) 56.1(5) C(62)–N(10)–C(60)–C(61)
 177.6(4) 
C(57)–N(9)–C(61)–C(60)  164.2(4) C(58)–N(9)–C(61)–C(60) 60.6(5) 
N(10)–C(60)–C(61)–N(9)  58.5(5) C(59)–N(10)–C(62)–C(63)  
84.0(5) 
C(60)–N(10)–C(62)–C(63) 154.5(4) C(64)–N(11)–C(63)–C(62)  
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89.4(5) 
C(71)–N(11)–C(63)–C(62) 86.6(5) N(10)–C(62)–C(63)–N(11)
 172.5(4) 
C(63)–N(11)–C(64)–O(6) 6.1(6) C(63)–N(11)–C(64)–C(65)  
172.9(4) 
C(71)–N(11)–C(64)–O(6)  169.6(4) C(71)–N(11)–C(64)–C(65) 11.4(7) 
O(6)–C(64)–C(65)–C(66) 42.8(6) O(6)–C(64)–C(65)–C(70)  
132.2(5) 
N(11)–C(64)–C(65)–C(66)  138.2(4) N(11)–C(64)–C(65)–C(70) 46.7(7) 
C(64)–C(65)–C(66)–C(67) 179.7(4) C(70)–C(65)–C(66)–C(67) 5.1(7) 
C(65)–C(66)–C(67)–C(68) 2.1(7) C(66)–C(67)–C(68)–F(3)  
178.8(4) 
C(66)–C(67)–C(68)–C(69) 1.7(8) F(3)–C(68)–C(69)–C(70) 178.1(4) 
C(67)–C(68)–C(69)–C(70)  2.5(8) C(64)–C(65)–C(70)–C(69)
 179.2(4) 
C(66)–C(65)–C(70)–C(69) 4.3(7) C(68)–C(69)–C(70)–C(65) 0.6(8) 
C(75)–N(12)–C(71)–N(11) 179.3(4) C(75)–N(12)–C(71)–C(72) 1.8(7) 
C(63)–N(11)–C(71)–N(12) 51.8(5) C(63)–N(11)–C(71)–C(72)  
127.0(5) 
C(64)–N(11)–C(71)–N(12)  132.5(5) C(64)–N(11)–C(71)–C(72) 48.6(6) 
N(11)–C(71)–C(72)–C(73)  177.8(4) N(12)–C(71)–C(72)–C(73) 3.5(7) 
C(71)–C(72)–C(73)–C(74)  2.2(7) C(72)–C(73)–C(74)–C(75) 0.4(7) 
C(71)–N(12)–C(75)–C(74)  1.1(7) C(73)–C(74)–C(75)–N(12) 2.2(8)
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Appendix: B Advion NanoTek reaction optimisation; isotopic exchange 
reactions 
Target 
precursor 
concentration in 
DMSO mg/mL 
Reaction 
Temperature 
(⁰C) 
Stoichiometry 
(Precursor: 
[
18
F]fluoride) 
Flow rate 
(µL/min) 
Reactor 
length 
(m) 
Radiochemical 
yield (%) 
18 190 1 5 4 0 
18 190 1 5 4 0 
18 190 1 5 4 0 
18 190 1 5 4 0 
18 190 1 5 4 0 
18 190 1 5 4 0 
20 190 1 5 4 12.46 
20 190 1 5 4 17.61 
20 190 1 5 4 19.98 
20 190 1 5 4 0 
20 190 1 5 4 0 
20 190 1 5 4 21.52 
20 190 1 5 4 10.15 
20 190 1 5 4 36.76 
20 190 1 5 4 14.69 
20 190 1 5 4 20.6 
20 190 1 5 4 0 
20 190 1 5 4 0 
20 190 1 5 4 0 
20 190 1 5 4 0 
20 190 1 5 4 0 
20 190 1 5 4 0 
20 190 1 5 4 0 
21 190 1 5 4 2.14 
21 190 1 5 4 2.94 
21 190 1 5 4 0 
      
20 200 1 5 4 0 
20 200 1 5 4 0 
      
20 190 1 10 4 21.18 
20 190 1 10 4 0 
      
20 200 1 10 4 0 
      
18 190 1 30 4 0 
20 190 1 30 4 0 
20 190 1 30 4 0 
20 190 1 30 4 0 
21 190 1 30 4 0 
21 190 1 30 4 0 
      
10 100 0.1 50 8 0 
      
10 110 0.5 10 8 0 
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Target 
precursor 
concentration in 
DMSO mg/mL 
Reaction 
Temperature 
(⁰C) 
Stoichiometry 
(Precursor: 
[
18
F]fluoride) 
Flow rate 
(µL/min) 
Reactor 
length 
(m) 
Radiochemical 
yield (%) 
10 110 1 10 8 0 
      
18 190 0.5 5 8 12.74 
18 190 0.5 5 8 12.92 
18 190 0.5 5 8 12.27 
25 190 0.5 5 8 7.85 
25 190 0.5 5 8 9.66 
25 190 0.5 5 8 0 
    8  
10 190 1 5 8 0 
18 190 1 5 8 11.37 
18 190 1 5 8 19.35 
18 190 1 5 8 15.32 
18 190 1 5 8 16.07 
18 190 1 5 8 12.17 
25 190 1 5 8 8.38 
25 190 1 5 8 7.47 
25 190 1 5 8 6.31 
      
10 190 0.5 10 8 0 
10 190 0.5 10 8 0 
      
10 190 1 10 8 0 
21 190 1 10 8 4.52 
21 190 1 10 8 0 
21 190 1 10 8 0 
21 190 1 10 8 5.67 
21 190 1 10 8 0 
23 190 1 10 8 0 
23 190 1 10 8 4.45 
23 190 1 10 8 5.54 
23 190 1 10 8 3.79 
      
23 190 1 15 8 5.15 
23 190 1 15 8 5.23 
23 190 1 15 8 4.04 
      
23 190 1 20 8 5.84 
23 190 1 20 8 5.88 
23 190 1 20 8 4.41 
25 190 1 20 8 16.81 
25 190 1 20 8 0 
      
23 190 1 25 8 4.15 
23 190 1 25 8 4.41 
23 190 1 25 8 4.06 
      
10 190 1 30 8 0 
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Target 
precursor 
concentration in 
DMSO mg/mL 
Reaction 
Temperature 
(⁰C) 
Stoichiometry 
(Precursor: 
[
18
F]fluoride) 
Flow rate 
(µL/min) 
Reactor 
length 
(m) 
Radiochemical 
yield (%) 
10 190 1 30  0 
10 190 1 30 8 0 
18 190 1 30 8 0 
21 190 1 30 8 0 
23 190 1 30 8 3.59 
23 190 1 30 8 3.98 
23 190 1 30 8 0 
23 190 1 30 8 0 
25 190 1 30 8 0 
25 190 1 30 8 10.36 
25 190 1 30 8 12.17 
      
10 190 2 10 8 0 
      
18 190 2 5 8 13.52 
      
10 200 0.1 50 8 0 
      
10 200 1 5 8 0 
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Appendix: C Advion NanoTek reaction optimisation; Fluorodenitration 
reactions 
Target 
precursor 
concentration 
in DMSO 
mg/mL 
Reaction 
Temperature 
(⁰C) 
Stoichiometry 
(Precursor: 
[
18
F]fluoride) 
Flow rate 
(µL/min) 
Reactor 
length (m) 
Radiochemical 
yield (%) 
10 190 0.1 10 4 0 
      
10 190 0.1 35 4 0 
      
10 190 0.2 10 4 0 
      
10 190 0.5 10 4 0 
      
10 190 1 30 4 0 
10 190 1 30 4 0 
10 190 1 30 4 0 
10 190 1 30 4 0 
      
10 170 1 5 8 8.42 
      
10 190 0.1 10 8 0 
      
10 190 0.5 10 8 0 
      
10 190 1 10 8 0 
      
10 190 1 5 8 6.61 
10 190 1 5 8 5.01 
10 190 1 5 8 5.57 
10 190 1 5 8 13.07 
10 190 1 5 8 16.07 
10 190 1 5 8 0 
      
10 190 1 30 8 0 
10 190 1 30 8 0 
10 190 1 30 8 0 
10 190 1 30 8 0 
10 190 1 30 8 0 
      
10 200 1 5 8 21.00 
10 200 1 5 8 24.95 
10 200 1 5 8 30.99 
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Appendix: D Eckert and Ziegler ModularLab reaction optimisation; 
Fluorodenitration reactions 
No. Precursor Reaction 
solvent 
Solvent 
Volume (mL) 
Microwave 
settings; Time (s) 
Microwave 
settings; Power 
(W) 
Microwave settings; 
Temperature (⁰C) 
Radio-
chemical 
yield (%) 
1 
4-MPPNO2 DMF 1.0 150 50 120 4.88 
4-MPPNO2 DMF 1.0 150 50 120 3.74 
4-MPPNO2 DMF 1.0 150 50 120 5.50 
4-MPPNO2 DMF 1.0 150 50 120 4.50 
4-MPPNO2 DMF 1.0 150 50 120 4.50 
4-MPPNO2 DMF 1.0 150 50 120 3.97 
4-MPPNO2 DMF 1.0 150 50 120 4.86 
4-MPPNO2 DMF 1.0 150 50 120 5.46 
4-MPPNO2 DMF 1.0 150 50 120 4.67 
4-MPPNO2 DMF 1.0 150 50 120 4.54 
4-MPPNO2 DMF 1.0 150 50 120 0.00 
Mean RCY: 4.66 
        
2 4-MPPNO2 DMF 1.0 150 70 120 4.20 
        
3 4-MPPNO2 DMF 1.0 150 ,150 50, 50 120, 120 3.58 
4-MPPNO2 DMF 1.0 150 ,150 50, 50 120, 120 4.27 
 Mean RCY: 3.93 
        
4 4-MPPNO2 DMF 
(Al2CO3) 
0.5 150 100 140 4.89 
4-MPPNO2 DMF 
(Al2CO3) 
0.5 150 100 140 8.50 
 Mean RCY: 6.70 
        
5 4-MPPNO2 DMSO 1.0 200 100 180 5.67 
        
6 4-MPPNO2 DMSO 
(Al2CO3) 
0.5 100 70 165 5.86 
        
7 
4-MPPNO2 DMSO 
(Al2CO3) 
0.5 100,100 70,100 165,165 20.62 
4-MPPNO2 DMSO 
(Al2CO3) 
0.5 100,100 70,100 165,165 15.50 
4-MPPNO2 DMSO 
(Al2CO3) 
0.5 100,100 70,100 165,165 8.22 
 Mean RCY: 14.78 
        
8 
4-MPPNO2 DMSO 
(Al2O3) 
0.5 100,100,100,
100,100,100 
70,70,70,100
100,100 
165,165,165, 
165,165, 165 
165,165,165 
24.67 
4-MPPNO2 DMSO 
(Al2O3) 
0.5 100,100,100,
100,100,100 
70,70,70,100
100,100 
165,165,165, 
165,165, 165 
25.99 
4-MPPNO2 DMSO 
(Al2O3) 
0.5 100,100,100,
100,100,100 
70,70,70,100
100,100 
165,165,165, 
165,165, 165 
13.30 
 Mean RCY: 21.32 
        
9 
4-MPPNO2 DMSO 
(Al2O3) 
0.5 100,100,100,
100 
100,100,70, 
70 
70 
175,175,170, 
170 
170 
18.78 
4-MPPNO2 DMSO 
(Al2O3) 
0.5 100,100,100,
100 
100,100,70, 
70 
175,175,170, 
170 
23.67 
4-MPPNO2 DMSO 
(Al2O3) 
0.5 100,100,100,
100 
100,100,70, 
70 
175,175,170, 
170 
24.48 
 Mean RCY: 22.31 
 Final conditions Mean 
RCY 10 4-MPPNO2 DMSO 
(Al2O3) 
0.5 100,100,100,
100 
100,100,70, 
70 
70 
175,175,175, 
175 
175 
33.48 (n 
= 36) 
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